Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.

Request ID: cder_mpl1r_wp241_nsdp_v02

Request Description: In this report, we characterized dispensing and administration patterns of 22 New Molecular Entities (NMEs) approved from May 1, 2020 to August 30, 2020, stratified by age and sex in the Sentinel Distributed Database (SDD).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis module, version 11.0.0

Data Source: We distributed this request to 13 Sentinel Data Partners on April 14, 2023. The study period included data from January 1, 2020 to December 31, 2022. Please see Appendix A for a list of dates of available data for each Data Partner.

Study Design: We identified individuals with incident use of the 22 NME drugs stratified by age and sex. We described demographic and clinical characteristics of each NME drug based on history recorded in the six months prior to initiation of treatment with NME. The analyses characterized dispensing patterns by examining cumulative exposure episode durations, first exposure episode durations, all exposure episode durations, days supplied per dispensing, and lengths of gaps between episodes. This was a Type 5 analysis in the Query Request Package (QRP) documentation.

Exposures of Interest: Our exposures of interest were NMEs approved between January 1, 2020, and December 31, 2020 administered or dispensed in any care setting. These were defined using Healthcare Common Procedure Coding System (HCPCS) procedure codes and National Drug Codes (NDCs). Please see Appendix B for a list of generic and brand names of medical products, and Appendix C for a list of procedure codes used to define exposures in this request. All valid exposure episodes were included.

Cohort Eligibility Criteria: We defined index date as the first dispensing for each NME. We required individuals to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to their index exposure, during which gaps in coverage of up to 45 days were allowed. The following age groups were included: 0-18, 19-64, 65+ years.

Baseline Characteristics: We described demographic characteristics such as sex, age, and calendar year on the day of each index NME exposure. We also described 31 clinical characteristics based on history recorded in the year prior to drug initiation. The set of clinical characteristics included 24 chronic conditions and 7 lifestyle-related conditions. Chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse1 (CCW) algorithms and included: acute myocardial infarction, Alzheimer's disease and related conditions, atrial fibrillation, diabetes mellitus, heart failure, hyperlipidemia, hypertension, depression, ischemic heart disease, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack (TIA), breast cancer, colorectal cancer, prostate cancer, lung cancer, endometrial cancer, acquired hypothyroidism, anemia, asthma, benign prostatic hyperplasia, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and bronchiectasis, glaucoma, and osteoporosis. Lifestyle-related conditions included: obesity, overweight, smoking, alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, and history of coronary angioplasty or bypass. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes, HCPCS procedure codes, Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, and NDCs were used to define the clinical characteristics. Please see Appendix D for a list of diagnosis and procedure codes used to define baseline characteristics in this request, Appendix E a list of generic and brand names of medical products used to define baseline characteristics in this request.

Please refer to Appendices F, G, and H for the specifications of parameters used in this request, baseline characteristics used in this request, and a design diagram.

Limitations: Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (https://dev.sentinelsystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse).

Table of Contents

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

    Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

    Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

    Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

    Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

    Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module*

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Characteristics of Capmatinib in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	754	N/A
Demographic Characteristics		
Age (years)	75.6	9.0
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	662	87.8%
Sex		
Female	416	55.2%
Male	338	44.8%
Race		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	56	7.4%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	167	22.1%
White	488	64.7%
Hispanic origin		
Yes	11	1.5%
No	539	71.5%
Unknown	204	27.1%
Year		
2020	224	29.7%
2021	335	44.4%
2022	195	25.9%
Health Characteristics		
Acute Myocardial Infarction	14	1.9%
Alzheimer's Disease and related conditions	55	7.3%
Atrial Fibrillation	119	15.8%
Diabetes Mellitus	148	19.6%
Heart Failure	109	14.5%
Hyperlipidemia	397	52.7%
Hypertension	490	65.0%
Depression	136	18.0%

Table 1a. Aggregated Characteristics of Capmatinib in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	269	35.7%
Rheumatoid Arthritis/Osteoarthritis	152	20.2%
Stroke/TIA	78	10.3%
Breast Cancer	51	6.8%
Colorectal Cancer	16	2.1%
Prostate Cancer	49	6.5%
Lung Cancer	740	98.1%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	131	17.4%
Anemia	316	41.9%
Asthma	52	6.9%
Benign Prostatic Hyperplasia	79	10.5%
Chronic Kidney Disease	175	23.2%
Chronic obstructive pulmonary disease (COPD) and Bronchiectasis	195	25.9%
Glaucoma	26	3.4%
Osteoporosis	54	7.2%
Obesity: diagnosed or identified by weight management procedures	93	12.3%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	73	9.7%
Smoking: diagnosed or identified by smoking cessation procedures	394	52.3%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	16	2.1%
Drug Abuse or Dependence	20	2.7%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	81	10.7%

Table 1a. Aggregated Characteristics of Capmatinib in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	25.9	14.7
Mean number of emergency room encounters	0.6	1.1
Mean number of inpatient hospital encounters	0.7	1.0
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	10.3	11.1
Mean number of filled prescriptions	21.7	14.7
Mean number of generics dispensed	10.4	5.4
Mean number of unique drug classes dispensed	9.5	4.7

N/A: Not Applicable

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1b. Aggregated Characteristics of Selpercatinib in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	370	N/A
Demographic Characteristics		
Age (years)	66.2	11.9
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	110	29.7%
≥ 65 years	237	64.1%
Sex		
Female	187	50.5%
Male	183	49.5%
Race		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	19	5.1%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	161	43.5%
White	174	47.0%
Hispanic origin		
Yes	13	3.5%
No	192	51.9%
Unknown	165	44.6%
Year		
2020	115	31.1%
2021	169	45.7%
2022	86	23.2%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	13	3.5%
Atrial Fibrillation	39	10.5%
Diabetes Mellitus	70	18.9%
Heart Failure	24	6.5%
Hyperlipidemia	142	38.4%
Hypertension	189	51.1%
Depression	66	17.8%

Table 1b. Aggregated Characteristics of Selpercatinib in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	72	19.5%
Rheumatoid Arthritis/Osteoarthritis	46	12.4%
Stroke/TIA	19	5.1%
Breast Cancer	17	4.6%
Colorectal Cancer	*****	*****
Prostate Cancer	19	5.1%
Lung Cancer	247	66.8%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	124	33.5%
Anemia	123	33.2%
Asthma	26	7.0%
Benign Prostatic Hyperplasia	29	7.8%
Chronic Kidney Disease	72	19.5%
COPD and Bronchiectasis	48	13.0%
Glaucoma	11	3.0%
Osteoporosis	15	4.1%
Obesity: diagnosed or identified by weight management procedures	43	11.6%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	37	10.0%
Smoking: diagnosed or identified by smoking cessation procedures	111	30.0%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	14	3.8%

Table 1b. Aggregated Characteristics of Selpercatinib in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.3	12.2
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.5	0.9
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	8.2	8.9
Mean number of filled prescriptions	18.9	13.0
Mean number of generics dispensed	8.9	5.4
Mean number of unique drug classes dispensed	8.2	4.8

N/A: Not Applicable

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1c. Aggregated Characteristics of Ripretinib in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	311	N/A
Demographic Characteristics		
Age (years)	68.2	10.6
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	209	67.2%
Sex		
Female	142	45.7%
Male	169	54.3%
Race		
American Indian or Alaska Native	0	0.0%
Asian	14	4.5%
Black or African American	44	14.1%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	92	29.6%
White	161	51.8%
Hispanic origin		
Yes	11	3.5%
No	200	64.3%
Unknown	100	32.2%
Year		
2020	113	36.3%
2021	123	39.5%
2022	75	24.1%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	13	4.2%
Atrial Fibrillation	35	11.3%
Diabetes Mellitus	66	21.2%
Heart Failure	56	18.0%
Hyperlipidemia	106	34.1%
Hypertension	191	61.4%
Depression	60	19.3%

Table 1c. Aggregated Characteristics of Ripretinib in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	68	21.9%
Rheumatoid Arthritis/Osteoarthritis	32	10.3%
Stroke/TIA	11	3.5%
Breast Cancer	*****	*****
Colorectal Cancer	81	26.0%
Prostate Cancer	16	5.1%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	69	22.2%
Anemia	164	52.7%
Asthma	12	3.9%
Benign Prostatic Hyperplasia	20	6.4%
Chronic Kidney Disease	85	27.3%
COPD and Bronchiectasis	28	9.0%
Glaucoma	*****	*****
Osteoporosis	20	6.4%
Obesity: diagnosed or identified by weight management procedures	46	14.8%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	31	10.0%
Smoking: diagnosed or identified by smoking cessation procedures	84	27.0%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	14	4.5%
Drug Abuse or Dependence	15	4.8%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	14	4.5%

Table 1c. Aggregated Characteristics of Ripretinib in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.2	13.0
Mean number of emergency room encounters	0.7	1.3
Mean number of inpatient hospital encounters	0.5	0.9
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	8.1	9.8
Mean number of filled prescriptions	22.6	16.4
Mean number of generics dispensed	10.0	5.4
Mean number of unique drug classes dispensed	9.2	4.7

N/A: Not Applicable

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1d. Aggregated Characteristics of Fluoroestradiol-F18 in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	205	N/A
Demographic Characteristics		
Age (years)	68.3	9.5
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	148	72.2%
Sex		
Female	*****	*****
Male	*****	*****
Race		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	125	61.0%
Hispanic origin		
Yes	*****	*****
No	102	49.8%
Unknown	*****	*****
Year		
2020	0	0.0%
2021	49	23.9%
2022	156	76.1%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	33	16.1%
Heart Failure	17	8.3%
Hyperlipidemia	65	31.7%
Hypertension	72	35.1%
Depression	47	22.9%

Table 1d. Aggregated Characteristics of Fluoroestradiol-F18 in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	28	13.7%
Rheumatoid Arthritis/Osteoarthritis	36	17.6%
Stroke/TIA	*****	*****
Breast Cancer	187	91.2%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	28	13.7%
Anemia	53	25.9%
Asthma	16	7.8%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	33	16.1%
COPD and Bronchiectasis	19	9.3%
Glaucoma	*****	*****
Osteoporosis	16	7.8%
Obesity: diagnosed or identified by weight management procedures	30	14.6%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	43	21.0%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

Table 1d. Aggregated Characteristics of Fluoroestradiol-F18 in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.6	13.2
Mean number of emergency room encounters	0.4	1.1
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.1	5.7
Mean number of filled prescriptions	14.9	11.8
Mean number of generics dispensed	7.3	5.1
Mean number of unique drug classes dispensed	6.9	4.7

N/A: Not Applicable

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1e. Aggregated Characteristics of Artesunate in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	63.1	9.8
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	0	0.0%
Unknown	*****	*****
Year		
2020	0	0.0%
2021	*****	*****
2022	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	0	0.0%
Heart Failure	0	0.0%
Hyperlipidemia	*****	*****
Hypertension	0	0.0%
Depression	0	0.0%

Table 1e. Aggregated Characteristics of Artesunate in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	0	0.0%
Anemia	*****	*****
Asthma	0	0.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	0	0.0%
COPD and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	0	0.0%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	0	0.0%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%

Table 1e. Aggregated Characteristics of Artesunate in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	27.0	8.5
Mean number of emergency room encounters	2.0	0.0
Mean number of inpatient hospital encounters	0.3	0.0
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	16.0	0.5
Mean number of filled prescriptions	15.0	7.5
Mean number of generics dispensed	8.0	3.0
Mean number of unique drug classes dispensed	7.7	3.0

N/A: Not Applicable

*NaN: Not a Number

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1f. Aggregated Characteristics of Flortaucipir F-18 in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-17 years	.	.
18-24 years	.	.
25-40 years	.	.
41-64 years	.	.
≥ 65 years	.	.
Sex		
Female	.	.
Male	.	.
Race		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2020	.	.
2021	.	.
2022	.	.
Health Characteristics		
Acute Myocardial Infarction	.	.
Alzheimer's Disease and related conditions	.	.
Atrial Fibrillation	.	.
Diabetes Mellitus	.	.
Heart Failure	.	.
Hyperlipidemia	.	.
Hypertension	.	.
Depression	.	.

Table 1f. Aggregated Characteristics of Flortaucipir F-18 in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	.	.
Rheumatoid Arthritis/Osteoarthritis	.	.
Stroke/TIA	.	.
Breast Cancer	.	.
Colorectal Cancer	.	.
Prostate Cancer	.	.
Lung Cancer	.	.
Endometrial Cancer	.	.
Acquired Hypothyroidism	.	.
Anemia	.	.
Asthma	.	.
Benign Prostatic Hyperplasia	.	.
Chronic Kidney Disease	.	.
COPD and Bronchiectasis	.	.
Glaucoma	.	.
Osteoporosis	.	.
Obesity: diagnosed or identified by weight management procedures	.	.
Obesity: identified by weight management-related prescriptions	.	.
Overweight	.	.
Smoking: diagnosed or identified by smoking cessation procedures	.	.
Smoking: identified by smoking-related prescriptions	.	.
Alcohol Abuse or Dependence	.	.
Drug Abuse or Dependence	.	.
History of Cardiac Arrest	.	.
History of Coronary Angioplasty or Bypass	.	.

Table 1f. Aggregated Characteristics of Flortaucipir F-18 in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

N/A: Not Applicable

Table 1g. Aggregated Characteristics of Inebilizumab-cdon in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	147	N/A
Demographic Characteristics		
Age (years)	57.1	12.6
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	70	47.6%
≥ 65 years	54	36.7%
Sex		
Female	120	81.6%
Male	27	18.4%
Race		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	46	31.3%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	50	34.0%
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	84	57.1%
Unknown	*****	*****
Year		
2020	*****	*****
2021	76	51.7%
2022	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	19	12.9%
Heart Failure	*****	*****
Hyperlipidemia	36	24.5%
Hypertension	54	36.7%
Depression	36	24.5%

Table 1g. Aggregated Characteristics of Inebilizumab-cdon in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	11	7.5%
Rheumatoid Arthritis/Osteoarthritis	30	20.4%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	22	15.0%
Anemia	32	21.8%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	17	11.6%
COPD and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	38	25.9%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	11	7.5%
Smoking: diagnosed or identified by smoking cessation procedures	29	19.7%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

Table 1g. Aggregated Characteristics of Inebilizumab-cdon in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.2	13.4
Mean number of emergency room encounters	0.6	1.3
Mean number of inpatient hospital encounters	0.3	0.6
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	7.1	8.9
Mean number of filled prescriptions	20.2	19.3
Mean number of generics dispensed	8.7	6.1
Mean number of unique drug classes dispensed	8.2	5.6

N/A: Not Applicable

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1h. Aggregated Characteristics of Lurbinectedin in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	3,217	N/A
Demographic Characteristics		
Age (years)	69.8	7.6
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	2,511	78.1%
Sex		
Female	1,623	50.5%
Male	1,594	49.5%
Race		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	179	5.6%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	647	20.1%
White	2,354	73.2%
Hispanic origin		
Yes	21	0.7%
No	2,309	71.8%
Unknown	887	27.6%
Year		
2020	133	4.1%
2021	2,035	63.3%
2022	1,049	32.6%
Health Characteristics		
Acute Myocardial Infarction	38	1.2%
Alzheimer's Disease and related conditions	123	3.8%
Atrial Fibrillation	395	12.3%
Diabetes Mellitus	823	25.6%
Heart Failure	398	12.4%
Hyperlipidemia	1,412	43.9%
Hypertension	1,896	58.9%
Depression	755	23.5%

Table 1h. Aggregated Characteristics of Lurbinectedin in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	1,058	32.9%
Rheumatoid Arthritis/Osteoarthritis	511	15.9%
Stroke/TIA	144	4.5%
Breast Cancer	188	5.8%
Colorectal Cancer	80	2.5%
Prostate Cancer	197	6.1%
Lung Cancer	3,009	93.5%
Endometrial Cancer	23	0.7%
Acquired Hypothyroidism	645	20.0%
Anemia	1,868	58.1%
Asthma	126	3.9%
Benign Prostatic Hyperplasia	272	8.5%
Chronic Kidney Disease	632	19.6%
COPD and Bronchiectasis	1,520	47.2%
Glaucoma	75	2.3%
Osteoporosis	142	4.4%
Obesity: diagnosed or identified by weight management procedures	517	16.1%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	328	10.2%
Smoking: diagnosed or identified by smoking cessation procedures	2,455	76.3%
Smoking: identified by smoking-related prescriptions	78	2.4%
Alcohol Abuse or Dependence	127	3.9%
Drug Abuse or Dependence	150	4.7%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	308	9.6%

Table 1h. Aggregated Characteristics of Lurbinectedin in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	37.0	14.3
Mean number of emergency room encounters	0.8	1.4
Mean number of inpatient hospital encounters	0.5	0.9
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	8.5	9.6
Mean number of filled prescriptions	24.7	16.7
Mean number of generics dispensed	11.1	5.8
Mean number of unique drug classes dispensed	10.2	5.2

N/A: Not Applicable

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1i. Aggregated Characteristics of Triheptanoin in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	54	N/A
Demographic Characteristics		
Age (years)	21.2	13.9
Age		
0-17 years	33	61.1%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	26	48.1%
Male	28	51.9%
Race		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	37	68.5%
White	*****	*****
Hispanic origin		
Yes	0	0.0%
No	15	27.8%
Unknown	39	72.2%
Year		
2020	*****	*****
2021	27	50.0%
2022	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	*****	*****
Hypertension	*****	*****
Depression	*****	*****

Table 1i. Aggregated Characteristics of Triheptanoin in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA	*****	*****
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	*****	*****
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD and Bronchiectasis	*****	*****
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%

Table 1i. Aggregated Characteristics of Triheptanoin in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.5	28.0
Mean number of emergency room encounters	0.6	1.2
Mean number of inpatient hospital encounters	0.3	0.6
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	7.1	14.4
Mean number of filled prescriptions	12.8	21.1
Mean number of generics dispensed	4.6	6.6
Mean number of unique drug classes dispensed	4.4	5.8

N/A: Not Applicable

*NaN: Not a Number

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1j. Aggregated Characteristics of Remimazolam in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	130	N/A
Demographic Characteristics		
Age (years)	62.1	13.8
Age		
0-17 years	*****	*****
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	55	42.3%
≥ 65 years	60	46.2%
Sex		
Female	66	50.8%
Male	64	49.2%
Race		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	98	75.4%
White	*****	*****
Hispanic origin		
Yes	0	0.0%
No	0	0.0%
Unknown	130	100.0%
Year		
2020	0	0.0%
2021	44	33.8%
2022	86	66.2%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	21	16.2%
Diabetes Mellitus	29	22.3%
Heart Failure	18	13.8%
Hyperlipidemia	40	30.8%
Hypertension	56	43.1%
Depression	27	20.8%

Table 1j. Aggregated Characteristics of Remimazolam in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	23	17.7%
Rheumatoid Arthritis/Osteoarthritis	30	23.1%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	13	10.0%
Anemia	25	19.2%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	24	18.5%
COPD and Bronchiectasis	12	9.2%
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	39	30.0%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	13	10.0%
Smoking: diagnosed or identified by smoking cessation procedures	27	20.8%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****

Table 1j. Aggregated Characteristics of Remimazolam in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.0	14.0
Mean number of emergency room encounters	0.8	2.0
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	3.4	6.3
Mean number of filled prescriptions	16.9	15.7
Mean number of generics dispensed	7.4	5.3
Mean number of unique drug classes dispensed	6.9	4.9

N/A: Not Applicable

*NaN: Not a Number

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1k. Aggregated Characteristics of Fostemsavir in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	595	N/A
Demographic Characteristics		
Age (years)	58.0	10.9
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	382	64.2%
≥ 65 years	161	27.1%
Sex		
Female	105	17.6%
Male	490	82.4%
Race		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	210	35.3%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	248	41.7%
Hispanic origin		
Yes	36	6.1%
No	437	73.4%
Unknown	122	20.5%
Year		
2020	191	32.1%
2021	263	44.2%
2022	141	23.7%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	14	2.4%
Atrial Fibrillation	20	3.4%
Diabetes Mellitus	135	22.7%
Heart Failure	48	8.1%
Hyperlipidemia	234	39.3%
Hypertension	248	41.7%
Depression	151	25.4%

Table 1k. Aggregated Characteristics of Fostemsavir in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	98	16.5%
Rheumatoid Arthritis/Osteoarthritis	68	11.4%
Stroke/TIA	16	2.7%
Breast Cancer	*****	*****
Colorectal Cancer	14	2.4%
Prostate Cancer	16	2.7%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	36	6.1%
Anemia	164	27.6%
Asthma	43	7.2%
Benign Prostatic Hyperplasia	39	6.6%
Chronic Kidney Disease	164	27.6%
COPD and Bronchiectasis	53	8.9%
Glaucoma	11	1.8%
Osteoporosis	16	2.7%
Obesity: diagnosed or identified by weight management procedures	68	11.4%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	53	8.9%
Smoking: diagnosed or identified by smoking cessation procedures	168	28.2%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	14	2.4%
Drug Abuse or Dependence	62	10.4%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	34	5.7%

Table 1k. Aggregated Characteristics of Fostemsavir in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.0	23.8
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.3	0.8
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	6.1	10.1
Mean number of filled prescriptions	44.4	28.1
Mean number of generics dispensed	12.3	6.0
Mean number of unique drug classes dispensed	9.8	5.2

N/A: Not Applicable

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1l. Aggregated Characteristics of Decitabine and Cedazuridine in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	1,822	N/A
Demographic Characteristics		
Age (years)	76.2	8.1
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	1,707	93.7%
Sex		
Female	690	37.9%
Male	1,132	62.1%
Race		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	112	6.1%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	243	13.3%
White	1,419	77.9%
Hispanic origin		
Yes	24	1.3%
No	1,504	82.5%
Unknown	294	16.1%
Year		
2020	385	21.1%
2021	934	51.3%
2022	503	27.6%
Health Characteristics		
Acute Myocardial Infarction	46	2.5%
Alzheimer's Disease and related conditions	98	5.4%
Atrial Fibrillation	351	19.3%
Diabetes Mellitus	536	29.4%
Heart Failure	414	22.7%
Hyperlipidemia	904	49.6%
Hypertension	1,240	68.1%
Depression	369	20.3%

Table 1l. Aggregated Characteristics of Decitabine and Cedazuridine in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	647	35.5%
Rheumatoid Arthritis/Osteoarthritis	410	22.5%
Stroke/TIA	76	4.2%
Breast Cancer	97	5.3%
Colorectal Cancer	55	3.0%
Prostate Cancer	123	6.8%
Lung Cancer	56	3.1%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	345	18.9%
Anemia	1,780	97.7%
Asthma	99	5.4%
Benign Prostatic Hyperplasia	245	13.4%
Chronic Kidney Disease	622	34.1%
COPD and Bronchiectasis	313	17.2%
Glaucoma	80	4.4%
Osteoporosis	128	7.0%
Obesity: diagnosed or identified by weight management procedures	343	18.8%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	231	12.7%
Smoking: diagnosed or identified by smoking cessation procedures	741	40.7%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	44	2.4%
Drug Abuse or Dependence	55	3.0%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	232	12.7%

Table 1l. Aggregated Characteristics of Decitabine and Cedazuridine in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	34.4	19.9
Mean number of emergency room encounters	0.7	1.6
Mean number of inpatient hospital encounters	0.7	1.1
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	10.0	13.2
Mean number of filled prescriptions	21.5	15.5
Mean number of generics dispensed	9.8	5.5
Mean number of unique drug classes dispensed	9.3	4.9

N/A: Not Applicable

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1m. Aggregated Characteristics of Abametapir in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-17 years	.	.
18-24 years	.	.
25-40 years	.	.
41-64 years	.	.
≥ 65 years	.	.
Sex		
Female	.	.
Male	.	.
Race		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2020	.	.
2021	.	.
2022	.	.
Health Characteristics		
Acute Myocardial Infarction	.	.
Alzheimer's Disease and related conditions	.	.
Atrial Fibrillation	.	.
Diabetes Mellitus	.	.
Heart Failure	.	.
Hyperlipidemia	.	.
Hypertension	.	.
Depression	.	.

Table 1m. Aggregated Characteristics of Abametapir in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	.	.
Rheumatoid Arthritis/Osteoarthritis	.	.
Stroke/TIA	.	.
Breast Cancer	.	.
Colorectal Cancer	.	.
Prostate Cancer	.	.
Lung Cancer	.	.
Endometrial Cancer	.	.
Acquired Hypothyroidism	.	.
Anemia	.	.
Asthma	.	.
Benign Prostatic Hyperplasia	.	.
Chronic Kidney Disease	.	.
COPD and Bronchiectasis	.	.
Glaucoma	.	.
Osteoporosis	.	.
Obesity: diagnosed or identified by weight management procedures	.	.
Obesity: identified by weight management-related prescriptions	.	.
Overweight	.	.
Smoking: diagnosed or identified by smoking cessation procedures	.	.
Smoking: identified by smoking-related prescriptions	.	.
Alcohol Abuse or Dependence	.	.
Drug Abuse or Dependence	.	.
History of Cardiac Arrest	.	.
History of Coronary Angioplasty or Bypass	.	.

Table 1m. Aggregated Characteristics of Abametapir in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

N/A: Not Applicable

Table 1n. Aggregated Characteristics of Tafasitamab-cxix in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	942	N/A
Demographic Characteristics		
Age (years)	76.9	9.0
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	864	91.7%
Sex		
Female	431	45.8%
Male	511	54.2%
Race		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	43	4.6%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	171	18.2%
White	705	74.8%
Hispanic origin		
Yes	19	2.0%
No	724	76.9%
Unknown	199	21.1%
Year		
2020	29	3.1%
2021	622	66.0%
2022	291	30.9%
Health Characteristics		
Acute Myocardial Infarction	15	1.6%
Alzheimer's Disease and related conditions	61	6.5%
Atrial Fibrillation	195	20.7%
Diabetes Mellitus Mellitus	237	25.2%
Heart Failure	229	24.3%
Hyperlipidemia	430	45.6%
Hypertension	577	61.3%
Depression	173	18.4%

Table 1n. Aggregated Characteristics of Tafasitamab-cxix in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	345	36.6%
Rheumatoid Arthritis/Osteoarthritis	193	20.5%
Stroke/TIA	43	4.6%
Breast Cancer	56	5.9%
Colorectal Cancer	31	3.3%
Prostate Cancer	52	5.5%
Lung Cancer	27	2.9%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	166	17.6%
Anemia	615	65.3%
Asthma	37	3.9%
Benign Prostatic Hyperplasia	117	12.4%
Chronic Kidney Disease	322	34.2%
COPD and Bronchiectasis	128	13.6%
Glaucoma	55	5.8%
Osteoporosis	60	6.4%
Obesity: diagnosed or identified by weight management procedures	151	16.0%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	125	13.3%
Smoking: diagnosed or identified by smoking cessation procedures	352	37.4%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	19	2.0%
Drug Abuse or Dependence	27	2.9%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	117	12.4%

Table 1n. Aggregated Characteristics of Tafasitamab-cxix in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	31.5	16.2
Mean number of emergency room encounters	0.7	1.2
Mean number of inpatient hospital encounters	0.9	1.4
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	11.7	15.0
Mean number of filled prescriptions	22.8	15.0
Mean number of generics dispensed	11.1	5.9
Mean number of unique drug classes dispensed	10.4	5.3

N/A: Not Applicable

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1o. Aggregated Characteristics of Belantamab Mafodotin-blmf in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	1,108	N/A
Demographic Characteristics		
Age (years)	71.1	8.5
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	883	79.7%
Sex		
Female	511	46.1%
Male	597	53.9%
Race		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	151	13.6%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	220	19.9%
White	716	64.6%
Hispanic origin		
Yes	21	1.9%
No	835	75.4%
Unknown	252	22.7%
Year		
2020	37	3.3%
2021	725	65.4%
2022	346	31.2%
Health Characteristics		
Acute Myocardial Infarction	23	2.1%
Alzheimer's Disease and related conditions	66	6.0%
Atrial Fibrillation	190	17.1%
Diabetes Mellitus	270	24.4%
Heart Failure	288	26.0%
Hyperlipidemia	408	36.8%
Hypertension	688	62.1%
Depression	260	23.5%

Table 1o. Aggregated Characteristics of Belantamab Mafodotin-blmf in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	292	26.4%
Rheumatoid Arthritis/Osteoarthritis	219	19.8%
Stroke/TIA	37	3.3%
Breast Cancer	45	4.1%
Colorectal Cancer	*****	*****
Prostate Cancer	53	4.8%
Lung Cancer	12	1.1%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	183	16.5%
Anemia	862	77.8%
Asthma	77	6.9%
Benign Prostatic Hyperplasia	101	9.1%
Chronic Kidney Disease	484	43.7%
COPD and Bronchiectasis	131	11.8%
Glaucoma	78	7.0%
Osteoporosis	70	6.3%
Obesity: diagnosed or identified by weight management procedures	190	17.1%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	128	11.6%
Smoking: diagnosed or identified by smoking cessation procedures	332	30.0%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	17	1.5%
Drug Abuse or Dependence	52	4.7%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	79	7.1%

Table 1o. Aggregated Characteristics of Belantamab Mafodotin-blmf in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	38.9	19.0
Mean number of emergency room encounters	0.7	1.3
Mean number of inpatient hospital encounters	0.8	1.3
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	12.7	14.1
Mean number of filled prescriptions	29.2	16.2
Mean number of generics dispensed	12.7	5.9
Mean number of unique drug classes dispensed	11.8	5.2

N/A: Not Applicable

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1p. Aggregated Characteristics of Nifurtimox in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-17 years	.	.
18-24 years	.	.
25-40 years	.	.
41-64 years	.	.
≥ 65 years	.	.
Sex		
Female	.	.
Male	.	.
Race		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2020	.	.
2021	.	.
2022	.	.
Health Characteristics		
Acute Myocardial Infarction	.	.
Alzheimer's Disease and related conditions	.	.
Atrial Fibrillation	.	.
Diabetes Mellitus	.	.
Heart Failure	.	.
Hyperlipidemia	.	.
Hypertension	.	.
Depression	.	.

Table 1p. Aggregated Characteristics of Nifurtimox in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	.	.
Rheumatoid Arthritis/Osteoarthritis	.	.
Stroke/TIA	.	.
Breast Cancer	.	.
Colorectal Cancer	.	.
Prostate Cancer	.	.
Lung Cancer	.	.
Endometrial Cancer	.	.
Acquired Hypothyroidism	.	.
Anemia	.	.
Asthma	.	.
Benign Prostatic Hyperplasia	.	.
Chronic Kidney Disease	.	.
COPD and Bronchiectasis	.	.
Glaucoma	.	.
Osteoporosis	.	.
Obesity: diagnosed or identified by weight management procedures	.	.
Obesity: identified by weight management-related prescriptions	.	.
Overweight	.	.
Smoking: diagnosed or identified by smoking cessation procedures	.	.
Smoking: identified by smoking-related prescriptions	.	.
Alcohol Abuse or Dependence	.	.
Drug Abuse or Dependence	.	.
History of Cardiac Arrest	.	.
History of Coronary Angioplasty or Bypass	.	.

Table 1p. Aggregated Characteristics of Nifurtimox in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

N/A: Not Applicable

Table 1q. Aggregated Characteristics of Risdiplam in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	499	N/A
Demographic Characteristics		
Age (years)	35.2	14.2
Age		
0-17 years	84	16.8%
18-24 years	55	11.0%
25-40 years	178	35.7%
41-64 years	157	31.5%
≥ 65 years	25	5.0%
Sex		
Female	281	56.3%
Male	218	43.7%
Race		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	193	38.7%
White	282	56.5%
Hispanic origin		
Yes	19	3.8%
No	292	58.5%
Unknown	188	37.7%
Year		
2020	201	40.3%
2021	224	44.9%
2022	74	14.8%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	33	6.6%
Heart Failure	*****	*****
Hyperlipidemia	35	7.0%
Hypertension	57	11.4%
Depression	98	19.6%

Table 1q. Aggregated Characteristics of Risdiplam in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	21	4.2%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	15	3.0%
Anemia	45	9.0%
Asthma	30	6.0%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	11	2.2%
COPD and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	21	4.2%
Obesity: diagnosed or identified by weight management procedures	50	10.0%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	12	2.4%
Smoking: diagnosed or identified by smoking cessation procedures	30	6.0%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	13	2.6%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****

Table 1q. Aggregated Characteristics of Risdiplam in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.2	9.6
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	10.3	22.8
Mean number of filled prescriptions	13.4	16.7
Mean number of generics dispensed	5.1	4.8
Mean number of unique drug classes dispensed	4.8	4.4

N/A: Not Applicable

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1r. Aggregated Characteristics of Oliceridine in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-17 years	.	.
18-24 years	.	.
25-40 years	.	.
41-64 years	.	.
≥ 65 years	.	.
Sex		
Female	.	.
Male	.	.
Race		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2020	.	.
2021	.	.
2022	.	.
Health Characteristics		
Acute Myocardial Infarction	.	.
Alzheimer's Disease and related conditions	.	.
Atrial Fibrillation	.	.
Diabetes Mellitus	.	.
Heart Failure	.	.
Hyperlipidemia	.	.
Hypertension	.	.
Depression	.	.

Table 1r. Aggregated Characteristics of Oliceridine in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	.	.
Rheumatoid Arthritis/Osteoarthritis	.	.
Stroke/TIA	.	.
Breast Cancer	.	.
Colorectal Cancer	.	.
Prostate Cancer	.	.
Lung Cancer	.	.
Endometrial Cancer	.	.
Acquired Hypothyroidism	.	.
Anemia	.	.
Asthma	.	.
Benign Prostatic Hyperplasia	.	.
Chronic Kidney Disease	.	.
COPD and Bronchiectasis	.	.
Glaucoma	.	.
Osteoporosis	.	.
Obesity: diagnosed or identified by weight management procedures	.	.
Obesity: identified by weight management-related prescriptions	.	.
Overweight	.	.
Smoking: diagnosed or identified by smoking cessation procedures	.	.
Smoking: identified by smoking-related prescriptions	.	.
Alcohol Abuse or Dependence	.	.
Drug Abuse or Dependence	.	.
History of Cardiac Arrest	.	.
History of Coronary Angioplasty or Bypass	.	.

Table 1r. Aggregated Characteristics of Oliceridine in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

N/A: Not Applicable

Table 1s. Aggregated Characteristics of Viltolarsen in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	16.4	6.9
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	0	0.0%
≥ 65 years	0	0.0%
Sex		
Female	0	0.0%
Male	*****	*****
Race		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2020	*****	*****
2021	*****	*****
2022	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	0	0.0%
Heart Failure	*****	*****
Hyperlipidemia	0	0.0%
Hypertension	*****	*****
Depression	0	0.0%

Table 1s. Aggregated Characteristics of Viltolarsen in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	0	0.0%
Anemia	0	0.0%
Asthma	0	0.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	0	0.0%
COPD and Bronchiectasis	0	0.0%
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	0	0.0%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%

Table 1s. Aggregated Characteristics of Viltolarsen in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.4	3.0
Mean number of emergency room encounters	0.4	0.0
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	19.9	1.9
Mean number of filled prescriptions	20.4	10.1
Mean number of generics dispensed	4.9	2.3
Mean number of unique drug classes dispensed	4.6	2.0

N/A: Not Applicable

*NaN: Not a Number

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1t. Aggregated Characteristics of Satralizumab-mwge in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	114	N/A
Demographic Characteristics		
Age (years)	55.4	14.3
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	52	45.6%
≥ 65 years	38	33.3%
Sex		
Female	94	82.5%
Male	20	17.5%
Race		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	39	34.2%
White	38	33.3%
Hispanic origin		
Yes	*****	*****
No	68	59.6%
Unknown	*****	*****
Year		
2020	12	10.5%
2021	68	59.6%
2022	34	29.8%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	24	21.1%
Heart Failure	*****	*****
Hyperlipidemia	33	28.9%
Hypertension	53	46.5%
Depression	35	30.7%

Table 1t. Aggregated Characteristics of Satralizumab-mwge in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	14	12.3%
Rheumatoid Arthritis/Osteoarthritis	19	16.7%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	23	20.2%
Anemia	36	31.6%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	17	14.9%
COPD and Bronchiectasis	12	10.5%
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	36	31.6%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	20	17.5%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

Table 1t. Aggregated Characteristics of Satralizumab-mwge in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.0	12.4
Mean number of emergency room encounters	0.8	1.5
Mean number of inpatient hospital encounters	0.7	1.3
Mean number of non-acute institutional encounters	0.2	0.5
Mean number of other ambulatory encounters	10.8	16.2
Mean number of filled prescriptions	28.8	23.6
Mean number of generics dispensed	10.8	6.7
Mean number of unique drug classes dispensed	10.1	6.0

N/A: Not Applicable

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1u. Aggregated Characteristics of Clascoterone in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	10,769	N/A
Demographic Characteristics		
Age (years)	27.7	11.6
Age		
0-17 years	2,655	24.7%
18-24 years	2,929	27.2%
25-40 years	3,569	33.1%
41-64 years	1,519	14.1%
≥ 65 years	97	0.9%
Sex		
Female	9,372	87.0%
Male	1,397	13.0%
Race		
American Indian or Alaska Native	*****	*****
Asian	179	1.7%
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	8,924	82.9%
White	1,505	14.0%
Hispanic origin		
Yes	140	1.3%
No	133	1.2%
Unknown	10,496	97.5%
Year		
2020	0	0.0%
2021	1,176	10.9%
2022	9,593	89.1%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	130	1.2%
Heart Failure	21	0.2%
Hyperlipidemia	272	2.5%
Hypertension	237	2.2%
Depression	1,573	14.6%

Table 1u. Aggregated Characteristics of Clascoterone in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	51	0.5%
Rheumatoid Arthritis/Osteoarthritis	197	1.8%
Stroke/TIA	*****	*****
Breast Cancer	40	0.4%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	247	2.3%
Anemia	435	4.0%
Asthma	167	1.6%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	56	0.5%
COPD and Bronchiectasis	14	0.1%
Glaucoma	18	0.2%
Osteoporosis	12	0.1%
Obesity: diagnosed or identified by weight management procedures	532	4.9%
Obesity: identified by weight management-related prescriptions	68	0.6%
Overweight	322	3.0%
Smoking: diagnosed or identified by smoking cessation procedures	159	1.5%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	72	0.7%
Drug Abuse or Dependence	80	0.7%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

Table 1u. Aggregated Characteristics of Clascoterone in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	8.0	9.1
Mean number of emergency room encounters	0.1	0.4
Mean number of inpatient hospital encounters	0.0	0.1
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	1.6	3.4
Mean number of filled prescriptions	7.5	8.6
Mean number of generics dispensed	3.8	3.4
Mean number of unique drug classes dispensed	3.5	3.1

N/A: Not Applicable

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1v. Aggregated Characteristics of Somapacitan-beco in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-17 years	.	.
18-24 years	.	.
25-40 years	.	.
41-64 years	.	.
≥ 65 years	.	.
Sex		
Female	.	.
Male	.	.
Race		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2020	.	.
2021	.	.
2022	.	.
Health Characteristics		
Acute Myocardial Infarction	.	.
Alzheimer's Disease and related conditions	.	.
Atrial Fibrillation	.	.
Diabetes Mellitus	.	.
Heart Failure	.	.
Hyperlipidemia	.	.
Hypertension	.	.
Depression	.	.

Table 1v. Aggregated Characteristics of Somapacitan-beco in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Ischemic Heart Disease	.	.
Rheumatoid Arthritis/Osteoarthritis	.	.
Stroke/TIA	.	.
Breast Cancer	.	.
Colorectal Cancer	.	.
Prostate Cancer	.	.
Lung Cancer	.	.
Endometrial Cancer	.	.
Acquired Hypothyroidism	.	.
Anemia	.	.
Asthma	.	.
Benign Prostatic Hyperplasia	.	.
Chronic Kidney Disease	.	.
COPD and Bronchiectasis	.	.
Glaucoma	.	.
Osteoporosis	.	.
Obesity: diagnosed or identified by weight management procedures	.	.
Obesity: identified by weight management-related prescriptions	.	.
Overweight	.	.
Smoking: diagnosed or identified by smoking cessation procedures	.	.
Smoking: identified by smoking-related prescriptions	.	.
Alcohol Abuse or Dependence	.	.
Drug Abuse or Dependence	.	.
History of Cardiac Arrest	.	.
History of Coronary Angioplasty or Bypass	.	.

Table 1v. Aggregated Characteristics of Somapacitan-beco in the SDD from January 1, 2020 to December 31, 2022

Patient Characteristics[1]	Number/Mean	Percent/ Standard Deviation[2]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Value represents standard deviation where no % follows the value.

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

N/A: Not Applicable

| | | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Capmatinib	3,915	3,863	98.7%	*****	*****	*****	*****	*****	*****
Selpercatinib	2,742	2,649	96.6%	*****	*****	*****	*****	*****	*****
Ripretinib	1,776	1,722	97.0%	*****	*****	*****	*****	0	0.0%
Fluoroestradiol-F18	217	217	100.0%	0	0.0%	0	0.0%	0	0.0%
Artesunate	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Flortaucipir-F18	0	.	.	.	.	.	.	.	.
Inebilizumab-cdon	330	*****	*****	0	0.0%	*****	*****	*****	*****
Lurbinectedin	12,922	12,922	100.0%	0	0.0%	0	0.0%	0	0.0%
Triheptanoin	494	*****	*****	*****	*****	*****	*****	0	0.0%
Remimazolam	142	142	100.0%	0	0.0%	0	0.0%	0	0.0%
Fostemsavir	5,684	5,622	98.9%	21	0.4%	41	0.7%	0	0.0%
Decitabine and Cedazuridine	7,808	7,678	98.3%	112	1.4%	*****	*****	*****	*****
Abametapir	0	.	.	.	.	.	.	.	.
Tafasitamab-cxix	10,982	10,982	100.0%	0	0.0%	0	0.0%	0	0.0%
Belantamab Mafodotin-blmf	3,894	3,894	100.0%	0	0.0%	0	0.0%	0	0.0%
Nifurtimox	0	.	.	.	.	.	.	.	.
Risdiplam	7,077	6,279	88.7%	798	11.3%	0	0.0%	0	0.0%
Oliceridine	0	.	.	.	.	.	.	.	.
Viltolarsen	169	169	100.0%	0	0.0%	0	0.0%	0	0.0%
Satralizumab-mwge	945	873	92.4%	30	3.2%	42	4.4%	0	0.0%
Clascoterone	15,217	15,112	99.3%	83	0.5%	22	0.1%	0	0.0%
Somapacitan-beco	0	.	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	3,915	1	28	28	28	93	27.0	5.6
Selpercatinib	2,742	1	30	30	30	180	28.9	9.4
Ripretinib	1,776	1	30	30	30	90	29.7	5.5
Fluoroestradiol-F18	217	1	1	1	1	1	1.0	0.0
Artesunate	*****	1	1	1	42	42	14.7	23.7
Flortaucipir-F18	0	.	.	.	.	.	.	.
Inebilizumab-cdon	330	1	1	1	1	179	4.5	20.2
Lurbinectedin	12,922	1	1	1	1	21	1.1	1.5
Triheptanoin	494	1	27	30	30	90	27.7	7.3
Remimazolam	142	1	1	1	1	1	1.0	0.0
Fostemsavir	5,684	1	30	30	30	90	29.3	7.0
Decitabine and Cedazuridine	7,808	1	28	28	28	140	26.2	7.4
Abametapir	0	.	.	.	.	.	.	.
Tafasitamab-cxix	10,982	1	1	1	1	28	1.1	1.6
Belantamab Mafodotin-blmf	3,894	1	1	1	1	28	1.0	0.9
Nifurtimox	0	.	.	.	.	.	.	.
Risdiplam	7,077	1	24	24	24	60	24.8	4.9
Oliceridine	0	.	.	.	.	.	.	.
Viltolarsen	169	1	1	1	1	21	1.1	1.5
Satralizumab-mwge	945	1	28	28	28	90	30.0	13.4
Clascoterone	15,217	1	30	30	30	90	27.9	7.1
Somapacitan-beco	0	.	.	.	.	.	.	.

*** Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

		Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Capmatinib	**3,915**	**3,863**	**100.0%**	*****	*****	*****	*****	*****	*****
Female	2,197	2,173	56.3%	*****	*****	*****	*****	*****	*****
Male	1,718	1,690	43.7%	*****	*****	*****	*****	*****	*****
Selpercatinib	**2,742**	**2,649**	**100.0%**	*****	*****	*****	*****	*****	*****
Female	1,389	1,344	50.7%	*****	*****	*****	*****	*****	*****
Male	1,353	1,305	49.3%	*****	*****	*****	*****	*****	*****
Ripretinib	**1,776**	**1,722**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
Female	744	708	41.1%	31	63.3%	*****	*****	0	NaN
Male	1,032	1,014	58.9%	18	36.7%	0	0.0%	0	NaN
Fluoroestradiol-F18	**217**	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN
Artesunate	*****	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	*****	0	0.0%	*****	*****	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Flortaucipir-F18		.	.	.	.	.	.	.	.
Female		.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.
Inebilizumab-cdon	**330**	*****	*****	**0**	**NaN**	*****	*****	*****	*****
Female	268	264	82.0%	0	NaN	*****	*****	*****	*****
Male	62	*****	*****	0	NaN	*****	*****	*****	*****
Lurbinectedin	**12,922**	**12,922**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	6,615	6,615	51.2%	0	NaN	0	NaN	0	NaN
Male	6,307	6,307	48.8%	0	NaN	0	NaN	0	NaN

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Triheptanoin	**494**	*****	*****	*****	*****	*****	*****	**0**	**NaN**
Female	238	234	48.0%	*****	*****	*****	*****	0	NaN
Male	256	253	52.0%	*****	*****	*****	*****	0	NaN
Remimazolam	**142**	**142**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	76	76	53.5%	0	NaN	0	NaN	0	NaN
Male	66	66	46.5%	0	NaN	0	NaN	0	NaN
Fostemsavir	**5,684**	**5,622**	**100.0%**	**21**	**100.0%**	**41**	**100.0%**	**0**	**NaN**
Female	873	862	15.3%	*****	*****	*****	*****	0	NaN
Male	4,811	4,760	84.7%	*****	*****	*****	*****	0	NaN
Decitabine and Cedazuridine	**7,808**	**7,678**	**100.0%**	**112**	**100.0%**	*****	*****	*****	*****
Female	2,706	2,662	34.7%	35	31.3%	*****	*****	*****	*****
Male	5,102	5,016	65.3%	77	68.8%	*****	*****	*****	*****
Abametapir		.	.	.	.	.	.	.	.
Female		.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.
Tafasitamab-cxix	**10,982**	**10,982**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	5,034	5,034	45.8%	0	NaN	0	NaN	0	NaN
Male	5,948	5,948	54.2%	0	NaN	0	NaN	0	NaN
Belantamab Mafodotin-blmf	**3,894**	**3,894**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	1,782	1,782	45.8%	0	NaN	0	NaN	0	NaN
Male	2,112	2,112	54.2%	0	NaN	0	NaN	0	NaN
Nifurtimox		.	.	.	.	.	.	.	.
Female		.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

| | | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Risdiplam	7,077	6,279	100.0%	798	100.0%	0	NaN	0	NaN
Female	3,802	3,300	52.6%	502	62.9%	0	NaN	0	NaN
Male	3,275	2,979	47.4%	296	37.1%	0	NaN	0	NaN
Oliceridine	.	.	.	.	.	.	.	.	.
Female		.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.
Viltolarsen	169	169	100.0%	0	NaN	0	NaN	0	NaN
Female	0	0	0.0%	0	NaN	0	NaN	0	NaN
Male	169	169	100.0%	0	NaN	0	NaN	0	NaN
Satralizumab-mwge	945	873	100.0%	30	100.0%	42	100.0%	0	NaN
Female	775	713	81.7%	*****	*****	*****	*****	0	NaN
Male	170	160	18.3%	*****	*****	*****	*****	0	NaN
Clascoterone	15,217	15,112	100.0%	83	100.0%	22	100.0%	0	NaN
Female	13,061	12,972	85.8%	*****	*****	*****	*****	0	NaN
Male	2,156	2,140	14.2%	*****	*****	*****	*****	0	NaN
Somapacitan-beco	.	.	.	.	.	.	.	.	.
Female		.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	**3,915**	**1**	**28**	**28**	**28**	**93**	**27.0**	**5.6**
Female	2,197	1	28	28	28	93	27.0	5.9
Male	1,718	1	28	28	28	84	27.2	5.2
Selpercatinib	**2,742**	**1**	**30**	**30**	**30**	**180**	**28.9**	**9.4**
Female	1,389	1	30	30	30	74	28.8	8.2
Male	1,353	1	30	30	30	180	28.9	10.5
Ripretinib	**1,776**	**1**	**30**	**30**	**30**	**90**	**29.7**	**5.5**
Female	744	2	30	30	30	90	30.1	6.8
Male	1,032	1	30	30	30	60	29.5	4.3
Fluoroestradiol-F18	**217**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
Artesunate	*****	**1**	**1**	**1**	**42**	**42**	**14.7**	**23.7**
Female	*****	42	42	42	42	42	42.0	NaN
Male	*****	1	1	1	1	1	1.0	0.0
Flortaucipir-F18	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Inebilizumab-cdon	**330**	**1**	**1**	**1**	**1**	**179**	**4.5**	**20.2**
Female	268	1	1	1	1	176	3.3	16.2
Male	62	1	1	1	1	179	9.6	31.7
Lurbinectedin	**12,922**	**1**	**1**	**1**	**1**	**21**	**1.1**	**1.5**
Female	6,615	1	1	1	1	21	1.1	1.6
Male	6,307	1	1	1	1	21	1.1	1.4
Triheptanoin	**494**	**1**	**27**	**30**	**30**	**90**	**27.7**	**7.3**

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	238	3	27	29	30	46	27.4	5.0
Male	256	1	27	30	30	90	28.0	9.0
Remimazolam	**142**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
Female	76	1	1	1	1	1	1.0	0.0
Male	66	1	1	1	1	1	1.0	0.0
Fostemsavir	**5,684**	**1**	**30**	**30**	**30**	**90**	**29.3**	**7.0**
Female	873	1	30	30	30	90	29.3	7.8
Male	4,811	1	30	30	30	90	29.3	6.8
Decitabine and Cedazuridine	**7,808**	**1**	**28**	**28**	**28**	**140**	**26.2**	**7.4**
Female	2,706	1	28	28	28	140	26.2	8.2
Male	5,102	1	28	28	28	84	26.3	7.0
Abametapir	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Tafasitamab-cxix	**10,982**	**1**	**1**	**1**	**1**	**28**	**1.1**	**1.6**
Female	5,034	1	1	1	1	28	1.2	2.3
Male	5,948	1	1	1	1	28	1.0	0.4
Belantamab Mafodotin-blmf	**3,894**	**1**	**1**	**1**	**1**	**28**	**1.0**	**0.9**
Female	1,782	1	1	1	1	21	1.0	0.9
Male	2,112	1	1	1	1	28	1.0	0.9
Nifurtimox	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Risdiplam	**7,077**	**1**	**24**	**24**	**24**	**60**	**24.8**	**4.9**
Female	3,802	1	24	24	24	36	25.0	5.1

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	3,275	1	24	24	24	60	24.6	4.7
Oliceridine	**0**	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Viltolarsen	**169**	**1**	**1**	**1**	**1**	**21**	**1.1**	**1.5**
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	169	1	1	1	1	21	1.1	1.5
Satralizumab-mwge	**945**	**1**	**28**	**28**	**28**	**90**	**30.0**	**13.4**
Female	775	1	28	28	28	90	30.1	14.0
Male	170	4	28	28	28	84	29.5	10.6
Clascoterone	**15,217**	**1**	**30**	**30**	**30**	**90**	**27.9**	**7.1**
Female	13,061	1	30	30	30	90	27.9	7.0
Male	2,156	1	30	30	30	90	27.9	7.6
Somapacitan-beco	**0**	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

		Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Capmatinib	**3,915**	**3,863**	**100.0%**	*****	*****	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
≥ 65 years	3,411	3,362	87.0%	*****	*****	*****	*****	*****	*****
Selpercatinib	**2,742**	**2,649**	**100.0%**	*****	*****	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	26	26	1.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	147	145	5.5%	*****	*****	0	0.0%	0	0.0%
41-64 years	1,028	990	37.4%	*****	*****	*****	*****	0	0.0%
≥ 65 years	1,541	1,488	56.2%	48	56.50%	*****	*****	*****	*****
Ripretinib	**1,776**	**1,722**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	65	65	3.8%	0	0.0%	0	0.0%	0	NaN
41-64 years	604	582	33.8%	*****	*****	0	0.0%	0	NaN
≥ 65 years	1,107	1,075	62.4%	27	55.1%	*****	*****	0	NaN
Fluoroestradiol-F18	**217**	**217**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	157	157	72.4%	0	NaN	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		**31-60 Days**		**61-90 Days**		**91+ Days**	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Artesunate	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Flortaucipir-F18	.	.	.	.	.	.	.	.	.
0-17 years	.	.	.	.	.	.	.	.	.
18-24 years	.	.	.	.	.	.	.	.	.
25-40 years	.	.	.	.	.	.	.	.	.
41-64 years	.	.	.	.	.	.	.	.	.
≥ 65 years	.	.	.	.	.	.	.	.	.
Inebilizumab-cdon	330	*****	*****	0	NaN	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	NaN	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	NaN	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	NaN	*****	*****	0	0.0%
41-64 years	161	157	48.8%	0	NaN	0	0.0%	*****	*****
≥ 65 years	116	113	35.1%	0	NaN	*****	*****	*****	*****
Lurbinectedin	12,922	12,922	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	2,708	2,708	21.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	10,178	10,178	78.8%	0	NaN	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Triheptanoin	**494**	**487**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
0-17 years	318	313	64.3%	*****	*****	*****	*****	0	NaN
18-24 years	62	62	12.7%	0	0.0%	0	0.0%	0	NaN
25-40 years	25	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	39	38	7.8%	0	0.0%	*****	*****	0	NaN
≥ 65 years	50	50	10.3%	0	0.0%	0	0.0%	0	NaN
Remimazolam	**142**	**142**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	65	65	45.8%	0	NaN	0	NaN	0	NaN
≥ 65 years	62	62	43.7%	0	NaN	0	NaN	0	NaN
Fostemsavir	**5,684**	**5,622**	**100.0%**	**21**	**100.0%**	**41**	**100.0%**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	3,734	3,699	65.8%	*****	*****	28	68.3%	0	NaN
≥ 65 years	1,501	1,474	26.2%	*****	*****	13	31.7%	0	NaN
Decitabine and Cedazuridine	**7,808**	**7,678**	**100.0%**	*****	*****	**15**	**100.0%**	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	18	18	0.2%	0	0.0%	0	0.0%	0	0.0%
41-64 years	448	439	5.7%	*****	*****	0	0.0%	0	0.0%
≥ 65 years	7,342	7,221	94.0%	103	92.0%	15	100.0%	*****	*****

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Abametapir	.	.	.	.	.	.	.	.	.
0-17 years	.	.	.	.	.	.	.	.	.
18-24 years	.	.	.	.	.	.	.	.	.
25-40 years	.	.	.	.	.	.	.	.	.
41-64 years	.	.	.	.	.	.	.	.	.
≥ 65 years	.	.	.	.	.	.	.	.	.
Tafasitamab-cxix	**10,982**	**10,982**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	14	14	0.1%	0	NaN	0	NaN	0	NaN
25-40 years	55	55	0.5%	0	NaN	0	NaN	0	NaN
41-64 years	677	677	6.2%	0	NaN	0	NaN	0	NaN
≥ 65 years	10,236	10,236	93.2%	0	NaN	0	NaN	0	NaN
Belantamab Mafodotin-blmf	**3,894**	**3,894**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	3,179	3,179	81.6%	0	NaN	0	NaN	0	NaN
Nifurtimox	.	.	.	.	.	.	.	.	.
0-17 years	.	.	.	.	.	.	.	.	.
18-24 years	.	.	.	.	.	.	.	.	.
25-40 years	.	.	.	.	.	.	.	.	.
41-64 years	.	.	.	.	.	.	.	.	.
≥ 65 years	.	.	.	.	.	.	.	.	.

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Risdiplam	**7,077**	**6,279**	**100.0%**	**798**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	1,218	1,170	18.6%	48	6.0%	0	NaN	0	NaN
18-24 years	837	813	12.9%	24	3.0%	0	NaN	0	NaN
25-40 years	2,565	2,200	35.0%	365	45.7%	0	NaN	0	NaN
41-64 years	2,139	1,835	29.2%	304	38.1%	0	NaN	0	NaN
≥ 65 years	318	261	4.2%	57	7.1%	0	NaN	0	NaN
Oliceridine	.	.	.	.	.	.	.	.	.
0-17 years	.	.	.	.	.	.	.	.	.
18-24 years	.	.	.	.	.	.	.	.	.
25-40 years	.	.	.	.	.	.	.	.	.
41-64 years	.	.	.	.	.	.	.	.	.
≥ 65 years	.	.	.	.	.	.	.	.	.
Viltolarsen	**169**	**169**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	104	104	61.5%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
Satralizumab-mwge	**945**	**873**	**100.0%**	**30**	**100.0%**	**42**	**100.0%**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	22	22	2.5%	0	0.0%	0	0.0%	0	NaN
25-40 years	149	140	16.0%	*****	*****	*****	*****	0	NaN
41-64 years	472	431	49.4%	15	50.0%	26	61.9%	0	NaN
≥ 65 years	302	280	32.1%	*****	*****	*****	*****	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

| | | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Clascoterone	**15,217**	**15,112**	**100.0%**	**83**	**100.0%**	**22**	**100.0%**	**0**	**NaN**
0-17 years	3,913	3,878	25.7%	26	31.3%	*****	*****	0	NaN
18-24 years	4,106	4,080	27.0%	19	22.9%	*****	*****	0	NaN
25-40 years	4,993	4,969	32.9%	20	24.1%	*****	*****	0	NaN
41-64 years	2,070	2,053	13.6%	*****	*****	*****	*****	0	NaN
≥ 65 years	135	132	0.9%	*****	*****	*****	*****	0	NaN
Somapacitan-beco		**.**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years		.	.	.	.	.	.	.	.
18-24 years		.	.	.	.	.	.	.	.
25-40 years		.	.	.	.	.	.	.	.
41-64 years		.	.	.	.	.	.	.	.
≥ 65 years		.	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	**3,915**	**1**	**28**	**28**	**28**	**93**	**27.0**	**5.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	14	14	28	28	28	22.4	7.2
41-64 years	*****	1	28	28	28	42	26.6	4.8
≥ 65 years	3,411	1	28	28	28	93	27.1	5.7
Selpercatinib	**2,742**	**1**	**30**	**30**	**30**	**180**	**28.9**	**9.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	26	15	15	30	30	30	23.3	7.4
25-40 years	147	4	30	30	30	45	27.4	6.5
41-64 years	1,028	1	30	30	30	90	28.3	9.1
≥ 65 years	1,541	1	30	30	30	180	29.5	9.8
Ripretinib	**1,776**	**1**	**30**	**30**	**30**	**90**	**29.7**	**5.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	65	7	30	30	30	30	28.7	4.3
41-64 years	604	2	30	30	30	60	29.7	4.9
≥ 65 years	1,107	1	30	30	30	90	29.8	5.8
Fluoroestradiol-F18	**217**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	157	1	1	1	1	1	1.0	0.0
Artesunate	*****	**1**	**1**	**1**	**42**	**42**	**14.7**	**23.7**

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	22	42	42	21.5	29.0
≥ 65 years	*****	1	1	1	1	1	1.0	NaN
Flortaucipir-F18	**0**	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Inebilizumab-cdon	**330**	**1**	**1**	**1**	**1**	**179**	**4.5**	**20.2**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	90	2.7	12.5
41-64 years	161	1	1	1	1	179	5.1	23.8
≥ 65 years	116	1	1	1	1	138	4.4	17.4
Lurbinectedin	**12,922**	**1**	**1**	**1**	**1**	**21**	**1.1**	**1.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	2,708	1	1	1	1	21	1.1	1.2
≥ 65 years	10,178	1	1	1	1	21	1.1	1.6
Triheptanoin	**494**	**1**	**27**	**30**	**30**	**90**	**27.7**	**7.3**
0-17 years	318	1	25	29	30	90	27.2	7.5

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	62	4	28	30	30	30	27.5	4.8
25-40 years	25	3	30	30	30	46	28.4	7.5
41-64 years	39	7	30	30	30	90	30.5	10.7
≥ 65 years	50	6	30	30	30	30	28.8	4.4
Remimazolam	**142**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	65	1	1	1	1	1	1.0	0.0
≥ 65 years	62	1	1	1	1	1	1.0	0.0
Fostemsavir	**5,684**	**1**	**30**	**30**	**30**	**90**	**29.3**	**7.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	30	30	30	30.0	0.0
25-40 years	*****	1	30	30	30	30	28.9	4.3
41-64 years	3,734	1	30	30	30	90	29.3	6.9
≥ 65 years	1,501	1	30	30	30	90	29.6	7.7
Decitabine and Cedazuridine	**7,808**	**1**	**28**	**28**	**28**	**140**	**26.2**	**7.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	18	7	28	28	28	30	27.1	5.0
41-64 years	448	1	28	28	28	58	25.6	7.9
≥ 65 years	7,342	1	28	28	28	140	26.3	7.4
Abametapir	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Tafasitamab-cxix	**10,982**	**1**	**1**	**1**	**1**	**28**	**1.1**	**1.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	14	1	1	1	1	1	1.0	0.0
25-40 years	55	1	1	1	1	1	1.0	0.0
41-64 years	677	1	1	1	1	28	1.1	1.2
≥ 65 years	10,236	1	1	1	1	28	1.1	1.6
Belantamab Mafodotin-blmf	**3,894**	**1**	**1**	**1**	**1**	**28**	**1.0**	**0.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	15	1.0	0.5
≥ 65 years	3,179	1	1	1	1	28	1.0	1.0
Nifurtimox	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Risdiplam	**7,077**	**1**	**24**	**24**	**24**	**60**	**24.8**	**4.9**
0-17 years	1,218	1	24	24	24	54	24.0	4.6
18-24 years	837	1	24	24	24	35	23.8	3.6
25-40 years	2,565	1	24	24	24	36	25.1	5.1

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	2,139	1	24	24	24	60	25.2	5.1
≥ 65 years	318	2	24	24	24	36	25.5	5.3
Oliceridine	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Viltolarsen	**169**	**1**	**1**	**1**	**1**	**21**	**1.1**	**1.5**
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	104	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	21	21	7.7	11.5
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Satralizumab-mwge	**945**	**1**	**28**	**28**	**28**	**90**	**30.0**	**13.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	22	14	28	28	28	28	26.8	3.4
25-40 years	149	1	28	28	28	90	28.8	11.6
41-64 years	472	3	28	28	28	90	30.8	14.6
≥ 65 years	302	1	28	28	28	84	29.4	12.8
Clascoterone	**15,217**	**1**	**30**	**30**	**30**	**90**	**27.9**	**7.1**
0-17 years	3,913	1	30	30	30	90	28.1	7.2
18-24 years	4,106	1	30	30	30	90	27.8	7.1
25-40 years	4,993	1	30	30	30	90	27.7	7.0
41-64 years	2,070	1	30	30	30	90	28.1	6.7

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	135	1	30	30	30	90	27.8	9.9
Somapacitan-beco	**0**	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3a. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Capmatinib	754	190	25.2%	211	28.0%	291	38.6%	*****	*****	*****	*****
Selpercatinib	370	78	21.1%	72	19.5%	148	40.0%	*****	*****	*****	*****
Ripretinib	311	54	17.4%	83	26.7%	137	44.1%	*****	*****	*****	*****
Fluoroestradiol-F18	205	205	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Artesunate	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Flortaucipir-F18	0	.	.	.	.	.	.	.	.	.	.
Inebilizumab-cdon	147	138	93.9%	*****	*****	*****	*****	0	0.0%	0	0.0%
Lurbinectedin	3,217	3,198	99.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
Triheptanoin	54	*****	*****	*****	*****	24	44.4%	17	31.5%	0	0.0%
Remimazolam	130	130	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Fostemsavir	595	*****	*****	87	14.6%	268	45.0%	187	31.4%	*****	*****
Decitabine and Cedazuridine	1,822	512	28.1%	549	30.1%	687	37.7%	74	4.1%	0	0.0%
Abametapir	0	.	.	.	.	.	.	.	.	.	.
Tafasitamab-cxix	942	881	93.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
Belantamab Mafodotin-blmf	1,108	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Nifurtimox	0	.	.	.	.	.	.	.	.	.	.
Risdiplam	499	*****	*****	54	10.8%	174	34.9%	239	47.9%	*****	*****
Oliceridine	0	.	.	.	.	.	.	.	.	.	.
Viltolarsen	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
Satralizumab-mwge	114	*****	*****	14	12.3%	63	55.3%	28	24.6%	*****	*****
Clascoterone	10,769	7,992	74.2%	2,375	22.1%	402	3.7%	0	0.0%	0	0.0%
Somapacitan-beco	0	.	.	.	.	.	.	.	.	.	.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	754	1	30	84	196	733	140.4	139.5
Selpercatinib	370	2	46	160	327	866	213.9	196.8
Ripretinib	311	9	60	120	240	861	169.8	156.9
Fluoroestradiol-F18	205	1	1	1	1	4	1.1	0.3
Artesunate	*****	1	1	1	42	42	14.7	23.7
Flortaucipir-F18	0	.	.	.	.	.	.	.
Inebilizumab-cdon	147	1	2	2	3	193	10.0	31.0
Lurbinectedin	3,217	1	2	3	5	152	4.5	6.8
Triheptanoin	54	4	96	208	430	707	253.5	196.1
Remimazolam	130	1	1	1	1	4	1.1	0.4
Fostemsavir	595	3	102	238	452	779	280.2	204.0
Decitabine and Cedazuridine	1,822	1	28	83	151	685	112.5	108.0
Abametapir	0	.	.	.	.	.	.	.
Tafasitamab-cxix	942	1	5	9	16	224	12.8	16.0
Belantamab Mafodotin-blmf	1,108	1	1	2	4	84	3.7	4.5
Nifurtimox	0	.	.	.	.	.	.	.
Risdiplam	499	2	144	360	539	791	351.8	212.9
Oliceridine	0	.	.	.	.	.	.	.
Viltolarsen	*****	2	8	19	21	104	27.0	34.6
Satralizumab-mwge	114	3	112	221	380	734	248.3	168.6
Clascoterone	10,769	1	30	30	35	330	39.4	28.2
Somapacitan-beco	0	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

Table 3c. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Capmatinib	**754**	**190**	**100.0%**	**211**	**100.0%**	**291**	**100.0%**	*****	*****	*****	*****
Female	416	112	58.9%	108	51.2%	159	54.6%	36	59.0%	*****	*****
Male	338	78	41.1%	103	48.8%	132	45.4%	*****	*****	0	0.0%
Selpercatinib	**370**	**78**	**100.0%**	**72**	**100.0%**	**148**	**100.0%**	*****	*****	*****	*****
Female	187	41	52.6%	38	52.8%	70	47.3%	37	53.6%	*****	*****
Male	183	37	47.4%	34	47.2%	78	52.7%	*****	*****	*****	*****
Ripretinib	**311**	**54**	**100.0%**	**83**	**100.0%**	**137**	**100.0%**	*****	*****	*****	*****
Female	142	23	42.6%	39	47.0%	68	49.6%	*****	*****	*****	*****
Male	169	31	57.4%	44	53.0%	69	50.4%	24	68.6%	*****	*****
Fluoroestradiol-F18	**205**	**205**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Artesunate	*****	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	*****	0	0.0%	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Flortaucipir-F18		.	.	.	.	.	.	.	.	.	.
Female		.	.	.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.	.	.
Inebilizumab-cdon	**147**	*****	*****	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	120	115	83.3%	*****	*****	*****	*****	0	NaN	0	NaN
Male	27	23	16.7%	*****	*****	*****	*****	0	NaN	0	NaN
Lurbinectedin	**3,217**	**3,198**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	1,623	1,614	50.5%	*****	*****	*****	*****	0	NaN	0	NaN

Table 3c. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Male	1,594	1,584	49.5%	*****	*****	*****	*****	0	NaN	0	NaN
Triheptanoin	**54**	*****	*****	*****	*****	**24**	**100.0%**	**17**	**100.0%**	**0**	**NaN**
Female	26	*****	*****	*****	*****	12	50.0%	*****	*****	0	NaN
Male	28	*****	*****	*****	*****	12	50.0%	*****	*****	0	NaN
Remimazolam	**130**	**130**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	66	66	50.8%	0	NaN	0	NaN	0	NaN	0	NaN
Male	64	64	49.2%	0	NaN	0	NaN	0	NaN	0	NaN
Fostemsavir	**595**	*****	*****	**87**	**100.0%**	**268**	**100.0%**	**187**	**100.0%**	*****	*****
Female	105	*****	*****	18	20.7%	53	19.8%	25	13.4%	0	0.0%
Male	490	40	81.6%	69	79.3%	215	80.2%	162	86.6%	*****	*****
Decitabine and Cedazuridine	**1,822**	**512**	**100.0%**	**549**	**100.0%**	**687**	**100.0%**	**74**	**100.0%**	**0**	**NaN**
Female	690	212	41.4%	214	39.0%	237	34.5%	27	36.5%	0	NaN
Male	1,132	300	58.6%	335	61.0%	450	65.5%	47	63.5%	0	NaN
Abametapir		.	.	.	.	.	.	.	.	.	.
Female		.	.	.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.	.	.
Tafasitamab-cxix	**942**	**881**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	431	397	45.1%	28	50.9%	*****	*****	0	NaN	0	NaN
Male	511	484	54.9%	*****	*****	0	0.0%	0	NaN	0	NaN
Belantamab Mafodotin-blmf	**1,108**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	511	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	597	596	53.9%	*****	*****	0	NaN	0	NaN	0	NaN
Nifurtimox		.	.	.	.	.	.	.	.	.	.

Table 3c. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female		.	.	.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.	.	.
Risdiplam	499	*****	*****	54	100.0%	174	100.0%	239	100.0%	*****	*****
Female	281	*****	*****	32	59.3%	111	63.8%	123	51.5%	*****	*****
Male	218	14	51.9%	22	40.7%	63	36.2%	116	48.5%	*****	*****
Oliceridine		.	.	.	.	.	.	.	.	.	.
Female		.	.	.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.	.	.
Viltolarsen	*****	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Female	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Satralizumab-mwge	114	*****	*****	14	100.0%	63	100.0%	28	100.0%	*****	*****
Female	94	*****	*****	*****	*****	51	81.0%	*****	*****	*****	*****
Male	20	*****	*****	*****	*****	12	19.0%	*****	*****	0	0.0%
Clascoterone	10,769	7,992	100.0%	2,375	100.0%	402	100.0%	0	NaN	0	NaN
Female	9,372	7,060	88.3%	1,985	83.6%	327	81.3%	0	NaN	0	NaN
Male	1,397	932	11.7%	390	16.4%	75	18.7%	0	NaN	0	NaN
Somapacitan-beco		.	.	.	.	.	.	.	.	.	.
Female		.	.	.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3d. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	**754**	**1**	**30**	**84**	**196**	**733**	**140.4**	**139.5**
Female	416	1	28	84	196	733	142.4	143.5
Male	338	2	43	84	196	703	138.1	134.4
Selpercatinib	**370**	**2**	**46**	**160**	**327**	**866**	**213.9**	**196.8**
Female	187	2	42	151	330	866	214.0	198.6
Male	183	5	59	165	327	860	213.9	195.5
Ripretinib	**311**	**9**	**60**	**120**	**240**	**861**	**169.8**	**156.9**
Female	142	9	60	120	224	764	157.5	141.5
Male	169	9	60	120	240	861	180.1	168.5
Fluoroestradiol-F18	**205**	**1**	**1**	**1**	**1**	**4**	**1.1**	**0.3**
Female	*****	1	1	1	1	4	1.1	0.3
Male	*****	1	1	1	1	1	1.0	0.0
Artesunate	*****	**1**	**1**	**1**	**42**	**42**	**14.7**	**23.7**
Female	*****	42	42	42	42	42	42.0	NaN
Male	*****	1	1	1	1	1	1.0	0.0
Flortaucipir-F18	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Inebilizumab-cdon	**147**	**1**	**2**	**2**	**3**	**193**	**10.0**	**31.0**
Female	120	1	2	2	3	177	7.3	24.2
Male	27	1	2	2	4	193	22.1	50.3
Lurbinectedin	**3,217**	**1**	**2**	**3**	**5**	**152**	**4.5**	**6.8**
Female	1,623	1	2	3	5	152	4.6	7.6
Male	1,594	1	2	3	5	105	4.3	6.0

Table 3d. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Triheptanoin	**54**	**4**	**96**	**208**	**430**	**707**	**253.5**	**196.1**
Female	26	21	60	214	430	707	250.7	202.8
Male	28	4	97	198	409	702	256.0	193.3
Remimazolam	**130**	**1**	**1**	**1**	**1**	**4**	**1.1**	**0.4**
Female	66	1	1	1	1	4	1.2	0.5
Male	64	1	1	1	1	2	1.0	0.2
Fostemsavir	**595**	**3**	**102**	**238**	**452**	**779**	**280.2**	**204.0**
Female	105	15	90	182	358	635	243.3	181.9
Male	490	3	107	245	460	779	288.1	207.7
Decitabine and Cedazuridine	**1,822**	**1**	**28**	**83**	**151**	**685**	**112.5**	**108.0**
Female	690	2	28	56	140	657	102.8	103.1
Male	1,132	1	28	84	168	685	118.4	110.5
Abametapir	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Tafasitamab-cxix	**942**	**1**	**5**	**9**	**16**	**224**	**12.8**	**16.0**
Female	431	1	5	9	16	224	14.2	21.4
Male	511	1	5	10	16	49	11.7	9.0
Belantamab Mafodotin-blmf	**1,108**	**1**	**1**	**2**	**4**	**84**	**3.7**	**4.5**
Female	511	1	2	3	4	84	3.6	4.6
Male	597	1	1	2	4	65	3.7	4.3
Nifurtimox	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.

Table 3d. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Risdiplam	**499**	**2**	**144**	**360**	**539**	**791**	**351.8**	**212.9**
Female	281	3	135	327	539	781	337.7	215.8
Male	218	2	192	395	538	791	369.9	208.1
Oliceridine	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Viltolarsen	*******	**2**	**8**	**19**	**21**	**104**	**27.0**	**34.6**
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	*****	2	8	19	21	104	27.0	34.6
Satralizumab-mwge	**114**	**3**	**112**	**221**	**380**	**734**	**248.3**	**168.6**
Female	94	3	111	223	354	734	247.8	171.1
Male	20	28	122	206	384	560	250.7	160.8
Clascoterone	**10,769**	**1**	**30**	**30**	**35**	**330**	**39.4**	**28.2**
Female	9,372	1	30	30	30	325	38.9	27.6
Male	1,397	1	30	30	60	330	43.1	31.8
Somapacitan-beco	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Capmatinib	**754**	**190**	**100.0%**	**211**	**100.0%**	**291**	**100.0%**	**61**	**100.0%**	**1**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	*****	13	6.8%	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	662	177	93.2%	181	85.8%	245	84.2%	*****	*****	*****	*****
Selpercatinib	**370**	**78**	**100.0%**	**72**	**100.0%**	**148**	**100.0%**	**69**	**100.0%**	**3**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	110	*****	*****	*****	*****	47	31.8%	*****	*****	*****	*****
≥ 65 years	237	61	78.2%	45	62.5%	91	61.5%	40	58.0%	0	0.0%
Ripretinib	**311**	**54**	**100.0%**	**83**	**100.0%**	**137**	**100.0%**	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	209	42	77.8%	56	67.5%	89	65.0%	21	60.0%	*****	*****
Fluoroestradiol-F18	**205**	**205**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	148	148	72.2%	0	NaN	0	NaN	0	NaN	0	NaN
Artesunate	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Flortaucipir-F18	.	.	.	.	.	.	.	.	.	.	.
0-17 years	.	.	.	.	.	.	.	.	.	.
18-24 years	.	.	.	.	.	.	.	.	.	.
25-40 years	.	.	.	.	.	.	.	.	.	.
41-64 years	.	.	.	.	.	.	.	.	.	.
≥ 65 years	.	.	.	.	.	.	.	.	.	.
Inebilizumab-cdon	147	138	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	70	66	47.8%	0	0.0%	*****	*****	0	NaN	0	NaN
≥ 65 years	54	50	36.2%	*****	*****	*****	*****	0	NaN	0	NaN
Lurbinectedin	3,217	3,198	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	696	695	21.7%	0	0.0%	*****	*****	0	NaN	0	NaN
≥ 65 years	2,511	2,493	78.0%	*****	*****	*****	*****	0	NaN	0	NaN
Triheptanoin	**54**	*****	*****	*****	*****	**24**	**100.0%**	**17**	**100.0%**	**0**	**NaN**
0-17 years	33	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
18-24 years	*****	0	0.0%	0	0.0%	*****	*****	*****	*****	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	*****	0	0.0%	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	*****	0	0.0%	0	0.0%	*****	*****	*****	*****	0	NaN
Remimazolam	**130**	**130**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	1.5%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	10.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	55	55	42.3%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	60	60	46.2%	0	NaN	0	NaN	0	NaN	0	NaN
Fostemsavir	**595**	*****	*****	**87**	**100.0%**	**268**	**100.0%**	**187**	**100.0%**	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	22	8.2%	15	8.0%	0	0.0%
41-64 years	382	28	57.1%	47	54.0%	187	69.8%	116	62.0%	*****	*****
≥ 65 years	161	15	30.6%	*****	*****	59	22.0%	56	29.9%	0	0.0%
Decitabine and Cedazuridine	**1,822**	**512**	**100.0%**	**549**	**100.0%**	**687**	**100.0%**	**74**	**100.0%**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	1,707	476	93.0%	517	94.2%	641	93.3%	*****	*****	0	NaN
Abametapir	.	.	.	.	.	.	.	.	.	.	.
0-17 years		.	.	.	.	.	.	.	.	.	.
18-24 years		.	.	.	.	.	.	.	.	.	.
25-40 years		.	.	.	.	.	.	.	.	.	.
41-64 years		.	.	.	.	.	.	.	.	.	.
≥ 65 years		.	.	.	.	.	.	.	.	.	.
Tafasitamab-cxix	942	881	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	864	807	91.6%	51	92.7%	*****	*****	0	NaN	0	NaN
Belantamab Mafodotin-blmf	1,108	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	0.3%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	20.1%	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	883	881	79.7%	*****	*****	0	NaN	0	NaN	0	NaN
Nifurtimox	.	.	.	.	.	.	.	.	.	.	.
0-17 years		.	.	.	.	.	.	.	.	.	.

Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

		Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
18-24 years		.	.	.	.	.	.	.	.	.	.
25-40 years		.	.	.	.	.	.	.	.	.	.
41-64 years		.	.	.	.	.	.	.	.	.	.
≥ 65 years		.	.	.	.	.	.	.	.	.	.
Risdiplam	499	*****	*****	54	100.0%	174	100.0%	239	100.0%	*****	*****
0-17 years	84	*****	*****	16	29.6%	22	12.6%	41	17.2%	*****	*****
18-24 years	55	*****	*****	*****	*****	*****	*****	22	9.2%	*****	*****
25-40 years	178	*****	*****	*****	*****	69	39.7%	88	36.8%	*****	*****
41-64 years	157	11	40.7%	17	31.5%	52	29.9%	77	32.2%	0	0.0%
≥ 65 years	25	*****	*****	*****	*****	*****	*****	11	4.6%	0	0.0%
Oliceridine	.	.	.	.	.	.	.	.	.	.	.
0-17 years		.	.	.	.	.	.	.	.	.	.
18-24 years		.	.	.	.	.	.	.	.	.	.
25-40 years		.	.	.	.	.	.	.	.	.	.
41-64 years		.	.	.	.	.	.	.	.	.	.
≥ 65 years		.	.	.	.	.	.	.	.	.	.
Viltolarsen	*****	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
18-24 years	*****	0	0.0%	0	NaN	*****	*****	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
Satralizumab-mwge	114	*****	*****	*****	*****	63	100.0%	28	100.0%	*****	*****

Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

		Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		**31-90 Days**		**91-365 Days**		**366-730 Days**		**731+ Days**	
	Total Number of Patients	**Number of Patients**	**Percent of Total Patients**	**Number of Patients**	**Percent of Total Patients**	**Number of Patients**	**Percent of Total Patients**	**Number of Patients**	**Percent of Total Patients**	**Number of Patients**	**Percent of Total Patients**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
25-40 years	20	0	0.0%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	52	*****	*****	*****	*****	27	42.9%	16	57.1%	*****	*****
≥ 65 years	38	*****	*****	*****	*****	21	33.3%	*****	*****	0	0.0%
Clascoterone	**10,769**	**7,992**	**100.0%**	**2,375**	**100.0%**	**402**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	2,655	1,855	23.2%	678	28.5%	122	30.3%	0	NaN	0	NaN
18-24 years	2,929	2,200	27.5%	622	26.2%	107	26.6%	0	NaN	0	NaN
25-40 years	3,569	2,698	33.8%	744	31.3%	127	31.6%	0	NaN	0	NaN
41-64 years	1,519	1,167	14.6%	309	13.0%	*****	*****	0	NaN	0	NaN
≥ 65 years	97	72	0.9%	22	0.9%	*****	*****	0	NaN	0	NaN
Somapacitan-beco		.	.	.	.	.	.	.	.	.	.
0-17 years		.	.	.	.	.	.	.	.	.	.
18-24 years		.	.	.	.	.	.	.	.	.	.
25-40 years		.	.	.	.	.	.	.	.	.	.
41-64 years		.	.	.	.	.	.	.	.	.	.
≥ 65 years		.	.	.	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	**754**	**1**	**30**	**84**	**196**	**733**	**140.4**	**139.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	84	84	112	140	140	112.0	39.6
41-64 years	*****	16	56	111	224	582	146.1	119.4
≥ 65 years	662	1	28	84	196	733	139.8	142.2
Selpercatinib	**370**	**2**	**46**	**160**	**327**	**866**	**213.9**	**196.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	19	30	60	210	228	101.0	93.0
25-40 years	*****	15	90	237	351	729	237.1	180.4
41-64 years	110	2	73	217	375	866	264.4	215.4
≥ 65 years	237	2	30	120	300	727	191.7	186.2
Ripretinib	**311**	**9**	**60**	**120**	**240**	**861**	**169.8**	**156.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	22	90	147	284	505	207.3	173.0
41-64 years	*****	12	60	120	270	861	193.1	171.4
≥ 65 years	209	9	60	120	210	764	157.8	148.7
Fluoroestradiol-F18	**205**	**1**	**1**	**1**	**1**	**4**	**1.1**	**0.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	2	1.2	0.4
41-64 years	*****	1	1	1	1	2	1.0	0.2
≥ 65 years	148	1	1	1	1	4	1.1	0.3

Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

| | Total Number of Patients | Distribution of Cumulative Treatment Episode Duration, days | | | | | | |
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Artesunate	*****	1	1	1	42	42	14.7	23.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	22	42	42	21.5	29.0
≥ 65 years	*****	1	1	1	1	1	1.0	NaN
Flortaucipir-F18	0	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Inebilizumab-cdon	147	1	2	2	3	193	10.0	31.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	2	2	3	90	6.7	19.1
41-64 years	70	1	2	2	3	193	11.8	37.6
≥ 65 years	54	1	2	2	3	140	9.4	25.6
Lurbinectedin	3,217	1	2	3	5	152	4.5	6.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	4	6	6	3.5	3.5
25-40 years	*****	1	2	4	6	7	3.6	2.3
41-64 years	696	1	2	3	5	126	4.2	6.0
≥ 65 years	2,511	1	2	3	5	152	4.6	7.1

Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Triheptanoin	**54**	**4**	**96**	**208**	**430**	**707**	**253.5**	**196.1**
0-17 years	33	4	107	225	383	702	261.9	186.7
18-24 years	*****	214	249	392	604	707	426.0	223.5
25-40 years	*****	21	30	30	123	430	101.4	149.0
41-64 years	*****	60	97	150	240	494	198.5	157.0
≥ 65 years	*****	96	177	347	542	649	359.5	237.5
Remimazolam	**130**	**1**	**1**	**1**	**1**	**4**	**1.1**	**0.4**
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	55	1	1	1	1	4	1.2	0.6
≥ 65 years	60	1	1	1	1	2	1.0	0.2
Fostemsavir	**595**	**3**	**102**	**238**	**452**	**779**	**280.2**	**204.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	60	60	60	60	60	60.0	NaN
25-40 years	*****	15	84	177	441	680	252.9	192.0
41-64 years	382	8	120	255	450	779	286.1	202.2
≥ 65 years	161	3	90	219	472	697	276.2	212.0
Decitabine and Cedazuridine	**1,822**	**1**	**28**	**83**	**151**	**685**	**112.5**	**108.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	28	28	56	112	121	69.6	43.7
41-64 years	*****	3	28	81	168	445	106.0	93.5
≥ 65 years	1,707	1	28	84	151	685	113.1	109.0

Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Abametapir	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Tafasitamab-cxix	**942**	**1**	**5**	**9**	**16**	**224**	**12.8**	**16.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	7	13	13	7.0	8.5
25-40 years	*****	15	15	17	23	23	18.3	4.2
41-64 years	*****	1	3	7	12	49	9.8	10.3
≥ 65 years	864	1	5	10	16	224	13.1	16.4
Belantamab Mafodotin-blmf	**1,108**	**1**	**1**	**2**	**4**	**84**	**3.7**	**4.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	2	4	27	3.3	3.2
≥ 65 years	883	1	1	2	4	84	3.8	4.7
Nifurtimox	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.

Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Risdiplam	**499**	**2**	**144**	**360**	**539**	**791**	**351.8**	**212.9**
0-17 years	84	15	95	365	574	745	348.6	232.6
18-24 years	55	3	189	334	546	791	362.3	221.7
25-40 years	178	2	168	365	539	781	361.9	204.2
41-64 years	157	3	120	360	533	701	342.7	211.4
≥ 65 years	25	15	120	323	507	638	323.9	204.9
Oliceridine	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Viltolarsen	*****	**2**	**8**	**19**	**21**	**104**	**27.0**	**34.6**
0-17 years	*****	8	12	18	19	19	15.5	5.2
18-24 years	*****	104	104	104	104	104	104.0	NaN
25-40 years	*****	2	2	12	21	21	11.5	13.4
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Satralizumab-mwge	**114**	**3**	**112**	**221**	**380**	**734**	**248.3**	**168.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	28	81	148	214	266	147.5	97.8
25-40 years	*****	56	94	204	281	560	214.7	144.8
41-64 years	52	28	124	240	444	734	280.0	186.3
≥ 65 years	38	3	111	219	336	531	233.3	155.3

Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Clascoterone	**10,769**	**1**	**30**	**30**	**35**	**330**	**39.4**	**28.2**
0-17 years	2,655	1	30	30	60	288	41.5	29.3
18-24 years	2,929	1	30	30	30	270	39.0	27.5
25-40 years	3,569	1	30	30	30	325	38.7	28.1
41-64 years	1,519	1	30	30	30	330	38.2	27.7
≥ 65 years	97	1	30	30	31	218	38.7	28.7
Somapacitan-beco	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Capmatinib	1,698	986	58.1%	428	25.2%	271	16.0%	*****	*****	*****	*****
Selpercatinib	1,034	572	55.3%	278	26.9%	153	14.8%	31	3.0%	0	0.0%
Ripretinib	783	433	55.3%	222	28.4%	*****	*****	*****	*****	0	0.0%
Fluoroestradiol-F18	217	217	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Artesunate	*****	*****	*****	*****	33.3%	0	0.0%	0	0.0%	0	0.0%
Flortaucipir-F18	0	.	.	.	.	.	.	.	.	.	.
Inebilizumab-cdon	326	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Lurbinectedin	12,874	12,857	99.9%	17	0.1%	0	0.0%	0	0.0%	0	0.0%
Triheptanoin	162	83	51.2%	42	25.9%	*****	*****	*****	*****	0	0.0%
Remimazolam	142	142	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Fostemsavir	1,641	824	50.2%	364	22.2%	357	21.8%	*****	*****	*****	*****
Decitabine and Cedazuridine	4,943	3,479	70.4%	1,139	23.0%	*****	*****	*****	*****	0	0.0%
Abametapir	0	.	.	.	.	.	.	.	.	.	.
Tafasitamab-cxix	10,936	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Belantamab Mafodotin-blmf	3,888	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Nifurtimox	0	.	.	.	.	.	.	.	.	.	.
Risdiplam	1,399	497	35.5%	376	26.9%	392	28.0%	*****	*****	*****	*****
Oliceridine	0	.	.	.	.	.	.	.	.	.	.
Viltolarsen	169	169	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Satralizumab-mwge	337	154	45.7%	98	29.1%	74	22.0%	11	3.3%	0	0.0%
Clascoterone	14,177	13,409	94.6%	683	4.8%	85	0.6%	0	0.0%	0	0.0%
Somapacitan-beco	0	.	.	.	.	.	.	.	.	.	.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	1,698	1	28	28	65	733	62.4	71.4
Selpercatinib	1,034	1	30	30	84	729	76.6	102.7
Ripretinib	783	2	30	30	90	706	67.4	72.3
Fluoroestradiol-F18	217	1	1	1	1	1	1.0	0.0
Artesunate	*****	1	1	1	42	42	14.7	23.7
Flortaucipir-F18	0	.	.	.	.	.	.	.
Inebilizumab-cdon	326	1	1	1	1	193	4.5	20.7
Lurbinectedin	12,874	1	1	1	1	84	1.1	2.2
Triheptanoin	162	1	30	30	88	707	84.5	115.9
Remimazolam	142	1	1	1	1	1	1.0	0.0
Fostemsavir	1,641	1	30	30	120	755	101.6	132.5
Decitabine and Cedazuridine	4,943	1	28	28	56	532	41.5	39.5
Abametapir	0	.	.	.	.	.	.	.
Tafasitamab-cxix	10,936	1	1	1	1	196	1.1	3.0
Belantamab Mafodotin-blmf	3,888	1	1	1	1	65	1.0	1.3
Nifurtimox	0	.	.	.	.	.	.	.
Risdiplam	1,399	1	24	48	144	791	125.5	159.7
Oliceridine	0	.	.	.	.	.	.	.
Viltolarsen	169	1	1	1	1	21	1.1	1.5
Satralizumab-mwge	337	1	28	56	100	532	84.0	95.8
Clascoterone	14,177	1	30	30	30	321	29.9	14.1
Somapacitan-beco	0	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

| | | Number of Treatment Episodes by Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Capmatinib	1,698	986	100.0%	428	100.0%	271	100.0%	*****	*****	*****	*****
Female	931	536	54.4%	245	57.2%	139	51.3%	*****	*****	*****	*****
Male	767	450	45.6%	183	42.8%	132	48.7%	*****	*****	0	0.0%
Selpercatinib	1,034	572	100.0%	278	100.0%	153	100.0%	31	100.0%	0	NaN
Female	497	267	46.7%	132	47.5%	82	53.6%	16	51.6%	0	NaN
Male	537	305	53.3%	146	52.5%	71	46.4%	15	48.4%	0	NaN
Ripretinib	783	433	100.0%	222	100.0%	*****	*****	*****	*****	0	NaN
Female	380	224	51.7%	105	47.3%	*****	*****	0	0.0%	0	NaN
Male	403	209	48.3%	117	52.7%	70	57.9%	*****	*****	0	NaN
Fluoroestradiol-F18	217	217	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Artesunate	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	*****	0	0.0%	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Flortaucipir-F18		.	.	.	.	.	.	.	.	.	.
Female		.	.	.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.	.	.
Inebilizumab-cdon	326	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	266	262	82.4%	*****	*****	*****	*****	0	NaN	0	NaN
Male	60	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Lurbinectedin	12,874	12,857	100.0%	17	100.0%	0	NaN	0	NaN	0	NaN
Female	6,588	6,580	51.2%	*****	*****	0	NaN	0	NaN	0	NaN

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	6,286	6,277	48.8%	*****	*****	0	NaN	0	NaN	0	NaN
Triheptanoin	**162**	**83**	**100.0%**	**42**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
Female	70	31	37.3%	21	50.0%	15	50.0%	*****	*****	0	NaN
Male	92	52	62.7%	21	50.0%	*****	*****	*****	*****	0	NaN
Remimazolam	**142**	**142**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	76	76	53.5%	0	NaN	0	NaN	0	NaN	0	NaN
Male	66	66	46.5%	0	NaN	0	NaN	0	NaN	0	NaN
Fostemsavir	**1,641**	**824**	**100.0%**	**364**	**100.0%**	**357**	**100.0%**	*****	*****	*****	*****
Female	317	168	20.4%	80	22.0%	62	17.4%	*****	*****	0	0.0%
Male	1,324	656	79.6%	284	78.0%	295	82.6%	87	92.6%	*****	*****
Decitabine and Cedazuridine	**4,943**	**3,479**	**100.0%**	**1,139**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
Female	1,811	1,318	37.9%	401	35.2%	*****	*****	*****	*****	0	NaN
Male	3,132	2,161	62.1%	738	64.8%	232	72.3%	*****	*****	0	NaN
Abametapir		.	.	.	.	.	.	.	.	.	.
Female		.	.	.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.	.	.
Tafasitamab-cxix	**10,936**	*****	*****	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	4,991	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	5,945	5,944	54.4%	*****	*****	0	0.0%	0	NaN	0	NaN
Belantamab Mafodotin-blmf	**3,888**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	1,780	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	2,108	2,107	54.2%	*****	*****	0	NaN	0	NaN	0	NaN
Nifurtimox		.	.	.	.	.	.	.	.	.	.

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

| | | Number of Treatment Episodes by Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Female		.	.	.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.	.	.
Risdiplam	**1,399**	**497**	**100.0%**	**376**	**100.0%**	**392**	**100.0%**	*****	*****	*****	*****
Female	747	245	49.3%	210	55.9%	227	57.9%	*****	*****	*****	*****
Male	652	252	50.7%	166	44.1%	165	42.1%	67	51.1%	*****	*****
Oliceridine		.	.	.	.	.	.	.	.	.	.
Female		.	.	.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.	.	.
Viltolarsen	**169**	**169**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	169	169	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Satralizumab-mwge	**337**	**154**	**100.0%**	**98**	**100.0%**	**74**	**100.0%**	*****	*****	**0**	**NaN**
Female	273	120	77.9%	81	82.7%	*****	*****	*****	*****	0	NaN
Male	64	34	22.1%	17	17.3%	*****	*****	*****	*****	0	NaN
Clascoterone	**14,177**	**13,409**	**100.0%**	**683**	**100.0%**	**85**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	12,215	11,585	86.4%	566	82.9%	64	75.3%	0	NaN	0	NaN
Male	1,962	1,824	13.6%	117	17.1%	21	24.7%	0	NaN	0	NaN
Somapacitan-beco		.	.	.	.	.	.	.	.	.	.
Female		.	.	.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	**1,698**	**1**	**28**	**28**	**65**	**733**	**62.4**	**71.4**
Female	931	1	28	28	56	733	63.6	78.0
Male	767	1	28	28	78	450	60.9	62.4
Selpercatinib	**1,034**	**1**	**30**	**30**	**84**	**729**	**76.6**	**102.7**
Female	497	2	30	30	90	729	80.5	110.4
Male	537	1	30	30	71	665	72.9	94.9
Ripretinib	**783**	**2**	**30**	**30**	**90**	**706**	**67.4**	**72.3**
Female	380	2	30	30	60	344	58.8	55.3
Male	403	3	30	30	90	706	75.5	84.6
Fluoroestradiol-F18	**217**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
Artesunate	*****	**1**	**1**	**1**	**42**	**42**	**14.7**	**23.7**
Female	*****	42	42	42	42	42	42.0	NaN
Male	*****	1	1	1	1	1	1.0	0.0
Flortaucipir-F18	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Inebilizumab-cdon	**326**	**1**	**1**	**1**	**1**	**193**	**4.5**	**20.7**
Female	266	1	1	1	1	176	3.3	16.3
Male	60	1	1	1	1	193	10.0	33.5
Lurbinectedin	**12,874**	**1**	**1**	**1**	**1**	**84**	**1.1**	**2.2**
Female	6,588	1	1	1	1	84	1.1	2.2
Male	6,286	1	1	1	1	81	1.1	2.1

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Triheptanoin	**162**	**1**	**30**	**30**	**88**	**707**	**84.5**	**115.9**
Female	70	11	30	48	96	707	93.1	123.0
Male	92	1	30	30	72	702	77.9	110.4
Remimazolam	**142**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
Female	76	1	1	1	1	1	1.0	0.0
Male	66	1	1	1	1	1	1.0	0.0
Fostemsavir	**1,641**	**1**	**30**	**30**	**120**	**755**	**101.6**	**132.5**
Female	317	1	30	30	90	590	80.6	96.3
Male	1,324	1	30	38	120	755	106.6	139.3
Decitabine and Cedazuridine	**4,943**	**1**	**28**	**28**	**56**	**532**	**41.5**	**39.5**
Female	1,811	1	28	28	46	532	39.2	37.4
Male	3,132	1	28	28	56	504	42.8	40.6
Abametapir	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Tafasitamab-cxix	**10,936**	**1**	**1**	**1**	**1**	**196**	**1.1**	**3.0**
Female	4,991	1	1	1	1	196	1.2	4.4
Male	5,945	1	1	1	1	44	1.0	0.6
Belantamab Mafodotin-blmf	**3,888**	**1**	**1**	**1**	**1**	**65**	**1.0**	**1.3**
Female	1,780	1	1	1	1	42	1.0	1.2
Male	2,108	1	1	1	1	65	1.0	1.4
Nifurtimox	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Risdiplam	**1,399**	**1**	**24**	**48**	**144**	**791**	**125.5**	**159.7**
Female	747	2	24	48	158	733	127.0	159.4
Male	652	1	24	48	144	791	123.7	160.1
Oliceridine	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Viltolarsen	**169**	**1**	**1**	**1**	**1**	**21**	**1.1**	**1.5**
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	169	1	1	1	1	21	1.1	1.5
Satralizumab-mwge	**337**	**1**	**28**	**56**	**100**	**532**	**84.0**	**95.8**
Female	273	1	28	56	109	532	85.3	93.6
Male	64	18	28	30	56	519	78.3	105.2
Clascoterone	**14,177**	**1**	**30**	**30**	**30**	**321**	**29.9**	**14.1**
Female	12,215	1	30	30	30	321	29.8	13.7
Male	1,962	1	30	30	30	270	30.7	16.2
Somapacitan-beco	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Capmatinib	**1,698**	**986**	**100.0%**	**428**	**100.0%**	**271**	**100.0%**	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	*****	*****	33	12.2%	*****	*****	0	0.0%
≥ 65 years	1,473	849	86.1%	375	87.6%	238	87.8%	*****	*****	*****	*****
Selpercatinib	**1,034**	**572**	**100.0%**	**278**	**100.0%**	**153**	**100.0%**	**31**	**100.0%**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	17	16	2.8%	0	0.0%	*****	*****	0	0.0%	0	NaN
25-40 years	60	41	7.2%	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	326	162	28.3%	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	631	353	61.7%	175	62.9%	88	57.5%	15	48.4%	0	NaN
Ripretinib	**783**	**433**	**100.0%**	**222**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	30	17	3.9%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	248	134	30.9%	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	505	282	65.1%	149	67.1%	69	57.0%	*****	*****	0	NaN
Fluoroestradiol-F18	**217**	**217**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	157	157	72.4%	0	NaN	0	NaN	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

| | | Number of Treatment Episodes by Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Artesunate	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	50.0%	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	50.0%	0	0.0%	0	NaN	0	NaN	0	NaN
Flortaucipir-F18	.	.	.	.	.	.	.	.	.	.	.
0-17 years	.	.	.	.	.	.	.	.	.	.	.
18-24 years	.	.	.	.	.	.	.	.	.	.	.
25-40 years	.	.	.	.	.	.	.	.	.	.	.
41-64 years	.	.	.	.	.	.	.	.	.	.	.
≥ 65 years	.	.	.	.	.	.	.	.	.	.	.
Inebilizumab-cdon	326	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	160	156	49.1%	0	0.0%	*****	*****	0	NaN	0	NaN
≥ 65 years	113	110	34.6%	*****	*****	*****	*****	0	NaN	0	NaN
Lurbinectedin	12,874	12,857	100.0%	17	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	2,705	2,704	21.0%	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	10,133	10,117	78.7%	*****	*****	0	NaN	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

		Number of Treatment Episodes by Duration								
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Triheptanoin	162	83	100.0%	42	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	107	50	60.2%	32	76.2%	22	73.3%	*****	*****	0	NaN
18-24 years	18	14	16.9%	*****	*****	0	0.0%	*****	*****	0	NaN
25-40 years	14	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	12	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	11	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Remimazolam	142	142	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	65	65	45.8%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	62	62	43.7%	0	NaN	0	NaN	0	NaN	0	NaN
Fostemsavir	1,641	824	100.0%	364	100.0%	357	100.0%	94	100.0%	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	35	9.6%	22	6.2%	*****	*****	0	0.0%
41-64 years	1,078	533	64.7%	246	67.6%	241	67.5%	56	59.6%	*****	*****
≥ 65 years	404	197	23.9%	83	22.8%	94	26.3%	*****	*****	0	0.0%
Decitabine and Cedazuridine	4,943	3,479	100.0%	1,139	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	4,658	3,282	94.3%	1,071	94.0%	301	93.8%	*****	*****	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Abametapir	.	.	.	.	.	.	.	.	.	.	.
0-17 years		.	.	.	.	.	.	.	.	.	.
18-24 years		.	.	.	.	.	.	.	.	.	.
25-40 years		.	.	.	.	.	.	.	.	.	.
41-64 years		.	.	.	.	.	.	.	.	.	.
≥ 65 years		.	.	.	.	.	.	.	.	.	.
Tafasitamab-cxix	10,936	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	55	55	0.5%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	674	673	6.2%	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	10,193	10,184	93.2%	*****	*****	*****	*****	0	NaN	0	NaN
Belantamab Mafodotin-blmf	3,888	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	3,173	3,171	81.6%	*****	*****	0	NaN	0	NaN	0	NaN
Nifurtimox	.	.	.	.	.	.	.	.	.	.	.
0-17 years		.	.	.	.	.	.	.	.	.	.
18-24 years		.	.	.	.	.	.	.	.	.	.
25-40 years		.	.	.	.	.	.	.	.	.	.
41-64 years		.	.	.	.	.	.	.	.	.	.
≥ 65 years		.	.	.	.	.	.	.	.	.	.

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

| | | Number of Treatment Episodes by Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Risdiplam	1,399	497	100.0%	376	100.0%	392	100.0%	*****	*****	*****	*****
0-17 years	222	77	15.5%	59	15.7%	64	16.3%	22	16.8%	0	0.0%
18-24 years	131	43	8.7%	31	8.2%	38	9.7%	*****	*****	*****	*****
25-40 years	548	205	41.2%	146	38.8%	149	38.0%	48	36.6%	0	0.0%
41-64 years	438	155	31.2%	123	32.7%	121	30.9%	39	29.8%	0	0.0%
≥ 65 years	60	17	3.4%	17	4.5%	20	5.1%	*****	*****	0	0.0%
Oliceridine	.	.	.	.	.	.	.	.	.	.	.
0-17 years		.	.	.	.	.	.	.	.	.	.
18-24 years		.	.	.	.	.	.	.	.	.	.
25-40 years		.	.	.	.	.	.	.	.	.	.
41-64 years		.	.	.	.	.	.	.	.	.	.
≥ 65 years		.	.	.	.	.	.	.	.	.	.
Viltolarsen	169	169	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	104	104	61.5%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Satralizumab-mwge	337	154	100.0%	98	100.0%	74	100.0%	11	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
25-40 years	*****	*****	*****	17	17.3%	*****	*****	0	0.0%	0	NaN
41-64 years	175	80	51.9%	53	54.1%	35	47.3%	*****	*****	0	NaN
≥ 65 years	98	43	27.9%	28	28.6%	23	31.1%	*****	*****	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

| | | Number of Treatment Episodes by Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Clascoterone	14,177	13,409	100.0%	683	100.0%	85	100.0%	0	NaN	0	NaN
0-17 years	3,618	3,402	25.4%	188	27.5%	28	32.9%	0	NaN	0	NaN
18-24 years	3,832	3,629	27.1%	181	26.5%	*****	*****	0	NaN	0	NaN
25-40 years	4,658	4,417	32.9%	216	31.6%	25	29.4%	0	NaN	0	NaN
41-64 years	1,942	1,843	13.7%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	127	118	0.9%	*****	*****	*****	*****	0	NaN	0	NaN
Somapacitan-beco	.	.	.	.	.	.	.	.	.	.	.
0-17 years		.	.	.	.	.	.	.	.	.	.
18-24 years		.	.	.	.	.	.	.	.	.	.
25-40 years		.	.	.	.	.	.	.	.	.	.
41-64 years		.	.	.	.	.	.	.	.	.	.
≥ 65 years		.	.	.	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	**1,698**	**1**	**28**	**28**	**65**	**733**	**62.4**	**71.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	14	14	28	28	56	24.9	13.6
41-64 years	*****	3	28	28	57	560	60.9	70.4
≥ 65 years	1,473	1	28	28	70	733	62.8	71.7
Selpercatinib	**1,034**	**1**	**30**	**30**	**84**	**729**	**76.6**	**102.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	17	15	19	30	30	198	35.6	42.4
25-40 years	60	13	28	30	60	729	67.2	107.2
41-64 years	326	2	30	35	90	689	89.2	116.7
≥ 65 years	631	1	30	30	63	690	72.0	94.7
Ripretinib	**783**	**2**	**30**	**30**	**90**	**706**	**67.4**	**72.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	30	18	30	30	90	270	62.2	57.5
41-64 years	248	3	30	30	81	464	72.4	77.1
≥ 65 years	505	2	30	30	90	706	65.3	70.6
Fluoroestradiol-F18	**217**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	157	1	1	1	1	1	1.0	0.0
Artesunate	*****	**1**	**1**	**1**	**42**	**42**	**14.7**	**23.7**

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	22	42	42	21.5	29.0
≥ 65 years	*****	1	1	1	1	1	1.0	NaN
Flortaucipir-F18	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Inebilizumab-cdon	**326**	**1**	**1**	**1**	**1**	**193**	**4.5**	**20.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	90	2.7	12.5
41-64 years	160	1	1	1	1	193	5.2	24.5
≥ 65 years	113	1	1	1	1	138	4.5	17.8
Lurbinectedin	**12,874**	**1**	**1**	**1**	**1**	**84**	**1.1**	**2.2**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	2,705	1	1	1	1	84	1.1	1.8
≥ 65 years	10,133	1	1	1	1	81	1.1	2.2
Triheptanoin	**162**	**1**	**30**	**30**	**88**	**707**	**84.5**	**115.9**
0-17 years	107	1	29	34	88	702	80.8	100.9

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	18	4	30	30	30	707	94.7	188.9
25-40 years	14	11	30	30	59	180	50.7	46.1
41-64 years	12	30	30	60	94	494	99.3	129.9
≥ 65 years	11	6	30	60	228	435	130.7	147.2
Remimazolam	**142**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	65	1	1	1	1	1	1.0	0.0
≥ 65 years	62	1	1	1	1	1	1.0	0.0
Fostemsavir	**1,641**	**1**	**30**	**30**	**120**	**755**	**101.6**	**132.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	30	30	30	30.0	0.0
25-40 years	*****	10	30	30	90	635	82.1	113.0
41-64 years	1,078	1	30	38	120	755	101.4	131.7
≥ 65 years	404	1	30	41	120	697	110.1	140.9
Decitabine and Cedazuridine	**4,943**	**1**	**28**	**28**	**56**	**532**	**41.5**	**39.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	7	28	43	56	114	48.7	31.7
41-64 years	*****	1	28	28	56	329	41.6	43.4
≥ 65 years	4,658	1	28	28	56	532	41.4	39.3
Abametapir	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Tafasitamab-cxix	**10,936**	**1**	**1**	**1**	**1**	**196**	**1.1**	**3.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	14	1	1	1	1	1	1.0	0.0
25-40 years	55	1	1	1	1	1	1.0	0.0
41-64 years	674	1	1	1	1	44	1.1	1.7
≥ 65 years	10,193	1	1	1	1	196	1.1	3.0
Belantamab Mafodotin-blmf	**3,888**	**1**	**1**	**1**	**1**	**65**	**1.0**	**1.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	15	1.0	0.5
≥ 65 years	3,173	1	1	1	1	65	1.0	1.4
Nifurtimox	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Risdiplam	**1,399**	**1**	**24**	**48**	**144**	**791**	**125.5**	**159.7**
0-17 years	222	5	24	60	168	714	131.9	161.1
18-24 years	131	1	24	48	216	791	152.1	192.8
25-40 years	548	1	24	48	144	724	117.6	153.0

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	438	2	24	48	144	673	122.8	156.1
≥ 65 years	60	2	24	72	170	638	135.0	158.2
Oliceridine	**0**	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Viltolarsen	**169**	**1**	**1**	**1**	**1**	**21**	**1.1**	**1.5**
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	104	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	21	21	7.7	11.5
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Satralizumab-mwge	**337**	**1**	**28**	**56**	**100**	**532**	**84.0**	**95.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	28	28	28	162	182	84.3	71.6
25-40 years	*****	1	28	55	84	336	75.3	76.9
41-64 years	175	4	28	56	90	532	83.2	100.0
≥ 65 years	98	3	28	49	112	454	90.5	100.0
Clascoterone	**14,177**	**1**	**30**	**30**	**30**	**321**	**29.9**	**14.1**
0-17 years	3,618	1	30	30	30	270	30.4	14.7
18-24 years	3,832	1	30	30	30	240	29.8	13.5
25-40 years	4,658	1	30	30	30	321	29.7	14.3
41-64 years	1,942	1	30	30	30	270	29.9	13.2

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

| | Total Number of Episodes | Distribution of Treatment Episode Durations, days | | | | | | |
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	127	1	30	30	30	120	29.6	14.5
Somapacitan-beco	**0**	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Capmatinib	754	412	54.6%	190	25.2%	140	18.6%	*****	*****	*****	*****
Selpercatinib	370	198	53.5%	92	24.9%	61	16.5%	19	5.1%	0	0.0%
Ripretinib	311	152	48.9%	94	30.2%	*****	*****	*****	*****	0	0.0%
Fluoroestradiol-F18	205	205	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Artesunate	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Flortaucipir-F18	0	.	.	.	.	.	.	.	.	.	.
Inebilizumab-cdon	147	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Lurbinectedin	3,217	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Triheptanoin	54	22	40.7%	*****	*****	13	24.1%	*****	*****	0	0.0%
Remimazolam	130	130	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Fostemsavir	595	241	40.5%	119	20.0%	166	27.9%	*****	*****	*****	*****
Decitabine and Cedazuridine	1,822	1,181	64.8%	488	26.8%	*****	*****	*****	*****	0	0.0%
Abametapir	0	.	.	.	.	.	.	.	.	.	.
Tafasitamab-cxix	942	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Belantamab Mafodotin-blmf	1,108	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Nifurtimox	0	.	.	.	.	.	.	.	.	.	.
Risdiplam	499	*****	*****	97	19.4%	194	38.9%	112	22.4%	*****	*****
Oliceridine	0	.	.	.	.	.	.	.	.	.	.
Viltolarsen	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Satralizumab-mwge	114	42	36.8%	*****	*****	34	29.8%	*****	*****	0	0.0%
Clascoterone	10,769	10,219	94.9%	490	4.6%	60	0.6%	0	0.0%	0	0.0%
Somapacitan-beco	0	.	.	.	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	754	1	28	28	84	733	70.7	85.1
Selpercatinib	370	2	30	30	90	729	93.3	128.3
Ripretinib	311	9	30	45	90	706	78.3	84.7
Fluoroestradiol-F18	205	1	1	1	1	1	1.0	0.0
Artesunate	*****	1	1	1	42	42	14.7	23.7
Flortaucipir-F18	0	.	.	.	.	.	.	.
Inebilizumab-cdon	147	1	1	1	1	193	4.5	19.9
Lurbinectedin	3,217	1	1	1	1	63	1.2	2.5
Triheptanoin	54	4	30	58	142	707	128.1	167.9
Remimazolam	130	1	1	1	1	1	1.0	0.0
Fostemsavir	595	3	30	60	163	755	142.7	172.7
Decitabine and Cedazuridine	1,822	1	28	28	56	532	45.6	45.0
Abametapir	0	.	.	.	.	.	.	.
Tafasitamab-cxix	942	1	1	1	1	140	1.4	5.6
Belantamab Mafodotin-blmf	1,108	1	1	1	1	65	1.1	2.3
Nifurtimox	0	.	.	.	.	.	.	.
Risdiplam	499	2	48	144	350	791	221.8	206.8
Oliceridine	0	.	.	.	.	.	.	.
Viltolarsen	*****	1	1	1	1	21	3.9	7.6
Satralizumab-mwge	114	3	28	56	126	519	105.8	113.8
Clascoterone	10,769	1	30	30	30	321	30.0	13.9
Somapacitan-beco	0	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Capmatinib	**754**	**412**	**100.0%**	**190**	**100.0%**	**140**	**100.0%**	*****	*****	*****	*****
Female	416	237	57.5%	97	51.1%	72	51.4%	*****	*****	*****	*****
Male	338	175	42.5%	93	48.9%	68	48.6%	*****	*****	0	0.0%
Selpercatinib	**370**	**198**	**100.0%**	**92**	**100.0%**	**61**	**100.0%**	**19**	**100.0%**	**0**	**NaN**
Female	187	100	50.5%	41	44.6%	32	52.5%	*****	*****	0	NaN
Male	183	98	49.5%	51	55.4%	29	47.5%	*****	*****	0	NaN
Ripretinib	**311**	**152**	**100.0%**	**94**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
Female	142	73	48.0%	44	46.8%	*****	*****	0	0.0%	0	NaN
Male	169	79	52.0%	50	53.2%	34	57.6%	*****	*****	0	NaN
Fluoroestradiol-F18	**205**	**205**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Artesunate	*****	*****	*****	**1**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	*****	0	0.0%	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Flortaucipir-F18		.	.	.	.	.	.	.	.	.	.
Female		.	.	.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.	.	.
Inebilizumab-cdon	**147**	*****	*****	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	120	118	81.9%	*****	*****	*****	*****	0	NaN	0	NaN
Male	27	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
Lurbinectedin	**3,217**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	1,623	1,622	50.5%	*****	*****	0	NaN	0	NaN	0	NaN

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

| | Total Number of Patients | Number of Patients by First Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Male	1,594	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Triheptanoin	**54**	**22**	**100.0%**	*****	*****	**13**	**100.0%**	*****	*****	**0**	**NaN**
Female	26	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	28	12	54.5%	*****	*****	*****	*****	*****	*****	0	NaN
Remimazolam	**130**	**130**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	66	66	50.8%	0	NaN	0	NaN	0	NaN	0	NaN
Male	64	64	49.2%	0	NaN	0	NaN	0	NaN	0	NaN
Fostemsavir	**595**	**241**	**100.0%**	**119**	**100.0%**	**166**	**100.0%**	*****	*****	*****	*****
Female	105	49	20.3%	25	21.0%	28	16.9%	*****	*****	0	0.0%
Male	490	192	79.7%	94	79.0%	138	83.1%	*****	*****	*****	*****
Decitabine and Cedazuridine	**1,822**	**1,181**	**100.0%**	**488**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
Female	690	457	38.7%	188	38.5%	*****	*****	*****	*****	0	NaN
Male	1,132	724	61.3%	300	61.5%	107	71.8%	*****	*****	0	NaN
Abametapir		.	.	.	.	.	.	.	.	.	.
Female		.	.	.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.	.	.
Tafasitamab-cxix	**942**	*****	*****	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	431	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	511	510	54.4%	*****	*****	0	0.0%	0	NaN	0	NaN
Belantamab Mafodotin-blmf	**1,108**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	511	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	597	596	53.9%	*****	*****	0	NaN	0	NaN	0	NaN
Nifurtimox		.	.	.	.	.	.	.	.	.	.

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

| | | Number of Patients by First Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female		.	.	.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.	.	.
Risdiplam	**499**	*****	*****	**97**	**100.0%**	**194**	**100.0%**	**112**	**100.0%**	*****	*****
Female	281	48	51.6%	61	62.9%	118	60.8%	53	47.3%	*****	*****
Male	218	*****	*****	36	37.1%	76	39.2%	59	52.7%	*****	*****
Oliceridine		.	.	.	.	.	.	.	.	.	.
Female		.	.	.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.	.	.
Viltolarsen	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Satralizumab-mwge	**114**	**42**	**100.0%**	*****	*****	**34**	**100.0%**	*****	*****	**0**	**NaN**
Female	94	*****	*****	23	74.2%	*****	*****	*****	*****	0	NaN
Male	20	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Clascoterone	**10,769**	**10,219**	**100.0%**	**490**	**100.0%**	**60**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	9,372	8,921	87.3%	408	83.3%	43	71.7%	0	NaN	0	NaN
Male	1,397	1,298	12.7%	82	16.7%	17	28.3%	0	NaN	0	NaN
Somapacitan-beco		.	.	.	.	.	.	.	.	.	.
Female		.	.	.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	**754**	**1**	**28**	**28**	**84**	**733**	**70.7**	**85.1**
Female	416	1	28	28	84	733	72.5	96.6
Male	338	2	28	30	84	450	68.6	68.4
Selpercatinib	**370**	**2**	**30**	**30**	**90**	**729**	**93.3**	**128.3**
Female	187	2	30	30	90	729	107.5	152.1
Male	183	5	30	30	90	621	78.7	96.5
Ripretinib	**311**	**9**	**30**	**45**	**90**	**706**	**78.3**	**84.7**
Female	142	9	30	30	90	300	66.8	61.6
Male	169	9	30	60	90	706	87.9	99.2
Fluoroestradiol-F18	**205**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
Artesunate	*****	**1**	**1**	**1**	**42**	**42**	**14.7**	**23.7**
Female	*****	42	42	42	42	42	42.0	NaN
Male	*****	1	1	1	1	1	1.0	0.0
Flortaucipir-F18	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Inebilizumab-cdon	**147**	**1**	**1**	**1**	**1**	**193**	**4.5**	**19.9**
Female	120	1	1	1	1	110	3.4	13.3
Male	27	1	1	1	1	193	9.7	37.1
Lurbinectedin	**3,217**	**1**	**1**	**1**	**1**	**63**	**1.2**	**2.5**
Female	1,623	1	1	1	1	42	1.2	1.9
Male	1,594	1	1	1	1	63	1.2	3.0
Triheptanoin	**54**	**4**	**30**	**58**	**142**	**707**	**128.1**	**167.9**

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	26	21	30	58	150	707	137.8	176.4
Male	28	4	30	56	114	702	119.1	162.3
Remimazolam	**130**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
Female	66	1	1	1	1	1	1.0	0.0
Male	64	1	1	1	1	1	1.0	0.0
Fostemsavir	**595**	**3**	**30**	**60**	**163**	**755**	**142.7**	**172.7**
Female	105	15	30	56	120	590	97.9	113.0
Male	490	3	30	60	180	755	152.3	181.6
Decitabine and Cedazuridine	**1,822**	**1**	**28**	**28**	**56**	**532**	**45.6**	**45.0**
Female	690	2	28	28	56	532	43.8	45.1
Male	1,132	1	28	28	56	504	46.7	44.9
Abametapir	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Tafasitamab-cxix	**942**	**1**	**1**	**1**	**1**	**140**	**1.4**	**5.6**
Female	431	1	1	1	1	140	1.9	8.0
Male	511	1	1	1	1	44	1.1	1.9
Belantamab Mafodotin-blmf	**1,108**	**1**	**1**	**1**	**1**	**65**	**1.1**	**2.3**
Female	511	1	1	1	1	42	1.1	1.8
Male	597	1	1	1	1	65	1.1	2.7
Nifurtimox	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Risdiplam	**499**	**2**	**48**	**144**	**350**	**791**	**221.8**	**206.8**
Female	281	3	48	141	323	733	212.4	203.5

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	218	2	48	168	385	791	234.0	211.0
Oliceridine	**0**	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Viltolarsen	*****	**1**	**1**	**1**	**1**	**21**	**3.9**	**7.6**
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	*****	1	1	1	1	21	3.9	7.6
Satralizumab-mwge	**114**	**3**	**28**	**56**	**126**	**519**	**105.8**	**113.8**
Female	94	3	28	56	134	454	104.9	102.8
Male	20	28	28	56	68	519	109.8	158.8
Clascoterone	**10,769**	**1**	**30**	**30**	**30**	**321**	**30.0**	**13.9**
Female	9,372	1	30	30	30	321	29.8	13.4
Male	1,397	1	30	30	30	270	31.0	16.7
Somapacitan-beco	**0**	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Patients	Number of Patients	1-30 Days	Percent of Total Patients	Number of Patients	31-90 Days	Percent of Total Patients	Number of Patients	91-365 Days	Percent of Total Patients	Number of Patients	366-730 Days	Percent of Total Patients	Number of Patients	731+ Days	Percent of Total Patients
		1-30 Days			**31-90 Days**			**91-365 Days**			**366-730 Days**			**731+ Days**		
Capmatinib	754	412	100.0%	190	100.0%	140	100.0%	*****	*****	*****	*****		
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%		
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%		
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%		
41-64 years	*****	*****	*****	*****	*****	14	10.0%	*****	*****	0	0.0%		
≥ 65 years	662	356	86.4%	170	89.5%	126	90.0%	*****	*****	*****	*****		
Selpercatinib	370	198	100.0%	92	100.0%	61	100.0%	19	100.0%	0	NaN		
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN		
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN		
25-40 years	*****	*****	*****	0	0.0%	*****	*****	*****	*****	0	NaN		
41-64 years	110	43	21.7%	29	31.5%	*****	*****	*****	*****	0	NaN		
≥ 65 years	237	136	68.7%	63	68.5%	31	50.8%	*****	*****	0	NaN		
Ripretinib	311	152	100.0%	94	100.0%	*****	*****	*****	*****	0	NaN		
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN		
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN		
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN		
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN		
≥ 65 years	209	99	65.1%	73	77.7%	33	55.9%	*****	*****	0	NaN		
Fluoroestradiol-F18	205	205	100.0%	0	NaN	0	NaN	0	NaN	0	NaN		
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN		
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN		
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN		
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN		
≥ 65 years	148	148	72.2%	0	NaN	0	NaN	0	NaN	0	NaN		

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

| | Total Number of Patients | Number of Patients by First Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Artesunate	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Flortaucipir-F18	.	.	.	.	.	.	.	.	.	.	.
0-17 years	.	.	.	.	.	.	.	.	.	.	.
18-24 years	.	.	.	.	.	.	.	.	.	.	.
25-40 years	.	.	.	.	.	.	.	.	.	.	.
41-64 years	.	.	.	.	.	.	.	.	.	.	.
≥ 65 years	.	.	.	.	.	.	.	.	.	.	.
Inebilizumab-cdon	147	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	70	69	47.9%	0	0.0%	*****	*****	0	NaN	0	NaN
≥ 65 years	54	53	36.8%	0	0.0%	*****	*****	0	NaN	0	NaN
Lurbinectedin	3,217	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	696	696	21.7%	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	2,511	2,504	78.0%	*****	*****	0	NaN	0	NaN	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Triheptanoin	54	22	100.0%	*****	*****	13	100.0%	*****	*****	0	NaN
0-17 years	33	14	63.6%	*****	*****	*****	*****	*****	*****	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	*****	*****	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Remimazolam	130	130	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	55	55	42.3%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	60	60	46.2%	0	NaN	0	NaN	0	NaN	0	NaN
Fostemsavir	595	241	100.0%	119	100.0%	166	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	382	144	59.8%	78	65.5%	120	72.3%	38	56.7%	*****	*****
≥ 65 years	161	64	26.6%	*****	*****	*****	*****	*****	*****	0	0.0%
Decitabine and Cedazuridine	1,822	1,181	100.0%	488	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	1,707	1,111	94.1%	454	93.0%	138	92.6%	*****	*****	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Abametapir	.	.	.	.	.	.	.	.	.	.	.
0-17 years	.	.	.	.	.	.	.	.	.	.	.
18-24 years	.	.	.	.	.	.	.	.	.	.	.
25-40 years	.	.	.	.	.	.	.	.	.	.	.
41-64 years	.	.	.	.	.	.	.	.	.	.	.
≥ 65 years	.	.	.	.	.	.	.	.	.	.	.
Tafasitamab-cxix	**942**	*****	*****	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	864	861	91.8%	*****	*****	*****	*****	0	NaN	0	NaN
Belantamab Mafodotin-blmf	**1,108**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	883	881	79.7%	*****	*****	0	NaN	0	NaN	0	NaN
Nifurtimox	.	.	.	.	.	.	.	.	.	.	.
0-17 years	.	.	.	.	.	.	.	.	.	.	.
18-24 years	.	.	.	.	.	.	.	.	.	.	.
25-40 years	.	.	.	.	.	.	.	.	.	.	.
41-64 years	.	.	.	.	.	.	.	.	.	.	.
≥ 65 years	.	.	.	.	.	.	.	.	.	.	.

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

| | | Number of Patients by First Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Risdiplam	499	*****	*****	97	100.0%	194	100.0%	112	100.0%	*****	*****
0-17 years	84	13	14.0%	25	25.8%	27	13.9%	19	17.0%	0	0.0%
18-24 years	55	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	178	35	37.6%	28	28.9%	77	39.7%	38	33.9%	0	0.0%
41-64 years	157	29	31.2%	29	29.9%	64	33.0%	35	31.3%	0	0.0%
≥ 65 years	25	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
Oliceridine	.	.	.	.	.	.	.	.	.	.	.
0-17 years	.	.	.	.	.	.	.	.	.	.	.
18-24 years	.	.	.	.	.	.	.	.	.	.	.
25-40 years	.	.	.	.	.	.	.	.	.	.	.
41-64 years	.	.	.	.	.	.	.	.	.	.	.
≥ 65 years	.	.	.	.	.	.	.	.	.	.	.
Viltolarsen	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Satralizumab-mwge	114	42	100.0%	*****	*****	34	100.0%	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	52	18	42.9%	16	51.6%	13	38.2%	*****	*****	0	NaN
≥ 65 years	38	13	31.0%	*****	*****	15	44.1%	*****	*****	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Clascoterone	**10,769**	**10,219**	**100.0%**	**490**	**100.0%**	**60**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	2,655	2,497	24.4%	136	27.8%	22	36.7%	0	NaN	0	NaN
18-24 years	2,929	2,782	27.2%	131	26.7%	16	26.7%	0	NaN	0	NaN
25-40 years	3,569	3,401	33.3%	153	31.2%	*****	*****	0	NaN	0	NaN
41-64 years	1,519	1,448	14.2%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	97	91	0.9%	*****	*****	0	0.0%	0	NaN	0	NaN
Somapacitan-beco		.	.	.	.	.	.	.	.	.	.
0-17 years		.	.	.	.	.	.	.	.	.	.
18-24 years		.	.	.	.	.	.	.	.	.	.
25-40 years		.	.	.	.	.	.	.	.	.	.
41-64 years		.	.	.	.	.	.	.	.	.	.
≥ 65 years		.	.	.	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	**754**	**1**	**28**	**28**	**84**	**733**	**70.7**	**85.1**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	28	28	42	56	56	42.0	19.8
41-64 years	*****	14	28	28	56	560	68.6	90.6
≥ 65 years	662	1	28	28	84	733	71.1	84.5
Selpercatinib	**370**	**2**	**30**	**30**	**90**	**729**	**93.3**	**128.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	19	30	30	30	30	28.2	4.5
25-40 years	*****	15	30	30	30	729	100.1	179.3
41-64 years	110	2	30	60	180	689	128.8	154.4
≥ 65 years	237	2	30	30	65	690	77.9	107.8
Ripretinib	**311**	**9**	**30**	**45**	**90**	**706**	**78.3**	**84.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	22	30	30	120	270	85.4	83.2
41-64 years	*****	12	30	30	120	464	87.3	93.1
≥ 65 years	209	9	30	46	90	706	74.0	80.8
Fluoroestradiol-F18	**205**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	148	1	1	1	1	1	1.0	0.0
Artesunate	*****	**1**	**1**	**1**	**42**	**42**	**14.7**	**23.7**

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	22	42	42	21.5	29.0
≥ 65 years	*****	1	1	1	1	1	1.0	NaN
Flortaucipir-F18	**0**	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Inebilizumab-cdon	**147**	**1**	**1**	**1**	**1**	**193**	**4.5**	**19.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	90	5.2	19.4
41-64 years	70	1	1	1	1	193	4.5	23.2
≥ 65 years	54	1	1	1	1	110	4.3	15.7
Lurbinectedin	**3,217**	**1**	**1**	**1**	**1**	**63**	**1.2**	**2.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	696	1	1	1	1	21	1.1	1.5
≥ 65 years	2,511	1	1	1	1	63	1.2	2.8
Triheptanoin	**54**	**4**	**30**	**58**	**142**	**707**	**128.1**	**167.9**
0-17 years	33	4	29	52	137	702	109.8	145.9

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	30	30	265	604	707	316.8	341.7
25-40 years	*****	21	30	30	123	180	65.7	61.3
41-64 years	*****	30	60	94	150	494	153.5	171.6
≥ 65 years	*****	30	45	90	278	435	161.3	186.3
Remimazolam	**130**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	55	1	1	1	1	1	1.0	0.0
≥ 65 years	60	1	1	1	1	1	1.0	0.0
Fostemsavir	**595**	**3**	**30**	**60**	**163**	**755**	**142.7**	**172.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	30	30	30	30.0	NaN
25-40 years	*****	15	30	30	90	635	97.5	149.8
41-64 years	382	8	30	60	180	755	144.7	170.6
≥ 65 years	161	3	30	60	210	697	153.2	183.1
Decitabine and Cedazuridine	**1,822**	**1**	**28**	**28**	**56**	**532**	**45.6**	**45.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	28	28	30	56	114	48.6	31.6
41-64 years	*****	3	28	28	56	329	49.1	52.0
≥ 65 years	1,707	1	28	28	56	532	45.4	44.6
Abametapir	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Tafasitamab-cxix	**942**	**1**	**1**	**1**	**1**	**140**	**1.4**	**5.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	73	1	1	1	1	44	1.6	5.0
≥ 65 years	864	1	1	1	1	140	1.4	5.7
Belantamab Mafodotin-blmf	**1,108**	**1**	**1**	**1**	**1**	**65**	**1.1**	**2.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	15	1.1	0.9
≥ 65 years	883	1	1	1	1	65	1.1	2.6
Nifurtimox	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Risdiplam	**499**	**2**	**48**	**144**	**350**	**791**	**221.8**	**206.8**
0-17 years	84	15	48	102	336	714	208.8	203.9
18-24 years	55	3	33	168	466	791	257.9	246.2
25-40 years	178	2	48	163	326	724	217.1	199.9

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	157	3	48	144	360	673	219.3	203.4
≥ 65 years	25	15	61	192	350	638	235.2	200.3
Oliceridine	**0**	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Viltolarsen	*****	1	1	1	1	21	3.9	7.6
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	11	21	21	11.0	14.1
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Satralizumab-mwge	**114**	3	28	56	126	519	105.8	113.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	28	28	81	148	162	88.0	70.2
25-40 years	*****	14	28	56	80	336	73.1	77.2
41-64 years	52	14	28	56	112	519	108.1	126.6
≥ 65 years	38	3	28	84	217	454	121.6	114.4
Clascoterone	**10,769**	1	30	30	30	321	30.0	13.9
0-17 years	2,655	1	30	30	30	270	30.6	15.1
18-24 years	2,929	1	30	30	30	240	29.8	13.2
25-40 years	3,569	1	30	30	30	321	29.6	13.8
41-64 years	1,519	1	30	30	30	270	29.9	13.1

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	97	1	30	30	30	90	30.1	10.9
Somapacitan-beco	**0**	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022

| | Total Number of Episodes | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Capmatinib	944	574	60.8%	238	25.2%	*****	*****	*****	*****	0	0.0%
Selpercatinib	664	374	56.3%	186	28.0%	92	13.9%	12	1.8%	0	0.0%
Ripretinib	472	281	59.5%	128	27.1%	*****	*****	*****	*****	0	0.0%
Fluoroestradiol-F18	12	12	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Artesunate	0	.	.	.	.	.	.	.	.	.	.
Flortaucipir-F18	0	.	.	.	.	.	.	.	.	.	.
Inebilizumab-cdon	179	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Lurbinectedin	9,657	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Triheptanoin	108	61	56.5%	30	27.8%	17	15.7%	0	0.0%	0	0.0%
Remimazolam	12	12	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Fostemsavir	1,046	583	55.7%	245	23.4%	191	18.3%	27	2.6%	0	0.0%
Decitabine and Cedazuridine	3,121	2,298	73.6%	651	20.9%	172	5.5%	0	0.0%	0	0.0%
Abametapir	0	.	.	.	.	.	.	.	.	.	.
Tafasitamab-cxix	9,994	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Belantamab Mafodotin-blmf	2,780	2,780	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Nifurtimox	0	.	.	.	.	.	.	.	.	.	.
Risdiplam	900	404	44.9%	279	31.0%	198	22.0%	19	2.1%	0	0.0%
Oliceridine	0	.	.	.	.	.	.	.	.	.	.
Viltolarsen	162	162	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Satralizumab-mwge	223	112	50.2%	67	30.0%	*****	*****	*****	*****	0	0.0%
Clascoterone	3,408	3,190	93.6%	193	5.7%	25	0.7%	0	0.0%	0	0.0%
Somapacitan-beco	0	.	.	.	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	944	1	28	28	56	442	55.7	57.3
Selpercatinib	664	1	30	30	62	671	67.2	83.7
Ripretinib	472	2	30	30	60	598	60.3	61.8
Fluoroestradiol-F18	12	1	1	1	1	1	1.0	0.0
Artesunate	0	.	.	.	.	.	.	.
Flortaucipir-F18	0	.	.	.	.	.	.	.
Inebilizumab-cdon	179	1	1	1	1	176	4.5	21.4
Lurbinectedin	9,657	1	1	1	1	84	1.1	2.0
Triheptanoin	108	1	30	30	60	358	62.7	69.2
Remimazolam	12	1	1	1	1	1	1.0	0.0
Fostemsavir	1,046	1	30	30	90	647	78.2	95.3
Decitabine and Cedazuridine	3,121	1	28	28	39	364	39.0	35.7
Abametapir	0	.	.	.	.	.	.	.
Tafasitamab-cxix	9,994	1	1	1	1	196	1.1	2.6
Belantamab Mafodotin-blmf	2,780	1	1	1	1	21	1.0	0.5
Nifurtimox	0	.	.	.	.	.	.	.
Risdiplam	900	1	24	36	74	623	72.0	89.1
Oliceridine	0	.	.	.	.	.	.	.
Viltolarsen	162	1	1	1	1	1	1.0	0.0
Satralizumab-mwge	223	1	28	30	84	532	72.9	83.2
Clascoterone	3,408	1	30	30	30	199	29.9	14.7
Somapacitan-beco	0	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

| | | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Capmatinib	**944**	**574**	**100.0%**	**238**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
Female	515	299	52.1%	148	62.2%	67	51.1%	*****	*****	0	NaN
Male	429	275	47.9%	90	37.8%	*****	*****	0	0.0%	0	NaN
Selpercatinib	**664**	**374**	**100.0%**	**186**	**100.0%**	**92**	**100.0%**	**12**	**100.0%**	**0**	**NaN**
Female	310	167	44.7%	91	48.9%	50	54.3%	*****	*****	0	NaN
Male	354	207	55.3%	95	51.1%	42	45.7%	*****	*****	0	NaN
Ripretinib	**472**	**281**	**100.0%**	**128**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
Female	238	151	53.7%	61	47.7%	*****	*****	0	0.0%	0	NaN
Male	234	130	46.3%	67	52.3%	36	58.1%	*****	*****	0	NaN
Fluoroestradiol-F18	**12**	**12**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	12	12	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Artesunate	.	.	.	.	.	.	.	.	.	.	.
Female	.	.	.	.	.	.	.	.	.	.	.
Male	.	.	.	.	.	.	.	.	.	.	.
Flortaucipir-F18	.	.	.	.	.	.	.	.	.	.	.
Female	.	.	.	.	.	.	.	.	.	.	.
Male	.	.	.	.	.	.	.	.	.	.	.
Inebilizumab-cdon	**179**	*****	*****	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	146	144	82.8%	0	0.0%	*****	*****	0	NaN	0	NaN
Male	33	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Lurbinectedin	**9,657**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	4,965	4,958	51.4%	*****	*****	0	NaN	0	NaN	0	NaN

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

| | | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	4,692	4,689	48.6%	*****	*****	0	NaN	0	NaN	0	NaN
Triheptanoin	**108**	**61**	**100.0%**	**30**	**100.0%**	**17**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	44	21	34.4%	15	50.0%	*****	*****	0	NaN	0	NaN
Male	64	40	65.6%	15	50.0%	*****	*****	0	NaN	0	NaN
Remimazolam	**12**	**12**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Fostemsavir	**1,046**	**583**	**100.0%**	**245**	**100.0%**	**191**	**100.0%**	**27**	**100.0%**	**0**	**NaN**
Female	212	119	20.4%	55	22.4%	34	17.8%	*****	*****	0	NaN
Male	834	464	79.6%	190	77.6%	157	82.2%	*****	*****	0	NaN
Decitabine and Cedazuridine	**3,121**	**2,298**	**100.0%**	**651**	**100.0%**	**172**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	1,121	861	37.5%	213	32.7%	47	27.3%	0	NaN	0	NaN
Male	2,000	1,437	62.5%	438	67.3%	125	72.7%	0	NaN	0	NaN
Abametapir		.	.	.	.	.	.	.	.	.	.
Female		.	.	.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.	.	.
Tafasitamab-cxix	**9,994**	*****	*****	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	4,560	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	5,434	5,434	54.4%	0	0.0%	0	0.0%	0	NaN	0	NaN
Belantamab Mafodotin-blmf	**2,780**	**2,780**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	1,269	1,269	45.6%	0	NaN	0	NaN	0	NaN	0	NaN
Male	1,511	1,511	54.4%	0	NaN	0	NaN	0	NaN	0	NaN
Nifurtimox		.	.	.	.	.	.	.	.	.	.

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

| | Total Number of Episodes | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Female		.	.	.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.	.	.
Risdiplam	**900**	**404**	**100.0%**	**279**	**100.0%**	**198**	**100.0%**	**19**	**100.0%**	**0**	**NaN**
Female	466	197	48.8%	149	53.4%	109	55.1%	*****	*****	0	NaN
Male	434	207	51.2%	130	46.6%	89	44.9%	*****	*****	0	NaN
Oliceridine		.	.	.	.	.	.	.	.	.	.
Female		.	.	.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.	.	.
Viltolarsen	**162**	**162**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	162	162	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Satralizumab-mwge	**223**	**112**	**100.0%**	**67**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
Female	179	86	76.8%	*****	*****	*****	*****	*****	*****	0	NaN
Male	44	26	23.2%	*****	*****	*****	*****	0	0.0%	0	NaN
Clascoterone	**3,408**	**3,190**	**100.0%**	**193**	**100.0%**	**25**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	2,843	2,664	83.5%	158	81.9%	*****	*****	0	NaN	0	NaN
Male	565	526	16.5%	35	18.1%	*****	*****	0	NaN	0	NaN
Somapacitan-beco		.	.	.	.	.	.	.	.	.	.
Female		.	.	.	.	.	.	.	.	.	.
Male		.	.	.	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	**944**	**1**	**28**	**28**	**56**	**442**	**55.7**	**57.3**
Female	515	1	28	28	56	442	56.5	58.0
Male	429	1	28	28	56	336	54.8	56.7
Selpercatinib	**664**	**1**	**30**	**30**	**62**	**671**	**67.2**	**83.7**
Female	310	2	30	30	63	671	64.2	70.2
Male	354	1	30	30	60	665	69.9	94.0
Ripretinib	**472**	**2**	**30**	**30**	**60**	**598**	**60.3**	**61.8**
Female	238	2	30	30	60	344	54.1	50.6
Male	234	3	30	30	77	598	66.6	71.0
Fluoroestradiol-F18	**12**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
Female	12	1	1	1	1	1	1.0	0.0
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Artesunate	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Flortaucipir-F18	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Inebilizumab-cdon	**179**	**1**	**1**	**1**	**1**	**176**	**4.5**	**21.4**
Female	146	1	1	1	1	176	3.2	18.5
Male	33	1	1	1	1	138	10.2	30.8
Lurbinectedin	**9,657**	**1**	**1**	**1**	**1**	**84**	**1.1**	**2.0**
Female	4,965	1	1	1	1	84	1.1	2.3
Male	4,692	1	1	1	1	81	1.1	1.7

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Triheptanoin	**108**	**1**	**30**	**30**	**60**	**358**	**62.7**	**69.2**
Female	44	11	30	32	78	286	66.7	65.2
Male	64	1	29	30	60	358	59.9	72.3
Remimazolam	**12**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
Fostemsavir	**1,046**	**1**	**30**	**30**	**90**	**647**	**78.2**	**95.3**
Female	212	1	30	30	82	588	72.0	86.0
Male	834	1	30	30	90	647	79.8	97.5
Decitabine and Cedazuridine	**3,121**	**1**	**28**	**28**	**39**	**364**	**39.0**	**35.7**
Female	1,121	1	28	28	30	364	36.3	31.5
Male	2,000	1	28	28	56	364	40.6	37.8
Abametapir	**0**	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Tafasitamab-cxix	**9,994**	**1**	**1**	**1**	**1**	**196**	**1.1**	**2.6**
Female	4,560	1	1	1	1	196	1.2	3.8
Male	5,434	1	1	1	1	1	1.0	0.0
Belantamab Mafodotin-blmf	**2,780**	**1**	**1**	**1**	**1**	**21**	**1.0**	**0.5**
Female	1,269	1	1	1	1	21	1.0	0.8
Male	1,511	1	1	1	1	1	1.0	0.0
Nifurtimox	**0**	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Risdiplam	**900**	**1**	**24**	**36**	**74**	**623**	**72.0**	**89.1**
Female	466	2	24	42	95	597	75.5	93.6
Male	434	1	24	35	72	623	68.3	83.9
Oliceridine	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Viltolarsen	**162**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	162	1	1	1	1	1	1.0	0.0
Satralizumab-mwge	**223**	**1**	**28**	**30**	**84**	**532**	**72.9**	**83.2**
Female	179	1	28	39	84	532	75.1	86.9
Male	44	18	28	30	56	252	64.0	66.4
Clascoterone	**3,408**	**1**	**30**	**30**	**30**	**199**	**29.9**	**14.7**
Female	2,843	1	30	30	30	199	29.9	14.7
Male	565	1	30	30	30	180	30.0	14.8
Somapacitan-beco	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Capmatinib	**944**	**574**	**100.0%**	**238**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	33	13.9%	*****	*****	0	0.0%	0	NaN
≥ 65 years	811	493	85.9%	205	86.1%	112	85.5%	*****	*****	0	NaN
Selpercatinib	**664**	**374**	**100.0%**	**186**	**100.0%**	**92**	**100.0%**	**12**	**100.0%**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	216	119	31.8%	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	394	217	58.0%	112	60.2%	57	62.0%	*****	*****	0	NaN
Ripretinib	**472**	**281**	**100.0%**	**128**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	21	12	4.3%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	155	86	30.6%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	296	183	65.1%	76	59.4%	36	58.1%	*****	*****	0	NaN
Fluoroestradiol-F18	**12**	**12**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

		Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Artesunate	.	.	.	.	.	.	.	.	.	.	.
0-17 years		.	.	.	.	.	.	.	.	.	.
18-24 years		.	.	.	.	.	.	.	.	.	.
25-40 years		.	.	.	.	.	.	.	.	.	.
41-64 years		.	.	.	.	.	.	.	.	.	.
≥ 65 years		.	.	.	.	.	.	.	.	.	.
Flortaucipir-F18	.	.	.	.	.	.	.	.	.	.	.
0-17 years		.	.	.	.	.	.	.	.	.	.
18-24 years		.	.	.	.	.	.	.	.	.	.
25-40 years		.	.	.	.	.	.	.	.	.	.
41-64 years		.	.	.	.	.	.	.	.	.	.
≥ 65 years		.	.	.	.	.	.	.	.	.	.
Inebilizumab-cdon	179	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	30	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	90	87	50.0%	0	0.0%	*****	*****	0	NaN	0	NaN
≥ 65 years	59	57	32.8%	*****	*****	*****	*****	0	NaN	0	NaN
Lurbinectedin	9,657	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN

| | | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | Total Number of Episodes | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	2,009	2,008	20.8%	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	7,622	7,613	78.9%	*****	*****	0	NaN	0	NaN	0	NaN
Triheptanoin	**108**	**61**	**100.0%**	**30**	**100.0%**	**17**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	74	36	59.0%	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	14	12	19.7%	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
Remimazolam	**12**	**12**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Fostemsavir	**1,046**	**583**	**100.0%**	**245**	**100.0%**	**191**	**100.0%**	**27**	**100.0%**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	28	11.4%	15	7.9%	*****	*****	0	NaN
41-64 years	696	389	66.7%	168	68.6%	121	63.4%	*****	*****	0	NaN
≥ 65 years	243	133	22.8%	49	20.0%	55	28.8%	*****	*****	0	NaN
Decitabine and Cedazuridine	**3,121**	**2,298**	**100.0%**	**651**	**100.0%**	**172**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

| | Total Number of Episodes | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	2,951	2,171	94.5%	617	94.8%	*****	*****	0	NaN	0	NaN
Abametapir	.	.	.	.	.	.	.	.	.	.	.
0-17 years	.	.	.	.	.	.	.	.	.	.	.
18-24 years	.	.	.	.	.	.	.	.	.	.	.
25-40 years	.	.	.	.	.	.	.	.	.	.	.
41-64 years	.	.	.	.	.	.	.	.	.	.	.
≥ 65 years	.	.	.	.	.	.	.	.	.	.	.
Tafasitamab-cxix	**9,994**	*****	*****	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	12	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	52	52	0.5%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	601	601	6.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	9,329	9,323	93.3%	*****	*****	*****	*****	0	NaN	0	NaN
Belantamab Mafodotin-blmf	**2,780**	**2,780**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	490	490	17.6%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	2,290	2,290	82.4%	0	NaN	0	NaN	0	NaN	0	NaN
Nifurtimox	.	.	.	.	.	.	.	.	.	.	.
0-17 years	.	.	.	.	.	.	.	.	.	.	.

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

| | Total Number of Episodes | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
18-24 years		.	.	.	.	.	.	.	.	.	.
25-40 years		.	.	.	.	.	.	.	.	.	.
41-64 years		.	.	.	.	.	.	.	.	.	.
≥ 65 years		.	.	.	.	.	.	.	.	.	.
Risdiplam	**900**	**404**	**100.0%**	**279**	**100.0%**	**198**	**100.0%**	**19**	**100.0%**	**0**	**NaN**
0-17 years	138	64	15.8%	34	12.2%	37	18.7%	*****	*****	0	NaN
18-24 years	76	31	7.7%	21	7.5%	*****	*****	*****	*****	0	NaN
25-40 years	370	170	42.1%	118	42.3%	72	36.4%	*****	*****	0	NaN
41-64 years	281	126	31.2%	94	33.7%	57	28.8%	*****	*****	0	NaN
≥ 65 years	35	13	3.2%	12	4.3%	*****	*****	0	0.0%	0	NaN
Oliceridine		.	.	.	.	.	.	.	.	.	.
0-17 years		.	.	.	.	.	.	.	.	.	.
18-24 years		.	.	.	.	.	.	.	.	.	.
25-40 years		.	.	.	.	.	.	.	.	.	.
41-64 years		.	.	.	.	.	.	.	.	.	.
≥ 65 years		.	.	.	.	.	.	.	.	.	.
Viltolarsen	**162**	**162**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	103	103	63.6%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Satralizumab-mwge	**223**	**112**	**100.0%**	**67**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

| | | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	123	62	55.4%	37	55.2%	22	55.0%	*****	*****	0	NaN
≥ 65 years	60	30	26.8%	*****	*****	*****	*****	*****	*****	0	NaN
Clascoterone	**3,408**	**3,190**	**100.0%**	**193**	**100.0%**	**25**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	963	905	28.4%	52	26.9%	*****	*****	0	NaN	0	NaN
18-24 years	903	847	26.6%	50	25.9%	*****	*****	0	NaN	0	NaN
25-40 years	1,089	1,016	31.8%	63	32.6%	*****	*****	0	NaN	0	NaN
41-64 years	423	395	12.4%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	30	27	0.8%	*****	*****	*****	*****	0	NaN	0	NaN
Somapacitan-beco	.	.	.	.	.	.	.	.	.	.	.
0-17 years	.	.	.	.	.	.	.	.	.	.	.
18-24 years	.	.	.	.	.	.	.	.	.	.	.
25-40 years	.	.	.	.	.	.	.	.	.	.	.
41-64 years	.	.	.	.	.	.	.	.	.	.	.
≥ 65 years	.	.	.	.	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	**944**	**1**	**28**	**28**	**56**	**442**	**55.7**	**57.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	14	14	14	28	28	20.0	7.5
41-64 years	*****	3	28	28	58	316	55.4	51.1
≥ 65 years	811	1	28	28	56	442	56.0	58.4
Selpercatinib	**664**	**1**	**30**	**30**	**62**	**671**	**67.2**	**83.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	11	15	15	30	30	198	39.7	53.0
25-40 years	43	13	28	30	60	315	54.2	57.3
41-64 years	216	4	30	30	84	671	69.0	85.3
≥ 65 years	394	1	30	30	60	665	68.5	85.9
Ripretinib	**472**	**2**	**30**	**30**	**60**	**598**	**60.3**	**61.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	21	18	30	30	60	193	52.2	41.0
41-64 years	155	3	30	30	60	354	63.5	64.3
≥ 65 years	296	2	30	30	60	598	59.2	61.8
Fluoroestradiol-F18	**12**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	1	1.0	0.0

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Artesunate	**0**	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Flortaucipir-F18	**0**	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Inebilizumab-cdon	**179**	**1**	**1**	**1**	**1**	**176**	**4.5**	**21.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	30	1	1	1	1	1	1.0	0.0
41-64 years	90	1	1	1	1	176	5.6	25.6
≥ 65 years	59	1	1	1	1	138	4.6	19.6
Lurbinectedin	**9,657**	**1**	**1**	**1**	**1**	**84**	**1.1**	**2.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	2,009	1	1	1	1	84	1.1	1.9
≥ 65 years	7,622	1	1	1	1	81	1.1	2.0

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Triheptanoin	**108**	**1**	**30**	**30**	**60**	**358**	**62.7**	**69.2**
0-17 years	74	1	29	32	81	300	67.8	70.0
18-24 years	14	4	30	30	30	60	31.2	14.5
25-40 years	*****	11	30	30	59	60	35.7	17.7
41-64 years	*****	30	30	30	60	90	45.0	25.1
≥ 65 years	*****	6	22	30	228	358	113.3	133.4
Remimazolam	**12**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Fostemsavir	**1,046**	**1**	**30**	**30**	**90**	**647**	**78.2**	**95.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	30	30	30	30.0	NaN
25-40 years	*****	10	30	30	90	515	74.7	90.0
41-64 years	696	1	30	30	90	647	77.6	96.7
≥ 65 years	243	1	30	30	95	555	81.5	94.0
Decitabine and Cedazuridine	**3,121**	**1**	**28**	**28**	**39**	**364**	**39.0**	**35.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	7	7	56	84	84	49.0	39.0
41-64 years	*****	1	28	28	30	274	36.8	36.1
≥ 65 years	2,951	1	28	28	39	364	39.2	35.7

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Abametapir	**0**	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Tafasitamab-cxix	**9,994**	**1**	**1**	**1**	**1**	**196**	**1.1**	**2.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	12	1	1	1	1	1	1.0	0.0
25-40 years	52	1	1	1	1	1	1.0	0.0
41-64 years	601	1	1	1	1	1	1.0	0.0
≥ 65 years	9,329	1	1	1	1	196	1.1	2.7
Belantamab Mafodotin-blmf	**2,780**	**1**	**1**	**1**	**1**	**21**	**1.0**	**0.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	490	1	1	1	1	1	1.0	0.0
≥ 65 years	2,290	1	1	1	1	21	1.0	0.6
Nifurtimox	**0**	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Risdiplam	**900**	**1**	**24**	**36**	**74**	**623**	**72.0**	**89.1**
0-17 years	138	5	24	40	97	596	85.1	104.2
18-24 years	76	1	24	48	96	431	75.5	81.6
25-40 years	370	1	24	35	72	623	69.6	91.9
41-64 years	281	2	24	37	72	576	68.9	82.6
≥ 65 years	35	2	24	43	96	175	63.3	49.5
Oliceridine	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Viltolarsen	**162**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	103	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Satralizumab-mwge	**223**	**1**	**28**	**30**	**84**	**532**	**72.9**	**83.2**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	28	28	28	182	182	79.3	88.9
25-40 years	*****	1	28	38	84	296	76.5	77.8
41-64 years	123	4	28	30	84	532	72.7	84.8
≥ 65 years	60	7	28	31	84	421	70.8	85.0

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Clascoterone	**3,408**	**1**	**30**	**30**	**30**	**199**	**29.9**	**14.7**
0-17 years	963	1	30	30	30	188	29.8	13.7
18-24 years	903	1	30	30	30	186	29.9	14.5
25-40 years	1,089	1	30	30	30	199	30.0	15.8
41-64 years	423	1	30	30	30	148	29.9	13.7
≥ 65 years	30	1	17	30	30	120	28.0	22.6
Somapacitan-beco	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	944	1	3	7	19	266	16.2	27.2
Selpercatinib	664	1	3	7	19	372	17.2	29.9
Ripretinib	472	1	3	6	16	332	17.4	35.3
Fluoroestradiol-F18	12	60	80	126	171	284	140.2	76.6
Artesunate	0	.	.	.	.	.	.	.
Flortaucipir-F18	0	.	.	.	.	.	.	.
Inebilizumab-cdon	179	1	13	150	181	391	102.2	92.2
Lurbinectedin	9,657	1	20	20	21	251	22.8	9.4
Triheptanoin	108	1	3	6	13	201	14.1	27.7
Remimazolam	12	12	17	57	148	248	87.0	78.9
Fostemsavir	1,046	1	3	6	17	392	16.8	31.9
Decitabine and Cedazuridine	3,121	1	5	13	27	448	21.1	28.9
Abametapir	0	.	.	.	.	.	.	.
Tafasitamab-cxix	9,994	1	6	6	13	328	9.6	9.6
Belantamab Mafodotin-blmf	2,780	2	20	21	41	467	34.7	30.1
Nifurtimox	0	.	.	.	.	.	.	.
Risdiplam	900	1	2	4	10	608	12.5	41.2
Oliceridine	0	.	.	.	.	.	.	.
Viltolarsen	162	4	6	6	20	83	13.1	12.1
Satralizumab-mwge	223	1	2	6	11	317	10.4	23.5
Clascoterone	3,408	1	17	43	81	373	58.6	55.2
Somapacitan-beco	0	.	.	.	.	.	.	.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	**944**	**1**	**3**	**7**	**19**	**266**	**16.2**	**27.2**
Female	515	1	3	7	20	266	16.4	27.4
Male	429	1	3	6	18	261	15.9	27.0
Selpercatinib	**664**	**1**	**3**	**7**	**19**	**372**	**17.2**	**29.9**
Female	310	1	3	6	20	209	17.7	30.0
Male	354	1	3	7	19	372	16.8	29.8
Ripretinib	**472**	**1**	**3**	**6**	**16**	**332**	**17.4**	**35.3**
Female	238	1	4	9	21	180	18.1	27.8
Male	234	1	2	4	12	332	16.6	41.6
Fluoroestradiol-F18	**12**	**60**	**80**	**126**	**171**	**284**	**140.2**	**76.6**
Female	12	60	80	126	171	284	140.2	76.6
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Artesunate	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Flortaucipir-F18	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Inebilizumab-cdon	**179**	**1**	**13**	**150**	**181**	**391**	**102.2**	**92.2**
Female	146	1	13	167	181	391	108.0	94.1
Male	33	4	13	18	172	195	76.9	79.8
Lurbinectedin	**9,657**	**1**	**20**	**20**	**21**	**251**	**22.8**	**9.4**
Female	4,965	1	20	20	21	200	22.8	8.9
Male	4,692	2	20	20	21	251	22.8	9.8
Triheptanoin	**108**	**1**	**3**	**6**	**13**	**201**	**14.1**	**27.7**

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	44	1	3	6	12	149	12.3	22.9
Male	64	1	3	5	13	201	15.3	30.7
Remimazolam	**12**	**12**	**17**	**57**	**148**	**248**	**87.0**	**78.9**
Female	10	12	14	89	156	248	96.6	83.1
Male	2	20	20	39	58	58	39.0	26.9
Fostemsavir	**1,046**	**1**	**3**	**6**	**17**	**392**	**16.8**	**31.9**
Female	212	1	3	6	20	258	19.3	36.4
Male	834	1	3	6	16	392	16.1	30.6
Decitabine and Cedazuridine	**3,121**	**1**	**5**	**13**	**27**	**448**	**21.1**	**28.9**
Female	1,121	1	6	13	28	448	22.8	33.0
Male	2,000	1	5	12	26	310	20.2	26.2
Abametapir	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Tafasitamab-cxix	**9,994**	**1**	**6**	**6**	**13**	**328**	**9.6**	**9.6**
Female	4,560	1	6	6	13	328	9.6	11.2
Male	5,434	1	6	6	13	254	9.6	8.0
Belantamab Mafodotin-blmf	**2,780**	**2**	**20**	**21**	**41**	**467**	**34.7**	**30.1**
Female	1,269	2	20	22	41	389	35.9	32.7
Male	1,511	17	20	20	41	467	33.7	27.8
Nifurtimox	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Risdiplam	**900**	**1**	**2**	**4**	**10**	**608**	**12.5**	**41.2**
Female	466	1	2	4	11	546	15.0	46.5

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

| | Total Number of Gaps | Distribution of Treatment Episode Gap Durations, days | | | | | | |
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	434	1	2	4	9	608	9.9	34.4
Oliceridine	**0**	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Viltolarsen	**162**	**4**	**6**	**6**	**20**	**83**	**13.1**	**12.1**
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	162	4	6	6	20	83	13.1	12.1
Satralizumab-mwge	**223**	**1**	**2**	**6**	**11**	**317**	**10.4**	**23.5**
Female	179	1	2	6	11	317	10.7	25.7
Male	44	1	3	6	10	47	9.1	10.5
Clascoterone	**3,408**	**1**	**17**	**43**	**81**	**373**	**58.6**	**55.2**
Female	2,843	1	18	45	82	373	59.3	55.2
Male	565	1	15	38	74	323	55.1	55.4
Somapacitan-beco	**0**	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	**944**	**1**	**3**	**7**	**19**	**266**	**16.2**	**27.2**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	7	4	5	14	18	22	12.7	6.5
41-64 years	126	1	3	6	11	219	14.0	29.0
≥ 65 years	811	1	3	7	20	266	16.5	27.0
Selpercatinib	**664**	**1**	**3**	**7**	**19**	**372**	**17.2**	**29.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	11	2	8	15	40	84	25.3	25.4
25-40 years	43	1	3	7	20	86	18.3	24.3
41-64 years	216	1	3	6	13	372	14.5	31.3
≥ 65 years	394	1	3	7	21	244	18.4	29.7
Ripretinib	**472**	**1**	**3**	**6**	**16**	**332**	**17.4**	**35.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	21	3	4	6	14	133	16.3	29.5
41-64 years	155	1	2	5	14	177	15.5	29.0
≥ 65 years	296	1	3	7	17	332	18.4	38.6
Fluoroestradiol-F18	**12**	**60**	**80**	**126**	**171**	**284**	**140.2**	**76.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	1	174	174	174	174	174	174.0	NaN
41-64 years	2	72	72	178	284	284	178.0	149.9
≥ 65 years	9	60	83	125	150	281	128.0	67.8
Artesunate	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Flortaucipir-F18	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Inebilizumab-cdon	**179**	**1**	**13**	**150**	**181**	**391**	**102.2**	**92.2**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	30	12	13	110	182	276	102.7	90.3
41-64 years	90	1	14	167	182	391	116.8	97.6
≥ 65 years	59	2	13	16	174	195	79.8	81.0
Lurbinectedin	**9,657**	**1**	**20**	**20**	**21**	**251**	**22.8**	**9.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	5	20	20	22	55	60	35.4	20.3
25-40 years	21	20	20	20	21	27	20.8	1.7
41-64 years	2,009	5	20	20	21	200	23.1	9.4
≥ 65 years	7,622	1	20	20	21	251	22.7	9.4
Triheptanoin	**108**	**1**	**3**	**6**	**13**	**201**	**14.1**	**27.7**
0-17 years	74	1	3	5	11	201	13.0	28.2

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	14	2	5	12	18	60	16.2	16.6
25-40 years	7	4	4	6	17	37	11.9	12.0
41-64 years	6	1	3	12	17	149	32.2	57.6
≥ 65 years	7	1	1	4	7	32	7.3	11.1
Remimazolam	**12**	**12**	**17**	**57**	**148**	**248**	**87.0**	**78.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	10	12	14	90	156	248	96.9	83.0
≥ 65 years	2	20	20	38	55	55	37.5	24.7
Fostemsavir	**1,046**	**1**	**3**	**6**	**17**	**392**	**16.8**	**31.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	1	135	135	135	135	135	135.0	NaN
25-40 years	106	1	3	7	21	171	18.2	29.6
41-64 years	696	1	3	6	17	392	17.7	35.2
≥ 65 years	243	1	2	5	15	154	13.0	19.3
Decitabine and Cedazuridine	**3,121**	**1**	**5**	**13**	**27**	**448**	**21.1**	**28.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	3	8	8	16	21	21	15.0	6.6
41-64 years	167	1	5	11	25	218	19.3	24.4
≥ 65 years	2,951	1	5	13	27	448	21.3	29.1
Abametapir	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Tafasitamab-cxix	**9,994**	**1**	**6**	**6**	**13**	**328**	**9.6**	**9.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	12	13	13	13	13	27	14.2	4.0
25-40 years	52	2	6	13	13	41	11.8	7.6
41-64 years	601	1	6	6	13	69	8.5	6.4
≥ 65 years	9,329	1	6	6	13	328	9.7	9.8
Belantamab Mafodotin-blmf	**2,780**	**2**	**20**	**21**	**41**	**467**	**34.7**	**30.1**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	490	17	20	21	38	356	34.7	30.8
≥ 65 years	2,290	2	20	21	41	467	34.7	30.0
Nifurtimox	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Risdiplam	**900**	**1**	**2**	**4**	**10**	**608**	**12.5**	**41.2**
0-17 years	138	1	2	5	11	546	18.6	65.1
18-24 years	76	1	2	5	11	126	9.5	16.2
25-40 years	370	1	3	5	11	608	13.7	41.4

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	281	1	2	4	8	394	9.6	31.7
≥ 65 years	35	1	2	5	10	32	6.9	7.1
Oliceridine	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Viltolarsen	**162**	**4**	**6**	**6**	**20**	**83**	**13.1**	**12.1**
0-17 years	58	6	13	27	27	60	23.1	11.0
18-24 years	103	4	6	6	6	46	6.8	4.5
25-40 years	1	83	83	83	83	83	83.0	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Satralizumab-mwge	**223**	**1**	**2**	**6**	**11**	**317**	**10.4**	**23.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	3	1	1	4	23	23	9.3	11.9
25-40 years	37	1	3	6	12	317	16.7	51.5
41-64 years	123	1	2	5	10	63	8.2	9.8
≥ 65 years	60	1	2	6	13	78	11.1	14.7
Clascoterone	**3,408**	**1**	**17**	**43**	**81**	**373**	**58.6**	**55.2**
0-17 years	963	1	20	47	85	323	60.3	54.2
18-24 years	903	1	19	44	82	373	60.3	56.2
25-40 years	1,089	1	15	39	78	311	55.3	53.4
41-64 years	423	1	14	44	84	341	60.1	58.0

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	30	1	13	38	60	326	58.3	78.1
Somapacitan-beco	**0**	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	374	1	3	7	20	266	16.8	28.6
Selpercatinib	209	1	3	8	23	372	21.2	40.1
Ripretinib	177	1	2	5	15	174	14.5	24.2
Fluoroestradiol-F18	10	72	83	139	174	284	153.9	76.8
Artesunate	0	.	.	.	.	.	.	.
Flortaucipir-F18	0	.	.	.	.	.	.	.
Inebilizumab-cdon	110	2	13	14	22	374	54.3	78.4
Lurbinectedin	2,475	1	20	20	21	244	22.8	9.6
Triheptanoin	30	1	3	5	11	60	10.4	14.3
Remimazolam	8	14	26	57	148	176	81.1	65.4
Fostemsavir	352	1	3	6	21	392	19.9	39.1
Decitabine and Cedazuridine	1,047	1	5	12	25	310	20.4	29.9
Abametapir	0	.	.	.	.	.	.	.
Tafasitamab-cxix	888	1	2	2	6	83	4.3	5.7
Belantamab Mafodotin-blmf	809	2	20	20	27	467	29.9	30.7
Nifurtimox	0	.	.	.	.	.	.	.
Risdiplam	250	1	2	4	11	608	20.8	69.7
Oliceridine	0	.	.	.	.	.	.	.
Viltolarsen	6	6	7	20	27	83	27.2	28.9
Satralizumab-mwge	71	1	4	9	19	317	18.6	38.8
Clascoterone	2,376	1	21	50	90	373	65.4	59.2
Somapacitan-beco	0	.	.	.	.	.	.	.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	**374**	**1**	**3**	**7**	**20**	**266**	**16.8**	**28.6**
Female	207	1	3	7	20	266	16.3	29.3
Male	167	1	3	7	21	218	17.5	27.7
Selpercatinib	**209**	**1**	**3**	**8**	**23**	**372**	**21.2**	**40.1**
Female	99	1	3	6	20	209	19.8	34.1
Male	110	1	4	8	25	372	22.4	45.0
Ripretinib	**177**	**1**	**2**	**5**	**15**	**174**	**14.5**	**24.2**
Female	86	1	3	7	22	146	16.8	24.1
Male	91	1	2	4	12	174	12.4	24.3
Fluoroestradiol-F18	**10**	**72**	**83**	**139**	**174**	**284**	**153.9**	**76.8**
Female	10	72	83	139	174	284	153.9	76.8
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Artesunate	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Flortaucipir-F18	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Inebilizumab-cdon	**110**	**2**	**13**	**14**	**22**	**374**	**54.3**	**78.4**
Female	90	2	13	14	152	374	61.7	83.8
Male	20	11	13	13	18	150	21.3	30.5
Lurbinectedin	**2,475**	**1**	**20**	**20**	**21**	**244**	**22.8**	**9.6**
Female	1,268	1	20	20	21	138	22.8	8.5
Male	1,207	2	20	20	21	244	22.8	10.7
Triheptanoin	**30**	**1**	**3**	**5**	**11**	**60**	**10.4**	**14.3**

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	13	1	3	5	6	32	7.3	8.1
Male	17	1	4	5	13	60	12.8	17.6
Remimazolam	**8**	**14**	**26**	**57**	**148**	**176**	**81.1**	**65.4**
Female	6	14	31	97	156	176	95.2	70.0
Male	2	20	20	39	58	58	39.0	26.9
Fostemsavir	**352**	**1**	**3**	**6**	**21**	**392**	**19.9**	**39.1**
Female	74	1	4	8	26	258	28.4	51.5
Male	278	1	3	6	19	392	17.6	34.8
Decitabine and Cedazuridine	**1,047**	**1**	**5**	**12**	**25**	**310**	**20.4**	**29.9**
Female	372	1	5	13	28	258	23.1	33.9
Male	675	1	4	11	24	310	18.9	27.3
Abametapir	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Tafasitamab-cxix	**888**	**1**	**2**	**2**	**6**	**83**	**4.3**	**5.7**
Female	406	1	2	2	6	49	4.6	5.6
Male	482	1	2	2	4	83	4.0	5.8
Belantamab Mafodotin-blmf	**809**	**2**	**20**	**20**	**27**	**467**	**29.9**	**30.7**
Female	385	2	20	20	27	356	30.8	31.5
Male	424	17	20	20	27	467	29.0	29.9
Nifurtimox	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Risdiplam	**250**	**1**	**2**	**4**	**11**	**608**	**20.8**	**69.7**
Female	140	1	2	5	14	546	24.7	72.4

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	110	1	2	4	8	608	15.8	65.9
Oliceridine	**0**	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Viltolarsen	**6**	**6**	**7**	**20**	**27**	**83**	**27.2**	**28.9**
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	6	6	7	20	27	83	27.2	28.9
Satralizumab-mwge	**71**	**1**	**4**	**9**	**19**	**317**	**18.6**	**38.8**
Female	57	1	4	10	24	317	20.6	43.0
Male	14	1	5	9	14	33	10.4	8.0
Clascoterone	**2,376**	**1**	**21**	**50**	**90**	**373**	**65.4**	**59.2**
Female	1,981	1	22	52	91	373	65.8	58.8
Male	395	1	19	44	88	323	63.2	61.2
Somapacitan-beco	**0**	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Capmatinib	**374**	**1**	**3**	**7**	**20**	**266**	**16.8**	**28.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	2	4	4	5	5	5	4.5	0.7
41-64 years	57	1	4	7	13	143	14.2	22.0
≥ 65 years	315	1	3	7	21	266	17.4	29.7
Selpercatinib	**209**	**1**	**3**	**8**	**23**	**372**	**21.2**	**40.1**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	4	4	6	12	35	55	20.5	23.4
25-40 years	12	1	2	4	12	26	7.8	8.3
41-64 years	62	1	4	8	15	372	19.2	48.5
≥ 65 years	131	1	3	9	27	244	23.4	37.9
Ripretinib	**177**	**1**	**2**	**5**	**15**	**174**	**14.5**	**24.2**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	6	3	5	7	7	14	7.0	3.7
41-64 years	56	1	2	4	12	131	12.4	22.9
≥ 65 years	115	1	2	6	21	174	16.0	25.4
Fluoroestradiol-F18	**10**	**72**	**83**	**139**	**174**	**284**	**153.9**	**76.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	1	174	174	174	174	174	174.0	NaN
41-64 years	2	72	72	178	284	284	178.0	149.9
≥ 65 years	7	76	83	127	167	281	144.1	68.7
Artesunate	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Flortaucipir-F18	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Inebilizumab-cdon	**110**	**2**	**13**	**14**	**22**	**374**	**54.3**	**78.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	16	12	13	13	14	195	27.1	45.8
41-64 years	54	11	13	15	181	374	74.3	92.9
≥ 65 years	40	2	13	13	18	185	38.3	59.3
Lurbinectedin	**2,475**	**1**	**20**	**20**	**21**	**244**	**22.8**	**9.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	1	22	22	22	22	22	22.0	NaN
25-40 years	6	20	20	20	20	23	20.5	1.2
41-64 years	545	5	20	20	22	112	23.2	8.8
≥ 65 years	1,923	1	20	20	21	244	22.7	9.9
Triheptanoin	**30**	**1**	**3**	**5**	**11**	**60**	**10.4**	**14.3**
0-17 years	21	1	3	5	6	54	7.8	11.1

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	2	23	23	42	60	60	41.5	26.2
25-40 years	1	4	4	4	4	4	4.0	NaN
41-64 years	3	1	1	10	13	13	8.0	6.2
≥ 65 years	3	2	2	4	32	32	12.7	16.8
Remimazolam	**8**	**14**	**26**	**57**	**148**	**176**	**81.1**	**65.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	6	14	31	99	156	176	95.7	69.6
≥ 65 years	2	20	20	38	55	55	37.5	24.7
Fostemsavir	**352**	**1**	**3**	**6**	**21**	**392**	**19.9**	**39.1**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	1	135	135	135	135	135	135.0	NaN
25-40 years	32	2	5	9	25	119	24.0	31.3
41-64 years	229	1	2	6	19	392	21.1	44.9
≥ 65 years	90	1	2	5	20	80	14.1	18.0
Decitabine and Cedazuridine	**1,047**	**1**	**5**	**12**	**25**	**310**	**20.4**	**29.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	3	8	8	16	21	21	15.0	6.6
41-64 years	57	1	5	10	21	84	16.9	18.2
≥ 65 years	987	1	5	12	26	310	20.6	30.4
Abametapir	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Tafasitamab-cxix	**888**	**1**	**2**	**2**	**6**	**83**	**4.3**	**5.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	1	13	13	13	13	13	13.0	NaN
25-40 years	3	2	2	2	6	6	3.3	2.3
41-64 years	66	1	2	2	6	16	3.8	3.0
≥ 65 years	818	1	2	2	5	83	4.3	5.9
Belantamab Mafodotin-blmf	**809**	**2**	**20**	**20**	**27**	**467**	**29.9**	**30.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	155	17	20	20	27	356	30.5	33.2
≥ 65 years	654	2	20	20	27	467	29.7	30.1
Nifurtimox	**0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Risdiplam	**250**	**1**	**2**	**4**	**11**	**608**	**20.8**	**69.7**
0-17 years	39	1	2	5	14	546	45.0	117.8
18-24 years	20	1	2	4	8	53	8.0	12.0
25-40 years	97	1	2	5	11	608	22.6	74.6

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	84	1	2	4	8	316	11.6	36.0
≥ 65 years	10	1	5	7	19	32	11.2	10.0
Oliceridine	**0**	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Viltolarsen	**6**	**6**	**7**	**20**	**27**	**83**	**27.2**	**28.9**
0-17 years	4	6	10	20	27	27	18.3	10.5
18-24 years	1	7	7	7	7	7	7.0	NaN
25-40 years	1	83	83	83	83	83	83.0	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Satralizumab-mwge	**71**	**1**	**4**	**9**	**19**	**317**	**18.6**	**38.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	1	23	23	23	23	23	23.0	NaN
25-40 years	14	1	3	9	14	317	30.1	82.8
41-64 years	34	1	5	10	24	63	14.9	14.0
≥ 65 years	22	1	5	10	27	78	16.7	19.1
Clascoterone	**2,376**	**1**	**21**	**50**	**90**	**373**	**65.4**	**59.2**
0-17 years	682	1	26	54	95	323	67.8	57.1
18-24 years	626	1	22	51	97	373	68.2	61.4
25-40 years	752	1	18	43	82	311	59.8	57.2
41-64 years	296	1	19	55	95	341	67.5	60.9

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	20	1	15	41	81	326	70.3	90.8
Somapacitan-beco	**0**	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022[1]

		Censoring Reason											
		End of exposure episode[2]		Occurence of request-defined censoring criteria[3]		Evidence of death[4]		Disenrollment[5]		End of data partner data[6]		End of query period[7]	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Capmatinib	1,698	1,635	96.3%	0	0.0%	60	3.5%	212	12.5%	180	10.6%	*****	*****
Selpercatinib	1,034	1,004	97.1%	0	0.0%	19	1.8%	183	17.7%	157	15.2%	*****	*****
Ripretinib	783	747	95.4%	0	0.0%	30	3.8%	78	10.0%	68	8.7%	*****	*****
Fluoroestradiol-F18	217	217	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Artesunate	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Flortaucipir-F18	0	.	.	.	.	.	.	.	.	.	.	.	.
Inebilizumab-cdon	326	326	100.0%	0	0.0%	0	0.0%	*****	*****	*****	*****	0	0.0%
Lurbinectedin	12,874	12,870	100.0%	0	0.0%	*****	*****	45	0.3%	38	0.3%	0	0.0%
Triheptanoin	162	160	98.8%	0	0.0%	0	0.0%	38	23.5%	30	18.5%	*****	*****
Remimazolam	142	142	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Fostemsavir	1,641	1,602	97.6%	0	0.0%	17	1.0%	389	23.7%	342	20.8%	22	1.3%
Decitabine and Cedazuridine	4,943	4,769	96.5%	0	0.0%	173	3.5%	420	8.5%	392	7.9%	20	0.4%
Abametapir	0	.	.	.	.	.	.	.	.	.	.	.	.
Tafasitamab-cxix	10,936	10,936	100.0%	0	0.0%	0	0.0%	34	0.3%	33	0.3%	0	0.0%
Belantamab Mafodotin-blmf	3,888	3,888	100.0%	0	0.0%	0	0.0%	11	0.3%	*****	*****	0	0.0%
Nifurtimox	0	.	.	.	.	.	.	.	.	.	.	.	.
Risdiplam	1,399	1,382	98.8%	0	0.0%	*****	*****	367	26.2%	320	22.9%	*****	*****
Oliceridine	0	.	.	.	.	.	.	.	.	.	.	.	.
Viltolarsen	169	169	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the SDD from January 1, 2020 to December 31, 2022[1]

		Censoring Reason												
		End of exposure episode[2]		Occurence of request-defined censoring criteria[3]		Evidence of death[4]		Disenrollment[5]		End of data partner data[6]		End of query period[7]		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Satralizumab-mwge	337	330	97.9%	0	0.0%	*****	*****	75	22.3%	71	21.1%	*****	*****
Clascoterone	14,177	13,547	95.6%	0	0.0%	*****	*****	1,630	11.5%	2,010	14.2%	692	4.9%
Somapacitan-beco	0	.	.	.	.	.	.	.	.	.	.	.	.

[1]An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

[2]Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

[3]Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

[4]Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

[5]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

[6]Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

[7]Represents episodes censored due to user-specified study end date.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 10. Summary of Patient Level Cohort Attrition in the SDD from January 1, 2020 to December 31, 2022

	Capmatinib		Selpercatinib		Ripretinib		Artesunate	
	Remaining	**Excluded**	**Remaining**	**Excluded**	**Remaining**	**Excluded**	**Remaining**	**Excluded**
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	163,592,699	N/A	163,592,699	N/A	163,592,699	N/A	163,592,699	N/A
Had required coverage type (medical and/or drug coverage)	102,254,697	61,338,002	102,254,697	61,338,002	102,254,697	61,338,002	102,254,697	61,338,002
Enrolled during specified age range	102,253,804	893	102,253,804	893	102,253,804	893	102,253,804	893
Had requestable medical charts	102,253,804	0	102,253,804	0	102,253,804	0	102,253,804	0
Met demographic requirements (sex, race, and Hispanic origin)	101,554,155	699,649	101,554,155	699,649	101,554,155	699,649	101,554,155	699,649
Members with a valid index event								
Had any cohort-defining claim during the query period	811	101,553,344	426	101,553,729	339	101,553,816	*****	101,554,151
Claim recorded during specified age range	811	0	426	0	339	0	*****	0
Episode defining index claim recorded during the query period	811	0	426	0	339	0	*****	0
Met exposure incidence criteria	811	0	426	0	339	0	*****	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	754	57	370	56	311	28	*****	*****
Met inclusion and exclusion criteria	754	0	370	0	311	0	*****	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	754	0	370	0	311	0	*****	0
Final cohort								
Number of members	754	N/A	370	N/A	311	N/A	*****	N/A
Number of episodes	754	N/A	370	N/A	311	N/A	*****	N/A

Table 10. Summary of Patient Level Cohort Attrition in the SDD from January 1, 2020 to December 31, 2022

	Fostemsavir		Decitabine and Cedazuridine		Abametapir		Tafasitamab-cxix	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	163,592,699	N/A	163,592,699	N/A	163,592,699	N/A	163,592,699	N/A
Had required coverage type (medical and/or drug coverage)	102,254,697	61,338,002	102,254,697	61,338,002	102,254,697	61,338,002	102,254,697	61,338,002
Enrolled during specified age range	102,253,804	893	102,253,804	893	102,253,804	893	102,253,804	893
Had requestable medical charts	102,253,804	0	102,253,804	0	102,253,804	0	102,253,804	0
Met demographic requirements (sex, race, and Hispanic origin)	101,554,155	699,649	101,554,155	699,649	101,554,155	699,649	101,554,155	699,649
Members with a valid index event								
Had any cohort-defining claim during the query period	685	101,553,470	1,928	101,552,227	0	101,554,155	989	101,553,166
Claim recorded during specified age range	685	0	1,928	0	0	0	989	0
Episode defining index claim recorded during the query period	685	0	1,928	0	0	0	989	0
Met exposure incidence criteria	685	0	1,928	0	0	0	989	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	595	90	1,822	106	0	0	942	47
Met inclusion and exclusion criteria	595	0	1,822	0	0	0	942	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	595	0	1,822	0	0	0	942	0
Final cohort								
Number of members	595	N/A	1,822	N/A	0	N/A	942	N/A
Number of episodes	595	N/A	1,822	N/A	0	N/A	942	N/A

Table 10. Summary of Patient Level Cohort Attrition in the SDD from January 1, 2020 to December 31, 2022

	Belantamab Mafodotin-blmf		Nifurtimox		Risdiplam		Oliceridine	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	163,592,699	N/A	163,592,699	N/A	163,592,699	N/A	163,592,699	N/A
Had required coverage type (medical and/or drug coverage)	102,254,697	61,338,002	102,254,697	61,338,002	102,254,697	61,338,002	102,254,697	61,338,002
Enrolled during specified age range	102,253,804	893	102,253,804	893	102,253,804	893	102,253,804	893
Had requestable medical charts	102,253,804	0	102,253,804	0	102,253,804	0	102,253,804	0
Met demographic requirements (sex, race, and Hispanic origin)	101,554,155	699,649	101,554,155	699,649	101,554,155	699,649	101,554,155	699,649
Members with a valid index event								
Had any cohort-defining claim during the query period	1,158	101,552,997	0	101,554,155	572	101,553,583	0	101,554,155
Claim recorded during specified age range	1,158	0	0	0	572	0	0	0
Episode defining index claim recorded during the query period	1,158	0	0	0	572	0	0	0
Met exposure incidence criteria	1,158	0	0	0	572	0	0	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	1,108	50	0	0	499	73	0	0
Met inclusion and exclusion criteria	1,108	0	0	0	499	0	0	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	1,108	0	0	0	499	0	0	0
Final cohort								
Number of members	1,108	N/A	0	N/A	499	N/A	0	N/A
Number of episodes	1,108	N/A	0	N/A	499	N/A	0	N/A

	Viltolarsen		Satralizumab-mwge		Clascoterone		Somapacitan-beco	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	163,592,699	N/A	163,592,699	N/A	163,592,699	N/A	163,592,699	N/A
Had required coverage type (medical and/or drug coverage)	102,254,697	61,338,002	102,254,697	61,338,002	102,254,697	61,338,002	102,254,697	61,338,002
Enrolled during specified age range	102,253,804	893	102,253,804	893	102,253,804	893	102,253,804	893
Had requestable medical charts	102,253,804	0	102,253,804	0	102,253,804	0	102,253,804	0
Met demographic requirements (sex, race, and Hispanic origin)	101,554,155	699,649	101,554,155	699,649	101,554,155	699,649	101,554,155	699,649
Members with a valid index event								
Had any cohort-defining claim during the query period	*****	101,554,148	135	101,554,020	12,072	101,542,083	0	101,554,155
Claim recorded during specified age range	*****	0	135	0	12,072	0	0	0
Episode defining index claim recorded during the query period	*****	0	135	0	12,072	0	0	0
Met exposure incidence criteria	*****	0	135	0	12,072	0	0	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	*****	0	114	21	10,769	1,303	0	0
Met inclusion and exclusion criteria	*****	0	114	0	10,769	0	0	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	*****	0	114	0	10,769	0	0	0
Final cohort								
Number of members	*****	N/A	114	N/A	10,769	N/A	0	N/A
Number of episodes	*****	N/A	114	N/A	10,769	N/A	0	N/A

N/A: Not Applicable

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Figure 1a. Patient Entry into Study by Month for Capmatinib in the SDD from January 1, 2020 to December 31, 2022

The FDA approval date for this drug was on May 6, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

Figure 1b. Patient Entry into Study by Month for Selpercatinib in the SDD from January 1, 2020 to December 31, 2022

The FDA approval date for this drug was on May 8, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

Figure 1c. Patient Entry into Study by Month for Ripretinib in the SDD from January 1, 2020 to December 31, 2022

The FDA approval date for this drug was on May 15, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

Figure 1d. Patient Entry into Study by Month for Fluoroestradiol F-18 in the SDD from January 1, 2020 to December 31, 2022

The FDA approval date for this drug was on May 20, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

Figure 1e. Patient Entry into Study by Month for Artesunate in the SDD from January 1, 2020 to December 31, 2022

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

The FDA approval date for this drug was on May 26, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

The FDA approval date for this drug was on May 28, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

Figure 1g. Patient Entry into Study by Month for Inebilizumab-cdon in the SDD from January 1, 2020 to December 31, 2022

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data*

The FDA approval date for this drug was on June 11, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

Figure 1h. Patient Entry into Study by Month for Lurbinectedin in the SDD from January 1, 2020 to December 31, 2022

The FDA approval date for this drug was on June 15, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data*

The FDA approval date for this drug was on June 30, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

Figure 1j. Patient Entry into Study by Month for Remimazolam in the SDD from January 1, 2020 to December 31, 2022

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data*

The FDA approval date for this drug was on July 2, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

Figure 1k. Patient Entry into Study by Month for Fostemsavir in the SDD from January 1, 2020 to December 31, 2022

The FDA approval date for this drug was on July 7, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

Figure 1l. Patient Entry into Study by Month for Decitabine and Cedazuridine in the SDD from January 1, 2020 to December 31, 2022

The FDA approval date for this drug was on July 24, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

Figure 1m. Patient Entry into Study by Month for Abametapir in the SDD from January 1, 2020 to December 31, 2022

The FDA approval date for this drug was on July 31, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

Figure 1n. Patient Entry into Study by Month for Tafasitamab-Cxix in the SDD from January 1, 2020 to December 31, 2022

The FDA approval date for this drug was on August 5, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

Figure 1o. Patient Entry into Study by Month for Belantamab Mafodotin-blmf in the SDD from January 1, 2020 to December 31, 2022

The FDA approval date for this drug was on August 6, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

Figure 1p. Patient Entry into Study by Month for Nifurtimox in the SDD from January 1, 2020 to December 31, 2022

The FDA approval date for this drug was on August 6, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

Figure 1q. Patient Entry into Study by Month for Risdiplam in the SDD from January 1, 2020 to December 31, 2022

The FDA approval date for this drug was on August 7, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

Figure 1r. Patient Entry into Study by Month for Oliceridine in the SDD from January 1, 2020 to December 31, 2022

The FDA approval date for this drug was on August 7, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

Figure 1s. Patient Entry into Study by Month for Viltolarsen in the SDD from January 1, 2020 to December 31, 2022

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data*

The FDA approval date for this drug was on August 12, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

Figure 1t. Patient Entry into Study by Month for Satralizumab-mwge in the SDD from January 1, 2020 to December 31, 2022

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

The FDA approval date for this drug was on August 14, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

The FDA approval date for this drug was on August 26, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

The FDA approval date for this drug was on August 28, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (April 14, 2023)

Masked DP ID	DP Start Date	DP End Date[1]
DP01	01/01/2000	08/31/2022
DP02	01/01/2000	07/31/2022
DP03	01/01/2000	12/31/2020
DP04	01/01/2000	05/31/2022
DP05	01/01/2004	11/30/2022
DP06	01/01/2007	09/30/2022
DP07	01/01/2008	08/31/2022
DP08	01/01/2005	07/31/2022
DP09	01/01/2000	08/31/2022
DP10	01/01/2000	10/31/2022
DP11	01/01/2010	06/30/2022
DP12	01/01/2008	12/31/2022
DP13	01/01/2006	10/31/2022

[1]End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Generic Name	Brand Name
Clascoterone	
Clascoterone	Winlevi
Satralizumab	
satralizumab-mwge	Enspryng
Viltolarsen	
Viltolarsen	Viltepso
Risdiplam	
Risdiplam	Evrysdi
Oliceridine	
Oliceridine fumarate	Olinvyk
Nifurtimox	
Nifurtimox	Lampit
Belantamab Mafodotin-Blmf	
belantamab mafodotin-blmf	Blenrep
Tafasitamab-cxix	
tafasitamab-cxix	Monjuvi
Abametapir	
Abametapir	Xeglyze
Decitabine and Cedazuridine	
decitabine/cedazuridine	Inqovi
Fostemsavir	
Fostemsavir tromethamine	Rukobia
Remimazolam	
Remimazolam besylate	Byfavo
Triheptanoin	
Triheptanoin	Dojolvi
Lurbinectedin	
Lurbinectedin	Zepzelca
Inebilizumab-Cdon	
inebilizumab-cdon	Uplizna
Flortaucipir F18	
Flortaucipir F-18	Tauvid
Fluoroestradiol F18	
fluoroestradiol F-18	Cerianna
Ripretinib	
ripretinib	Qinlock
Selpercatinib	
selpercatinib	Retevmo
Capmatinib	
capmatinib hydrochloride	Tabrecta

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
Viltolarsen			
C9071	Injection, Viltolarsen, 10 mg	Procedure	HCPCS
J1427	Injection, Viltolarsen, 10 mg	Procedure	HCPCS
Belantamab Mafodotin-Blmf			
C9069	Injection, belantamab mafodontin-blmf, 0.5 mg	Procedure	HCPCS
J9037	Injection, belantamab mafodontin-blmf, 0.5 mg	Procedure	HCPCS
Tafasitamab-cxix			
C9070	Injection, tafasitamab-cxix, 2 mg	Procedure	HCPCS
J9349	Injection, tafasitamab-cxix, 2 mg	Procedure	HCPCS
Inebilizumab-Cdon			
J1823	Injection, inebilizumab-cdon, 1 mg	Procedure	HCPCS
Flortaucipir F18			
A9601	Flortaucipir F 18 injection, diagnostic, 1 mCi	Procedure	HCPCS
Fluoroestradiol F18			
C9060	Fluoroestradiol F18, diagnostic, 1 mci	Procedure	HCPCS
A9591	Fluoroestradiol f 18, diagnostic, 1 mCi	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
Acquired Hypothyroidism			
244.0	Postsurgical hypothyroidism	Diagnosis	ICD-9-CM
244.1	Other postablative hypothyroidism	Diagnosis	ICD-9-CM
244.2	Iodine hypothyroidism	Diagnosis	ICD-9-CM
244.3	Other iatrogenic hypothyroidism	Diagnosis	ICD-9-CM
244.8	Other specified acquired hypothyroidism	Diagnosis	ICD-9-CM
244.9	Unspecified hypothyroidism	Diagnosis	ICD-9-CM
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
Alcohol Abuse			
291.0	Alcohol withdrawal delirium	Diagnosis	ICD-9-CM
291.1	Alcohol-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
291.2	Alcohol-induced persisting dementia	Diagnosis	ICD-9-CM
291.3	Alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
291.4	Idiosyncratic alcohol intoxication	Diagnosis	ICD-9-CM
291.5	Alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
291.8	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.81	Alcohol withdrawal	Diagnosis	ICD-9-CM
291.82	Alcohol induced sleep disorders	Diagnosis	ICD-9-CM
291.89	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.9	Unspecified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
303.00	Acute alcoholic intoxication, unspecified	Diagnosis	ICD-9-CM
303.01	Acute alcoholic intoxication, continuous	Diagnosis	ICD-9-CM
303.02	Acute alcoholic intoxication, episodic	Diagnosis	ICD-9-CM
303.90	Other and unspecified alcohol dependence, unspecified	Diagnosis	ICD-9-CM
303.91	Other and unspecified alcohol dependence, continuous	Diagnosis	ICD-9-CM
303.92	Other and unspecified alcohol dependence, episodic	Diagnosis	ICD-9-CM
305.00	Nondependent alcohol abuse, unspecified	Diagnosis	ICD-9-CM
305.01	Nondependent alcohol abuse, continuous	Diagnosis	ICD-9-CM
305.02	Nondependent alcohol abuse, episodic	Diagnosis	ICD-9-CM
357.5	Alcoholic polyneuropathy	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
425.5	Alcoholic cardiomyopathy	Diagnosis	ICD-9-CM
535.30	Alcoholic gastritis without mention of hemorrhage	Diagnosis	ICD-9-CM
535.31	Alcoholic gastritis with hemorrhage	Diagnosis	ICD-9-CM
571.0	Alcoholic fatty liver	Diagnosis	ICD-9-CM
571.1	Acute alcoholic hepatitis	Diagnosis	ICD-9-CM
571.2	Alcoholic cirrhosis of liver	Diagnosis	ICD-9-CM
571.3	Unspecified alcoholic liver damage	Diagnosis	ICD-9-CM
760.71	Noxious influences affecting fetus or newborn via placenta or breast milk, alcohol	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.61	Alcohol rehabilitation	Procedure	ICD-9-CM
94.62	Alcohol detoxification	Procedure	ICD-9-CM
94.63	Alcohol rehabilitation and detoxification	Procedure	ICD-9-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
980.0	Toxic effect of ethyl alcohol	Diagnosis	ICD-9-CM
E860.0	Accidental poisoning by alcoholic beverages	Diagnosis	ICD-9-CM
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
V79.1	Screening for alcoholism	Diagnosis	ICD-9-CM
Z65.8	Other specified problems related to psychosocial circumstances	Diagnosis	ICD-10-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
Alzheimers			
290.0	Senile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.10	Presenile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.11	Presenile dementia with delirium	Diagnosis	ICD-9-CM
290.12	Presenile dementia with delusional features	Diagnosis	ICD-9-CM
290.13	Presenile dementia with depressive features	Diagnosis	ICD-9-CM
290.20	Senile dementia with delusional features	Diagnosis	ICD-9-CM
290.21	Senile dementia with depressive features	Diagnosis	ICD-9-CM
290.3	Senile dementia with delirium	Diagnosis	ICD-9-CM
290.40	Vascular dementia, uncomplicated	Diagnosis	ICD-9-CM
290.41	Vascular dementia, with delirium	Diagnosis	ICD-9-CM
290.42	Vascular dementia, with delusions	Diagnosis	ICD-9-CM
290.43	Vascular dementia, with depressed mood	Diagnosis	ICD-9-CM
294.0	Amnestic disorder in conditions classified elsewhere	Diagnosis	ICD-9-CM
294.10	Dementia in conditions classified elsewhere without behavioral disturbance	Diagnosis	ICD-9-CM
294.11	Dementia in conditions classified elsewhere with behavioral disturbance	Diagnosis	ICD-9-CM
294.20	Dementia, unspecified, without behavioral disturbance	Diagnosis	ICD-9-CM
294.21	Dementia, unspecified, with behavioral disturbance	Diagnosis	ICD-9-CM
294.8	Other persistent mental disorders due to conditions classified elsewhere	Diagnosis	ICD-9-CM
331.0	Alzheimer's disease	Diagnosis	ICD-9-CM
331.11	Pick's disease	Diagnosis	ICD-9-CM
331.19	Other frontotemporal dementia	Diagnosis	ICD-9-CM
331.2	Senile degeneration of brain	Diagnosis	ICD-9-CM
331.7	Cerebral degeneration in diseases classified elsewhere	Diagnosis	ICD-9-CM
797	Senility without mention of psychosis	Diagnosis	ICD-9-CM
F01.50	Vascular dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F01.51	Vascular dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere without behavioral disturbance	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere with behavioral disturbance	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F04	Amnestic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
F06.1	Catatonic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F06.8	Other specified mental disorders due to known physiological condition	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal dementia	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
R54	Age-related physical debility	Diagnosis	ICD-10-CM
Acute Myocardial Infraction			
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
Anemia			
280.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-9-CM
280.1	Iron deficiency anemia secondary to inadequate dietary iron intake	Diagnosis	ICD-9-CM
280.8	Other specified iron deficiency anemias	Diagnosis	ICD-9-CM
280.9	Unspecified iron deficiency anemia	Diagnosis	ICD-9-CM
281.0	Pernicious anemia	Diagnosis	ICD-9-CM
281.1	Other vitamin B12 deficiency anemia	Diagnosis	ICD-9-CM
281.2	Folate-deficiency anemia	Diagnosis	ICD-9-CM
281.3	Other specified megaloblastic anemias not elsewhere classified	Diagnosis	ICD-9-CM
281.4	Protein-deficiency anemia	Diagnosis	ICD-9-CM
281.8	Anemia associated with other specified nutritional deficiency	Diagnosis	ICD-9-CM
281.9	Unspecified deficiency anemia	Diagnosis	ICD-9-CM
282.0	Hereditary spherocytosis	Diagnosis	ICD-9-CM
282.1	Hereditary elliptocytosis	Diagnosis	ICD-9-CM
282.2	Anemias due to disorders of glutathione metabolism	Diagnosis	ICD-9-CM
282.3	Other hemolytic anemias due to enzyme deficiency	Diagnosis	ICD-9-CM
282.40	Thalassemia, unspecified	Diagnosis	ICD-9-CM
282.41	Sickle-cell thalassemia without crisis	Diagnosis	ICD-9-CM
282.42	Sickle-cell thalassemia with crisis	Diagnosis	ICD-9-CM
282.43	Alpha thalassemia	Diagnosis	ICD-9-CM
282.44	Beta thalassemia	Diagnosis	ICD-9-CM
282.45	Delta-beta thalassemia	Diagnosis	ICD-9-CM
282.46	Thalassemia minor	Diagnosis	ICD-9-CM
282.47	Hemoglobin E-beta thalassemia	Diagnosis	ICD-9-CM
282.49	Other thalassemia	Diagnosis	ICD-9-CM
282.5	Sickle-cell trait	Diagnosis	ICD-9-CM
282.60	Sickle-cell disease, unspecified	Diagnosis	ICD-9-CM
282.61	Hb-SS disease without crisis	Diagnosis	ICD-9-CM
282.62	Hb-SS disease with crisis	Diagnosis	ICD-9-CM
282.63	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-9-CM
282.64	Sickle-cell/Hb-C disease with crisis	Diagnosis	ICD-9-CM
282.68	Other sickle-cell disease without crisis	Diagnosis	ICD-9-CM
282.69	Other sickle-cell disease with crisis	Diagnosis	ICD-9-CM
282.7	Other hemoglobinopathies	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
282.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-9-CM
282.9	Unspecified hereditary hemolytic anemia	Diagnosis	ICD-9-CM
283.0	Autoimmune hemolytic anemias	Diagnosis	ICD-9-CM
283.10	Unspecified non-autoimmune hemolytic anemia	Diagnosis	ICD-9-CM
283.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
283.19	Other non-autoimmune hemolytic anemias	Diagnosis	ICD-9-CM
283.2	Hemoglobinuria due to hemolysis from external causes	Diagnosis	ICD-9-CM
283.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-9-CM
284.01	Constitutional red blood cell aplasia	Diagnosis	ICD-9-CM
284.09	Other constitutional aplastic anemia	Diagnosis	ICD-9-CM
284.11	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-9-CM
284.12	Other drug induced pancytopenia	Diagnosis	ICD-9-CM
284.19	Other pancytopenia	Diagnosis	ICD-9-CM
284.2	Myelophthisis	Diagnosis	ICD-9-CM
284.81	Red cell aplasia (acquired) (adult) (with thymoma)	Diagnosis	ICD-9-CM
284.89	Other specified aplastic anemias	Diagnosis	ICD-9-CM
284.9	Unspecified aplastic anemia	Diagnosis	ICD-9-CM
285.0	Sideroblastic anemia	Diagnosis	ICD-9-CM
285.1	Acute posthemorrhagic anemia	Diagnosis	ICD-9-CM
285.21	Anemia in chronic kidney disease	Diagnosis	ICD-9-CM
285.22	Anemia in neoplastic disease	Diagnosis	ICD-9-CM
285.29	Anemia of other chronic disease	Diagnosis	ICD-9-CM
285.3	Antineoplastic chemotherapy induced anemia	Diagnosis	ICD-9-CM
285.8	Other specified anemias	Diagnosis	ICD-9-CM
285.9	Unspecified anemia	Diagnosis	ICD-9-CM
C94.6	Myelodysplastic disease, not elsewhere classified	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D50.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CM
D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
D50.8	Other iron deficiency anemias	Diagnosis	ICD-10-CM
D50.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
D51.1	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria	Diagnosis	ICD-10-CM
D51.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CM
D51.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CM
D51.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CM
D51.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D52.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CM
D52.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CM
D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CM
D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CM
D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CM
D53.2	Scorbutic anemia	Diagnosis	ICD-10-CM
D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.03	Hb-SS disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.09	Hb-SS disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia with acute chest syndrome	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.419	Sickle-cell thalassemia with crisis, unspecified	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis	ICD-10-CM
D57.44	Sickle-cell thalassemia beta plus without crisis	Diagnosis	ICD-10-CM
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome	Diagnosis	ICD-10-CM
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration	Diagnosis	ICD-10-CM
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
D58.0	Hereditary spherocytosis	Diagnosis	ICD-10-CM
D58.1	Hereditary elliptocytosis	Diagnosis	ICD-10-CM
D58.2	Other hemoglobinopathies	Diagnosis	ICD-10-CM
D58.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-10-CM
D58.9	Hereditary hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.0	Drug-induced autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.1	Other autoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.2	Drug-induced nonautoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.4	Other nonautoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]	Diagnosis	ICD-10-CM
D59.6	Hemoglobinuria due to hemolysis from other external causes	Diagnosis	ICD-10-CM
D59.8	Other acquired hemolytic anemias	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
D59.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D60.0	Chronic acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.1	Transient acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.8	Other acquired pure red cell aplasias	Diagnosis	ICD-10-CM
D60.9	Acquired pure red cell aplasia, unspecified	Diagnosis	ICD-10-CM
D61.01	Constitutional (pure) red blood cell aplasia	Diagnosis	ICD-10-CM
D61.09	Other constitutional aplastic anemia	Diagnosis	ICD-10-CM
D61.1	Drug-induced aplastic anemia	Diagnosis	ICD-10-CM
D61.2	Aplastic anemia due to other external agents	Diagnosis	ICD-10-CM
D61.3	Idiopathic aplastic anemia	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D61.811	Other drug-induced pancytopenia	Diagnosis	ICD-10-CM
D61.818	Other pancytopenia	Diagnosis	ICD-10-CM
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes	Diagnosis	ICD-10-CM
D61.9	Aplastic anemia, unspecified	Diagnosis	ICD-10-CM
D62	Acute posthemorrhagic anemia	Diagnosis	ICD-10-CM
D63.0	Anemia in neoplastic disease	Diagnosis	ICD-10-CM
D63.1	Anemia in chronic kidney disease	Diagnosis	ICD-10-CM
D63.8	Anemia in other chronic diseases classified elsewhere	Diagnosis	ICD-10-CM
D64.0	Hereditary sideroblastic anemia	Diagnosis	ICD-10-CM
D64.1	Secondary sideroblastic anemia due to disease	Diagnosis	ICD-10-CM
D64.2	Secondary sideroblastic anemia due to drugs and toxins	Diagnosis	ICD-10-CM
D64.3	Other sideroblastic anemias	Diagnosis	ICD-10-CM
D64.4	Congenital dyserythropoietic anemia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D64.89	Other specified anemias	Diagnosis	ICD-10-CM
D64.9	Anemia, unspecified	Diagnosis	ICD-10-CM
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM
Asthma			
493.00	Extrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.01	Extrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.02	Extrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.10	Intrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.11	Intrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.12	Intrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.20	Chronic obstructive asthma, unspecified	Diagnosis	ICD-9-CM
493.21	Chronic obstructive asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.22	Chronic obstructive asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.81	Exercise induced bronchospasm	Diagnosis	ICD-9-CM
493.82	Cough variant asthma	Diagnosis	ICD-9-CM
493.90	Asthma, unspecified, unspecified status	Diagnosis	ICD-9-CM
493.91	Asthma, unspecified with status asthmaticus	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
493.92	Asthma, unspecified, with (acute) exacerbation	Diagnosis	ICD-9-CM
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
J82.83	Eosinophilic asthma	Diagnosis	ICD-10-CM
Atrial Fibrillation			
427.31	Atrial fibrillation	Diagnosis	ICD-9-CM
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
Benign Prostatic Hyperplasia			
600.00	Hypertrophy (benign) of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.01	Hypertrophy (benign) of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.10	Nodular prostate without urinary obstruction	Diagnosis	ICD-9-CM
600.11	Nodular prostate with urinary obstruction	Diagnosis	ICD-9-CM
600.20	Benign localized hyperplasia of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.21	Benign localized hyperplasia of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
600.3	Cyst of prostate	Diagnosis	ICD-9-CM
600.90	Hyperplasia of prostate, unspecified, without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.91	Hyperplasia of prostate, unspecified, with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.3	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N42.83	Cyst of prostate	Diagnosis	ICD-10-CM
Breast Cancer			
174.0	Malignant neoplasm of nipple and areola of female breast	Diagnosis	ICD-9-CM
174.1	Malignant neoplasm of central portion of female breast	Diagnosis	ICD-9-CM
174.2	Malignant neoplasm of upper-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.3	Malignant neoplasm of lower-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.4	Malignant neoplasm of upper-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.5	Malignant neoplasm of lower-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.6	Malignant neoplasm of axillary tail of female breast	Diagnosis	ICD-9-CM
174.8	Malignant neoplasm of other specified sites of female breast	Diagnosis	ICD-9-CM
174.9	Malignant neoplasm of breast (female), unspecified site	Diagnosis	ICD-9-CM
175.0	Malignant neoplasm of nipple and areola of male breast	Diagnosis	ICD-9-CM
175.9	Malignant neoplasm of other and unspecified sites of male breast	Diagnosis	ICD-9-CM
233.0	Carcinoma in situ of breast	Diagnosis	ICD-9-CM
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
V10.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-9-CM
Z17.0	Estrogen receptor positive status [ER+]	Diagnosis	ICD-10-CM
Z17.1	Estrogen receptor negative status [ER-]	Diagnosis	ICD-10-CM
Z19.1	Hormone sensitive malignancy status	Diagnosis	ICD-10-CM
Z19.2	Hormone resistant malignancy status	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z86.000	Personal history of in-situ neoplasm of breast	Diagnosis	ICD-10-CM
Cardiac Arrest			
V12.53	Personal history of sudden cardiac arrest	Diagnosis	ICD-9-CM
Z86.74	Personal history of sudden cardiac arrest	Diagnosis	ICD-10-CM
Chronic Kidney Disease			
016.00	Tuberculosis of kidney, confirmation unspecified	Diagnosis	ICD-9-CM
016.01	Tuberculosis of kidney, bacteriological or histological examination not done	Diagnosis	ICD-9-CM
016.02	Tuberculosis of kidney, bacteriological or histological examination unknown (at present)	Diagnosis	ICD-9-CM
016.03	Tuberculosis of kidney, tubercle bacilli found (in sputum) by microscopy	Diagnosis	ICD-9-CM
016.04	Tuberculosis of kidney, tubercle bacilli not found (in sputum) by microscopy, but found by bacterial culture	Diagnosis	ICD-9-CM
016.05	Tuberculosis of kidney, tubercle bacilli not found by bacteriological examination, but tuberculosis confirmed histologically	Diagnosis	ICD-9-CM
016.06	Tuberculosis of kidney, tubercle bacilli not found by bacteriological or histological examination, but tuberculosis confirmed by other methods [inoculation of animals]	Diagnosis	ICD-9-CM
095.4	Syphilis of kidney	Diagnosis	ICD-9-CM
189.0	Malignant neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
189.9	Malignant neoplasm of urinary organ, site unspecified	Diagnosis	ICD-9-CM
223.0	Benign neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
236.91	Neoplasm of uncertain behavior of kidney and ureter	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
271.4	Renal glycosuria	Diagnosis	ICD-9-CM
274.10	Gouty nephropathy, unspecified	Diagnosis	ICD-9-CM
283.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
440.1	Atherosclerosis of renal artery	Diagnosis	ICD-9-CM
442.1	Aneurysm of renal artery	Diagnosis	ICD-9-CM
572.4	Hepatorenal syndrome	Diagnosis	ICD-9-CM
580.0	Acute glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
580.4	Acute glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
580.81	Acute glomerulonephritis with other specified pathological lesion in kidney in disease classified elsewhere	Diagnosis	ICD-9-CM
580.89	Other acute glomerulonephritis with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
580.9	Acute glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.0	Nephrotic syndrome with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.1	Nephrotic syndrome with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
581.2	Nephrotic syndrome with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.3	Nephrotic syndrome with lesion of minimal change glomerulonephritis	Diagnosis	ICD-9-CM
581.81	Nephrotic syndrome with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM
581.89	Other nephrotic syndrome with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.9	Nephrotic syndrome with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.0	Chronic glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.1	Chronic glomerulonephritis with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
582.2	Chronic glomerulonephritis with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.4	Chronic glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
582.81	Chronic glomerulonephritis with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM
582.89	Other chronic glomerulonephritis with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.9	Chronic glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
583.0	Nephritis and nephropathy, not specified as acute or chronic, with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
583.1	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
583.2	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
583.4	Nephritis and nephropathy, not specified as acute or chronic, with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
583.6	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
583.7	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal medullary necrosis	Diagnosis	ICD-9-CM
583.81	Nephritis and nephropathy, not specified as acute or chronic, with other specified pathological lesion in kidney, in diseases classified elsewhere	Diagnosis	ICD-9-CM
583.89	Other nephritis and nephropathy, not specified as acute or chronic, with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
583.9	Nephritis and nephropathy, not specified as acute or chronic, with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.5	Acute kidney failure with lesion of tubular necrosis	Diagnosis	ICD-9-CM
584.6	Acute kidney failure with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
584.7	Acute kidney failure with lesion of medullary [papillary] necrosis	Diagnosis	ICD-9-CM
584.8	Acute kidney failure with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.9	Acute kidney failure, unspecified	Diagnosis	ICD-9-CM
585.1	Chronic kidney disease, Stage I	Diagnosis	ICD-9-CM
585.2	Chronic kidney disease, Stage II (mild)	Diagnosis	ICD-9-CM
585.3	Chronic kidney disease, Stage III (moderate)	Diagnosis	ICD-9-CM
585.4	Chronic kidney disease, Stage IV (severe)	Diagnosis	ICD-9-CM
585.5	Chronic kidney disease, Stage V	Diagnosis	ICD-9-CM
585.6	End stage renal disease	Diagnosis	ICD-9-CM
585.9	Chronic kidney disease, unspecified	Diagnosis	ICD-9-CM
586	Unspecified renal failure	Diagnosis	ICD-9-CM
587	Unspecified renal sclerosis	Diagnosis	ICD-9-CM
588.0	Renal osteodystrophy	Diagnosis	ICD-9-CM
588.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-9-CM
588.81	Secondary hyperparathyroidism (of renal origin)	Diagnosis	ICD-9-CM
588.89	Other specified disorders resulting from impaired renal function	Diagnosis	ICD-9-CM
588.9	Unspecified disorder resulting from impaired renal function	Diagnosis	ICD-9-CM
591	Hydronephrosis	Diagnosis	ICD-9-CM
753.12	Congenital polycystic kidney, unspecified type	Diagnosis	ICD-9-CM
753.13	Congenital polycystic kidney, autosomal dominant	Diagnosis	ICD-9-CM
753.14	Congenital polycystic kidney, autosomal recessive	Diagnosis	ICD-9-CM
753.15	Congenital renal dysplasia	Diagnosis	ICD-9-CM
753.16	Congenital medullary cystic kidney	Diagnosis	ICD-9-CM
753.17	Congenital medullary sponge kidney	Diagnosis	ICD-9-CM
753.19	Other specified congenital cystic kidney disease	Diagnosis	ICD-9-CM
753.20	Unspecified obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
753.21	Congenital obstruction of ureteropelvic junction	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
753.22	Congenital obstruction of ureterovesical junction	Diagnosis	ICD-9-CM
753.23	Congenital ureterocele	Diagnosis	ICD-9-CM
753.29	Other obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
794.4	Nonspecific abnormal results of kidney function study	Diagnosis	ICD-9-CM
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
D30.00	Benign neoplasm of unspecified kidney	Diagnosis	ICD-10-CM
D30.01	Benign neoplasm of right kidney	Diagnosis	ICD-10-CM
D30.02	Benign neoplasm of left kidney	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E74.8	Other specified disorders of carbohydrate metabolism	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I70.1	Atherosclerosis of renal artery	Diagnosis	ICD-10-CM
I72.2	Aneurysm of renal artery	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sicca syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
M35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
N00.0	Acute nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N00.1	Acute nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N00.2	Acute nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N00.3	Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
N00.4	Acute nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.5	Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N00.6	Acute nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N00.7	Acute nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N00.8	Acute nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N00.9	Acute nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N00.A	Acute nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N13.1	Hydronephrosis with ureteral stricture, not elsewhere classified	Diagnosis	ICD-10-CM
N13.2	Hydronephrosis with renal and ureteral calculous obstruction	Diagnosis	ICD-10-CM
N13.30	Unspecified hydronephrosis	Diagnosis	ICD-10-CM
N13.39	Other hydronephrosis	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N17.0	Acute kidney failure with tubular necrosis	Diagnosis	ICD-10-CM
N17.1	Acute kidney failure with acute cortical necrosis	Diagnosis	ICD-10-CM
N17.2	Acute kidney failure with medullary necrosis	Diagnosis	ICD-10-CM
N17.8	Other acute kidney failure	Diagnosis	ICD-10-CM
N17.9	Acute kidney failure, unspecified	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM
N25.0	Renal osteodystrophy	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.81	Secondary hyperparathyroidism of renal origin	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Q62.0	Congenital hydronephrosis	Diagnosis	ICD-10-CM
Q62.10	Congenital occlusion of ureter, unspecified	Diagnosis	ICD-10-CM
Q62.11	Congenital occlusion of ureteropelvic junction	Diagnosis	ICD-10-CM
Q62.12	Congenital occlusion of ureterovesical orifice	Diagnosis	ICD-10-CM
Q62.2	Congenital megaureter	Diagnosis	ICD-10-CM
Q62.31	Congenital ureterocele, orthotopic	Diagnosis	ICD-10-CM
Q62.32	Cecoureterocele	Diagnosis	ICD-10-CM
Q62.39	Other obstructive defects of renal pelvis and ureter	Diagnosis	ICD-10-CM
R94.4	Abnormal results of kidney function studies	Diagnosis	ICD-10-CM
Colorectal Cancer			
153.0	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-9-CM
153.1	Malignant neoplasm of transverse colon	Diagnosis	ICD-9-CM
153.2	Malignant neoplasm of descending colon	Diagnosis	ICD-9-CM
153.3	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-9-CM
153.4	Malignant neoplasm of cecum	Diagnosis	ICD-9-CM
153.5	Malignant neoplasm of appendix	Diagnosis	ICD-9-CM
153.6	Malignant neoplasm of ascending colon	Diagnosis	ICD-9-CM
153.7	Malignant neoplasm of splenic flexure	Diagnosis	ICD-9-CM
153.8	Malignant neoplasm of other specified sites of large intestine	Diagnosis	ICD-9-CM
153.9	Malignant neoplasm of colon, unspecified site	Diagnosis	ICD-9-CM
154.0	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-9-CM
154.1	Malignant neoplasm of rectum	Diagnosis	ICD-9-CM
230.3	Carcinoma in situ of colon	Diagnosis	ICD-9-CM
230.4	Carcinoma in situ of rectum	Diagnosis	ICD-9-CM
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
V10.05	Personal history of malignant neoplasm of large intestine	Diagnosis	ICD-9-CM
V10.06	Personal history of malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
Chronic Obstructive Pulmonary Disease			
490	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-9-CM
491.0	Simple chronic bronchitis	Diagnosis	ICD-9-CM
491.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-9-CM
491.20	Obstructive chronic bronchitis, without exacerbation	Diagnosis	ICD-9-CM
491.21	Obstructive chronic bronchitis, with (acute) exacerbation	Diagnosis	ICD-9-CM
491.22	Obstructive chronic bronchitis with acute bronchitis	Diagnosis	ICD-9-CM
491.8	Other chronic bronchitis	Diagnosis	ICD-9-CM
491.9	Unspecified chronic bronchitis	Diagnosis	ICD-9-CM
492.0	Emphysematous bleb	Diagnosis	ICD-9-CM
492.8	Other emphysema	Diagnosis	ICD-9-CM
494.0	Bronchiectasis without acute exacerbation	Diagnosis	ICD-9-CM
494.1	Bronchiectasis with acute exacerbation	Diagnosis	ICD-9-CM
496	Chronic airway obstruction, not elsewhere classified	Diagnosis	ICD-9-CM
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM
Coronary Angioplasty Bypass			
V45.81	Postprocedural aortocoronary bypass status	Diagnosis	ICD-9-CM
V45.82	Postprocedural percutaneous transluminal coronary angioplasty status	Diagnosis	ICD-9-CM
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
Z98.61	Coronary angioplasty status	Diagnosis	ICD-10-CM
Depression			
296.20	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-9-CM
296.21	Major depressive disorder, single episode, mild	Diagnosis	ICD-9-CM
296.22	Major depressive disorder, single episode, moderate	Diagnosis	ICD-9-CM
296.23	Major depressive disorder, single episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.24	Major depressive disorder, single episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.25	Major depressive disorder, single episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.26	Major depressive disorder, single episode in full remission	Diagnosis	ICD-9-CM
296.30	Major depressive disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.31	Major depressive disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.32	Major depressive disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.33	Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.34	Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.35	Major depressive disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.36	Major depressive disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
296.51	Bipolar I disorder, most recent episode (or current) depressed, mild	Diagnosis	ICD-9-CM
296.52	Bipolar I disorder, most recent episode (or current) depressed, moderate	Diagnosis	ICD-9-CM
296.53	Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.54	Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.55	Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.56	Bipolar I disorder, most recent episode (or current) depressed, in full remission	Diagnosis	ICD-9-CM
296.60	Bipolar I disorder, most recent episode (or current) mixed, unspecified	Diagnosis	ICD-9-CM
296.61	Bipolar I disorder, most recent episode (or current) mixed, mild	Diagnosis	ICD-9-CM
296.62	Bipolar I disorder, most recent episode (or current) mixed, moderate	Diagnosis	ICD-9-CM
296.63	Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
296.64	Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.65	Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.66	Bipolar I disorder, most recent episode (or current) mixed, in full remission	Diagnosis	ICD-9-CM
296.89	Other and unspecified bipolar disorders	Diagnosis	ICD-9-CM
298.0	Depressive type psychosis	Diagnosis	ICD-9-CM
300.4	Dysthymic disorder	Diagnosis	ICD-9-CM
309.1	Prolonged depressive reaction as adjustment reaction	Diagnosis	ICD-9-CM
311	Depressive disorder, not elsewhere classified	Diagnosis	ICD-9-CM
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
Diabetes			
249.00	Secondary diabetes mellitus without mention of complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.01	Secondary diabetes mellitus without mention of complication, uncontrolled	Diagnosis	ICD-9-CM
249.10	Secondary diabetes mellitus with ketoacidosis, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.11	Secondary diabetes mellitus with ketoacidosis, uncontrolled	Diagnosis	ICD-9-CM
249.20	Secondary diabetes mellitus with hyperosmolarity, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.21	Secondary diabetes mellitus with hyperosmolarity, uncontrolled	Diagnosis	ICD-9-CM
249.30	Secondary diabetes mellitus with other coma, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.31	Secondary diabetes mellitus with other coma, uncontrolled	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.50	Secondary diabetes mellitus with ophthalmic manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.51	Secondary diabetes mellitus with ophthalmic manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.60	Secondary diabetes mellitus with neurological manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.61	Secondary diabetes mellitus with neurological manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.70	Secondary diabetes mellitus with peripheral circulatory disorders, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.71	Secondary diabetes mellitus with peripheral circulatory disorders, uncontrolled	Diagnosis	ICD-9-CM
249.80	Secondary diabetes mellitus with other specified manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.81	Secondary diabetes mellitus with other specified manifestations, uncontrolled	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
249.90	Secondary diabetes mellitus with unspecified complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.91	Secondary diabetes mellitus with unspecified complication, uncontrolled	Diagnosis	ICD-9-CM
250.00	Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.01	Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.02	Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.03	Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.10	Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.11	Diabetes with ketoacidosis, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.12	Diabetes with ketoacidosis, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.13	Diabetes with ketoacidosis, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.20	Diabetes with hyperosmolarity, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.21	Diabetes with hyperosmolarity, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.22	Diabetes with hyperosmolarity, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.23	Diabetes with hyperosmolarity, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.30	Diabetes with other coma, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.31	Diabetes with other coma, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.32	Diabetes with other coma, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.33	Diabetes with other coma, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.50	Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.51	Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.52	Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.53	Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.60	Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.61	Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.62	Diabetes with neurological manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.63	Diabetes with neurological manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.70	Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.71	Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.72	Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.73	Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
250.80	Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.81	Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.82	Diabetes with other specified manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.83	Diabetes with other specified manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.90	Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.91	Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.92	Diabetes with unspecified complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.93	Diabetes with unspecified complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
357.2	Polyneuropathy in diabetes	Diagnosis	ICD-9-CM
362.01	Background diabetic retinopathy	Diagnosis	ICD-9-CM
362.02	Proliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.03	Nonproliferative diabetic retinopathy NOS	Diagnosis	ICD-9-CM
362.04	Mild nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.05	Moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.06	Severe nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
366.41	Diabetic cataract	Diagnosis	ICD-9-CM
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
Drug Abuse			
292.0	Drug withdrawal	Diagnosis	ICD-9-CM
292.11	Drug-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
292.12	Drug-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
292.2	Pathological drug intoxication	Diagnosis	ICD-9-CM
292.81	Drug-induced delirium	Diagnosis	ICD-9-CM
292.82	Drug-induced persisting dementia	Diagnosis	ICD-9-CM
292.83	Drug-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
292.84	Drug-induced mood disorder	Diagnosis	ICD-9-CM
292.85	Drug induced sleep disorders	Diagnosis	ICD-9-CM
292.89	Other specified drug-induced mental disorder	Diagnosis	ICD-9-CM
292.9	Unspecified drug-induced mental disorder	Diagnosis	ICD-9-CM
304.00	Opioid type dependence, unspecified	Diagnosis	ICD-9-CM
304.01	Opioid type dependence, continuous	Diagnosis	ICD-9-CM
304.02	Opioid type dependence, episodic	Diagnosis	ICD-9-CM
304.10	Sedative, hypnotic or anxiolytic dependence, unspecified	Diagnosis	ICD-9-CM
304.11	Sedative, hypnotic or anxiolytic dependence, continuous	Diagnosis	ICD-9-CM
304.12	Sedative, hypnotic or anxiolytic dependence, episodic	Diagnosis	ICD-9-CM
304.2	Cocaine dependence	Diagnosis	ICD-9-CM
304.20	Cocaine dependence, unspecified	Diagnosis	ICD-9-CM
304.21	Cocaine dependence, continuous	Diagnosis	ICD-9-CM
304.22	Cocaine dependence, episodic	Diagnosis	ICD-9-CM
304.3	Cannabis dependence	Diagnosis	ICD-9-CM
304.30	Cannabis dependence, unspecified	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
304.31	Cannabis dependence, continuous	Diagnosis	ICD-9-CM
304.32	Cannabis dependence, episodic	Diagnosis	ICD-9-CM
304.4	Amphetamine and other psychostimulant dependence	Diagnosis	ICD-9-CM
304.40	Amphetamine and other psychostimulant dependence, unspecified	Diagnosis	ICD-9-CM
304.41	Amphetamine and other psychostimulant dependence, continuous	Diagnosis	ICD-9-CM
304.42	Amphetamine and other psychostimulant dependence, episodic	Diagnosis	ICD-9-CM
304.5	Hallucinogen dependence	Diagnosis	ICD-9-CM
304.50	Hallucinogen dependence, unspecified	Diagnosis	ICD-9-CM
304.51	Hallucinogen dependence, continuous	Diagnosis	ICD-9-CM
304.52	Hallucinogen dependence, episodic	Diagnosis	ICD-9-CM
304.6	Other specified drug dependence	Diagnosis	ICD-9-CM
304.60	Other specified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.61	Other specified drug dependence, continuous	Diagnosis	ICD-9-CM
304.62	Other specified drug dependence, episodic	Diagnosis	ICD-9-CM
304.7	Combinations of opioid type drug with any other drug dependence	Diagnosis	ICD-9-CM
304.70	Combinations of opioid type drug with any other drug dependence, unspecified	Diagnosis	ICD-9-CM
304.71	Combinations of opioid type drug with any other drug dependence, continuous	Diagnosis	ICD-9-CM
304.72	Combinations of opioid type drug with any other drug dependence, episodic	Diagnosis	ICD-9-CM
304.8	Combinations of drug dependence excluding opioid type drug	Diagnosis	ICD-9-CM
304.80	Combinations of drug dependence excluding opioid type drug, unspecified	Diagnosis	ICD-9-CM
304.81	Combinations of drug dependence excluding opioid type drug, continuous	Diagnosis	ICD-9-CM
304.82	Combinations of drug dependence excluding opioid type drug, episodic	Diagnosis	ICD-9-CM
304.9	Unspecified drug dependence	Diagnosis	ICD-9-CM
304.90	Unspecified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.91	Unspecified drug dependence, continuous	Diagnosis	ICD-9-CM
304.92	Unspecified drug dependence, episodic	Diagnosis	ICD-9-CM
305.2	Nondependent cannabis abuse	Diagnosis	ICD-9-CM
305.20	Nondependent cannabis abuse, unspecified	Diagnosis	ICD-9-CM
305.21	Nondependent cannabis abuse, continuous	Diagnosis	ICD-9-CM
305.22	Nondependent cannabis abuse, episodic	Diagnosis	ICD-9-CM
305.3	Nondependent hallucinogen abuse	Diagnosis	ICD-9-CM
305.30	Nondependent hallucinogen abuse, unspecified	Diagnosis	ICD-9-CM
305.31	Nondependent hallucinogen abuse, continuous	Diagnosis	ICD-9-CM
305.32	Nondependent hallucinogen abuse, episodic	Diagnosis	ICD-9-CM
305.4	Nondependent sedative, hypnotic or anxiolytic abuse	Diagnosis	ICD-9-CM
305.40	Nondependent sedative, hypnotic or anxiolytic abuse, unspecified	Diagnosis	ICD-9-CM
305.41	Nondependent sedative hypnotic or anxiolytic abuse, continuous	Diagnosis	ICD-9-CM
305.42	Nondependent sedative, hypnotic or anxiolytic abuse, episodic	Diagnosis	ICD-9-CM
305.5	Nondependent opioid abuse	Diagnosis	ICD-9-CM
305.50	Nondependent opioid abuse, unspecified	Diagnosis	ICD-9-CM
305.51	Nondependent opioid abuse, continuous	Diagnosis	ICD-9-CM
305.52	Nondependent opioid abuse, episodic	Diagnosis	ICD-9-CM
305.6	Nondependent cocaine abuse	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
305.60	Nondependent cocaine abuse, unspecified	Diagnosis	ICD-9-CM
305.61	Nondependent cocaine abuse, continuous	Diagnosis	ICD-9-CM
305.62	Nondependent cocaine abuse, episodic	Diagnosis	ICD-9-CM
305.7	Nondependent amphetamine or related acting sympathomimetic abuse	Diagnosis	ICD-9-CM
305.70	Nondependent amphetamine or related acting sympathomimetic abuse, unspecified	Diagnosis	ICD-9-CM
305.71	Nondependent amphetamine or related acting sympathomimetic abuse, continuous	Diagnosis	ICD-9-CM
305.72	Nondependent amphetamine or related acting sympathomimetic abuse, episodic	Diagnosis	ICD-9-CM
305.8	Nondependent antidepressant type abuse	Diagnosis	ICD-9-CM
305.80	Nondependent antidepressant type abuse, unspecified	Diagnosis	ICD-9-CM
305.81	Nondependent antidepressant type abuse, continuous	Diagnosis	ICD-9-CM
305.82	Nondependent antidepressant type abuse, episodic	Diagnosis	ICD-9-CM
305.9	Other, mixed, or unspecified nondependent drug abuse	Diagnosis	ICD-9-CM
305.90	Other, mixed, or unspecified nondependent drug abuse, unspecified	Diagnosis	ICD-9-CM
305.91	Other, mixed, or unspecified nondependent drug abuse, continuous	Diagnosis	ICD-9-CM
305.92	Other, mixed, or unspecified nondependent drug abuse, episodic	Diagnosis	ICD-9-CM
648.3	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium	Diagnosis	ICD-9-CM
648.30	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care	Diagnosis	ICD-9-CM
648.31	Maternal drug dependence, with delivery	Diagnosis	ICD-9-CM
648.32	Maternal drug dependence, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
648.33	Maternal drug dependence, antepartum	Diagnosis	ICD-9-CM
648.34	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication	Diagnosis	ICD-9-CM
655.5	Suspected damage to fetus from drugs, affecting management of mother	Diagnosis	ICD-9-CM
655.50	Suspected damage to fetus from drugs, affecting management of mother, unspecified as to episode of care	Diagnosis	ICD-9-CM
655.51	Suspected damage to fetus from drugs, affecting management of mother, delivered	Diagnosis	ICD-9-CM
655.53	Suspected damage to fetus from drugs, affecting management of mother, antepartum	Diagnosis	ICD-9-CM
760.72	Noxious influences affecting fetus or newborn via placenta or breast milk, narcotics	Diagnosis	ICD-9-CM
760.73	Noxious influences affecting fetus or newborn via placenta or breast milk, hallucinogenic agents	Diagnosis	ICD-9-CM
760.75	Noxious influences affecting fetus or newborn via placenta or breast milk, cocaine	Diagnosis	ICD-9-CM
779.5	Drug withdrawal syndrome in newborn	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.64	Drug rehabilitation	Procedure	ICD-9-CM
94.65	Drug detoxification	Procedure	ICD-9-CM
94.66	Drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
965.0	Poisoning by opiates and related narcotics	Diagnosis	ICD-9-CM
965.00	Poisoning by opium (alkaloids), unspecified	Diagnosis	ICD-9-CM
965.01	Poisoning by heroin	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
965.02	Poisoning by methadone	Diagnosis	ICD-9-CM
965.09	Poisoning by opiates and related narcotics, other	Diagnosis	ICD-9-CM
E850.0	Accidental poisoning by heroin	Diagnosis	ICD-9-CM
E850.1	Accidental poisoning by methadone	Diagnosis	ICD-9-CM
E850.2	Accidental poisoning by other opiates and related narcotics	Diagnosis	ICD-9-CM
E854.1	Accidental poisoning by psychodysleptics (hallucinogens)	Diagnosis	ICD-9-CM
E935.0	Heroin causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E935.1	Methadone causing averse effect in therapeutic use	Diagnosis	ICD-9-CM
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.11	Opioid abuse, in remission	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.11	Cannabis abuse, in remission	Diagnosis	ICD-10-CM
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.13	Cannabis abuse with withdrawal	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.11	Cocaine abuse, in remission	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.13	Cocaine abuse, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.93	Cocaine use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.11	Other stimulant abuse, in remission	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.13	Other stimulant abuse with withdrawal	Diagnosis	ICD-10-CM
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.11	Hallucinogen abuse, in remission	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.11	Inhalant abuse, in remission	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.11	Other psychoactive substance abuse, in remission	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.131	Other psychoactive substance abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.139	Other psychoactive substance abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.21	Other psychoactive substance dependence, in remission	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ41ZZZ	Group Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ42ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ43ZZZ	Group Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ44ZZZ	Group Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ45ZZZ	Group Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ46ZZZ	Group Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ47ZZZ	Group Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ48ZZZ	Group Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ49ZZZ	Group Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ4BZZZ	Group Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ50ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ51ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ52ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ53ZZZ	Individual Psychotherapy for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ54ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ55ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interactive	Procedure	ICD-10-PCS
HZ56ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ57ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ58ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ59ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Supportive	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
HZ5BZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis	Procedure	ICD-10-PCS
HZ5CZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic	Procedure	ICD-10-PCS
HZ5DZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological	Procedure	ICD-10-PCS
HZ63ZZZ	Family Counseling for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ83ZZZ	Medication Management for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ88ZZZ	Medication Management for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ89ZZZ	Medication Management for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ98ZZZ	Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ99ZZZ	Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified	Diagnosis	ICD-10-CM
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM
O35.5XX9	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.711A	Poisoning by cannabis, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.721A	Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
Z71.51	Drug abuse counseling and surveillance of drug abuser	Diagnosis	ICD-10-CM
Endometrial Cancer			
182.0	Malignant neoplasm of corpus uteri, except isthmus	Diagnosis	ICD-9-CM
233.2	Carcinoma in situ of other and unspecified parts of uterus	Diagnosis	ICD-9-CM
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
V10.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-9-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
Glaucoma			
365.00	Unspecified preglaucoma	Diagnosis	ICD-9-CM
365.01	Borderline glaucoma, open angle with borderline findings, low risk	Diagnosis	ICD-9-CM
365.02	Borderline glaucoma with anatomical narrow angle	Diagnosis	ICD-9-CM
365.03	Borderline glaucoma with steroid responders	Diagnosis	ICD-9-CM
365.04	Borderline glaucoma with ocular hypertension	Diagnosis	ICD-9-CM
365.10	Unspecified open-angle glaucoma	Diagnosis	ICD-9-CM
365.11	Primary open-angle glaucoma	Diagnosis	ICD-9-CM
365.12	Low tension open-angle glaucoma	Diagnosis	ICD-9-CM
365.13	Pigmentary open-angle glaucoma	Diagnosis	ICD-9-CM
365.15	Residual stage of open angle glaucoma	Diagnosis	ICD-9-CM
365.20	Unspecified primary angle-closure glaucoma	Diagnosis	ICD-9-CM
365.21	Intermittent angle-closure glaucoma	Diagnosis	ICD-9-CM
365.22	Acute angle-closure glaucoma	Diagnosis	ICD-9-CM
365.23	Chronic angle-closure glaucoma	Diagnosis	ICD-9-CM
365.24	Residual stage of angle-closure glaucoma	Diagnosis	ICD-9-CM
365.31	Corticosteroid-induced glaucoma, glaucomatous stage	Diagnosis	ICD-9-CM
365.32	Corticosteroid-induced glaucoma, residual stage	Diagnosis	ICD-9-CM
365.41	Glaucoma associated with chamber angle anomalies	Diagnosis	ICD-9-CM
365.42	Glaucoma associated with anomalies of iris	Diagnosis	ICD-9-CM
365.43	Glaucoma associated with other anterior segment anomalies	Diagnosis	ICD-9-CM
365.51	Phacolytic glaucoma	Diagnosis	ICD-9-CM
365.52	Pseudoexfoliation glaucoma	Diagnosis	ICD-9-CM
365.59	Glaucoma associated with other lens disorders	Diagnosis	ICD-9-CM
365.60	Glaucoma associated with unspecified ocular disorder	Diagnosis	ICD-9-CM
365.61	Glaucoma associated with pupillary block	Diagnosis	ICD-9-CM
365.62	Glaucoma associated with ocular inflammations	Diagnosis	ICD-9-CM
365.63	Glaucoma associated with vascular disorders of eye	Diagnosis	ICD-9-CM
365.64	Glaucoma associated with tumors or cysts	Diagnosis	ICD-9-CM
365.65	Glaucoma associated with ocular trauma	Diagnosis	ICD-9-CM
365.81	Hypersecretion glaucoma	Diagnosis	ICD-9-CM
365.82	Glaucoma with increased episcleral venous pressure	Diagnosis	ICD-9-CM
365.83	Aqueous misdirection	Diagnosis	ICD-9-CM
365.89	Other specified glaucoma	Diagnosis	ICD-9-CM
365.9	Unspecified glaucoma	Diagnosis	ICD-9-CM
377.14	Glaucomatous atrophy (cupping) of optic disc	Diagnosis	ICD-9-CM
H40.001	Preglaucoma, unspecified, right eye	Diagnosis	ICD-10-CM
H40.002	Preglaucoma, unspecified, left eye	Diagnosis	ICD-10-CM
H40.003	Preglaucoma, unspecified, bilateral	Diagnosis	ICD-10-CM
H40.009	Preglaucoma, unspecified, unspecified eye	Diagnosis	ICD-10-CM
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.031	Anatomical narrow angle, right eye	Diagnosis	ICD-10-CM
H40.032	Anatomical narrow angle, left eye	Diagnosis	ICD-10-CM
H40.033	Anatomical narrow angle, bilateral	Diagnosis	ICD-10-CM
H40.039	Anatomical narrow angle, unspecified eye	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
Heart Failure			
398.91	Rheumatic heart failure (congestive)	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
428.0	Congestive heart failure, unspecified	Diagnosis	ICD-9-CM
428.1	Left heart failure	Diagnosis	ICD-9-CM
428.20	Unspecified systolic heart failure	Diagnosis	ICD-9-CM
428.21	Acute systolic heart failure	Diagnosis	ICD-9-CM
428.22	Chronic systolic heart failure	Diagnosis	ICD-9-CM
428.23	Acute on chronic systolic heart failure	Diagnosis	ICD-9-CM
428.30	Unspecified diastolic heart failure	Diagnosis	ICD-9-CM
428.31	Acute diastolic heart failure	Diagnosis	ICD-9-CM
428.32	Chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.33	Acute on chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.40	Unspecified combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.41	Acute combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.42	Chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.43	Acute on chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.9	Unspecified heart failure	Diagnosis	ICD-9-CM
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
P29.0	Neonatal cardiac failure	Diagnosis	ICD-10-CM
Hyperlipidemia			
272.0	Pure hypercholesterolemia	Diagnosis	ICD-9-CM
272.1	Pure hyperglyceridemia	Diagnosis	ICD-9-CM
272.2	Mixed hyperlipidemia	Diagnosis	ICD-9-CM
272.3	Hyperchylomicronemia	Diagnosis	ICD-9-CM
272.4	Other and unspecified hyperlipidemia	Diagnosis	ICD-9-CM
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
Hypertension			
362.11	Hypertensive retinopathy	Diagnosis	ICD-9-CM
401.0	Essential hypertension, malignant	Diagnosis	ICD-9-CM
401.1	Essential hypertension, benign	Diagnosis	ICD-9-CM
401.9	Unspecified essential hypertension	Diagnosis	ICD-9-CM
402.00	Malignant hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.10	Benign hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.90	Unspecified hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
403.00	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.10	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.90	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.00	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.10	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.90	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
405.01	Secondary renovascular hypertension, malignant	Diagnosis	ICD-9-CM
405.09	Other secondary hypertension, malignant	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
405.11	Secondary renovascular hypertension, benign	Diagnosis	ICD-9-CM
405.19	Other secondary hypertension, benign	Diagnosis	ICD-9-CM
405.91	Secondary renovascular hypertension, unspecified	Diagnosis	ICD-9-CM
405.99	Other secondary hypertension, unspecified	Diagnosis	ICD-9-CM
437.2	Hypertensive encephalopathy	Diagnosis	ICD-9-CM
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
Ischemic Heart Disease			
410.00	Acute myocardial infarction of anterolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.02	Acute myocardial infarction of anterolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.10	Acute myocardial infarction of other anterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.12	Acute myocardial infarction of other anterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.20	Acute myocardial infarction of inferolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.22	Acute myocardial infarction of inferolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.30	Acute myocardial infarction of inferoposterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
410.32	Acute myocardial infarction of inferoposterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.40	Acute myocardial infarction of other inferior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.42	Acute myocardial infarction of other inferior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.50	Acute myocardial infarction of other lateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.52	Acute myocardial infarction of other lateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.60	Acute myocardial infarction, true posterior wall infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.62	Acute myocardial infarction, true posterior wall infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.70	Acute myocardial infarction, subendocardial infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
410.72	Acute myocardial infarction, subendocardial infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.80	Acute myocardial infarction of other specified sites, episode of care unspecified	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.82	Acute myocardial infarction of other specified sites, subsequent episode of care	Diagnosis	ICD-9-CM
410.90	Acute myocardial infarction, unspecified site, episode of care unspecified	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
410.92	Acute myocardial infarction, unspecified site, subsequent episode of care	Diagnosis	ICD-9-CM
411.0	Postmyocardial infarction syndrome	Diagnosis	ICD-9-CM
411.1	Intermediate coronary syndrome	Diagnosis	ICD-9-CM
411.81	Acute coronary occlusion without myocardial infarction	Diagnosis	ICD-9-CM
411.89	Other acute and subacute form of ischemic heart disease	Diagnosis	ICD-9-CM
412	Old myocardial infarction	Diagnosis	ICD-9-CM
413.0	Angina decubitus	Diagnosis	ICD-9-CM
413.1	Prinzmetal angina	Diagnosis	ICD-9-CM
413.9	Other and unspecified angina pectoris	Diagnosis	ICD-9-CM
414.00	Coronary atherosclerosis of unspecified type of vessel, native or graft	Diagnosis	ICD-9-CM
414.01	Coronary atherosclerosis of native coronary artery	Diagnosis	ICD-9-CM
414.02	Coronary atherosclerosis of autologous vein bypass graft	Diagnosis	ICD-9-CM
414.03	Coronary atherosclerosis of nonautologous biological bypass graft	Diagnosis	ICD-9-CM
414.04	Coronary atherosclerosis of artery bypass graft	Diagnosis	ICD-9-CM
414.05	Coronary atherosclerosis of unspecified type of bypass graft	Diagnosis	ICD-9-CM
414.06	Coronary atherosclerosis, of native coronary artery of transplanted heart	Diagnosis	ICD-9-CM
414.07	Coronary atherosclerosis, of bypass graft (artery) (vein) of transplanted heart	Diagnosis	ICD-9-CM
414.12	Dissection of coronary artery	Diagnosis	ICD-9-CM
414.2	Chronic total occlusion of coronary artery	Diagnosis	ICD-9-CM
414.3	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-9-CM
414.4	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-9-CM
414.8	Other specified forms of chronic ischemic heart disease	Diagnosis	ICD-9-CM
414.9	Unspecified chronic ischemic heart disease	Diagnosis	ICD-9-CM
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.2	Old myocardial infarction	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
Lung Cancer			
162.2	Malignant neoplasm of main bronchus	Diagnosis	ICD-9-CM
162.3	Malignant neoplasm of upper lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.4	Malignant neoplasm of middle lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.5	Malignant neoplasm of lower lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.8	Malignant neoplasm of other parts of bronchus or lung	Diagnosis	ICD-9-CM
162.9	Malignant neoplasm of bronchus and lung, unspecified site	Diagnosis	ICD-9-CM
231.2	Carcinoma in situ of bronchus and lung	Diagnosis	ICD-9-CM
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
V10.11	Personal history of malignant neoplasm of bronchus and lung	Diagnosis	ICD-9-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
Obesity			
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
0D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZH	Bypass Jejunum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
0D1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
0DB90ZZ	Excision of Duodenum, Open Approach	Procedure	ICD-10-PCS
0DBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DQ64ZZ	Repair Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
0TRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
278.0	Overweight and obesity	Diagnosis	ICD-9-CM
278.00	Obesity, unspecified	Diagnosis	ICD-9-CM
278.01	Morbid obesity	Diagnosis	ICD-9-CM
278.03	Obesity hypoventilation syndrome	Diagnosis	ICD-9-CM
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
V85.3	Body Mass Index between 30-39, adult	Diagnosis	ICD-9-CM
V85.30	Body Mass Index 30.0-30.9, adult	Diagnosis	ICD-9-CM
V85.31	Body Mass Index 31.0-31.9, adult	Diagnosis	ICD-9-CM
V85.32	Body Mass Index 32.0-32.9, adult	Diagnosis	ICD-9-CM
V85.33	Body Mass Index 33.0-33.9, adult	Diagnosis	ICD-9-CM
V85.34	Body Mass Index 34.0-34.9, adult	Diagnosis	ICD-9-CM
V85.35	Body Mass Index 35.0-35.9, adult	Diagnosis	ICD-9-CM
V85.36	Body Mass Index 36.0-36.9, adult	Diagnosis	ICD-9-CM
V85.37	Body Mass Index 37.0-37.9, adult	Diagnosis	ICD-9-CM
V85.38	Body Mass Index 38.0-38.9, adult	Diagnosis	ICD-9-CM
V85.39	Body Mass Index 39.0-39.9, adult	Diagnosis	ICD-9-CM
V85.4	Body Mass Index 40 and over, adult	Diagnosis	ICD-9-CM
V85.41	Body Mass Index 40.0-44.9, adult	Diagnosis	ICD-9-CM
V85.42	Body Mass Index 45.0-49.9, adult	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
V85.43	Body Mass Index 50.0-59.9, adult	Diagnosis	ICD-9-CM
V85.44	Body Mass Index 60.0-69.9, adult	Diagnosis	ICD-9-CM
V85.45	Body Mass Index 70 and over, adult	Diagnosis	ICD-9-CM
Z68.30	Body mass index (BMI) 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index (BMI) 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index (BMI) 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index (BMI) 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index (BMI) 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index (BMI) 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index (BMI) 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index (BMI) 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index (BMI) 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index (BMI) 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index (BMI) 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index (BMI) 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index (BMI) 50-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index (BMI) 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index (BMI) 70 or greater, adult	Diagnosis	ICD-10-CM
Osteoporosis			
733.00	Unspecified osteoporosis	Diagnosis	ICD-9-CM
733.01	Senile osteoporosis	Diagnosis	ICD-9-CM
733.02	Idiopathic osteoporosis	Diagnosis	ICD-9-CM
733.03	Disuse osteoporosis	Diagnosis	ICD-9-CM
733.09	Other osteoporosis	Diagnosis	ICD-9-CM
M80.00X A	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.011 A	Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.012 A	Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.019 A	Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.021 A	Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.022 A	Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.029 A	Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.031 A	Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.032 A	Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M80.039A	Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.041A	Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.042A	Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.049A	Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.051A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.061A	Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.062A	Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.069A	Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.071A	Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.072A	Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.079A	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.08XA	Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0AXA	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.80XA	Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.811A	Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.812A	Other osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.819A	Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.821A	Other osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.822A	Other osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M80.829 A	Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.831 A	Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.832 A	Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.839 A	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.841 A	Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.842 A	Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.849 A	Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.851 A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852 A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.859 A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.861 A	Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.862 A	Other osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.869 A	Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.871 A	Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.872 A	Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.879 A	Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.88X A	Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8AX A	Other osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M81.0	Age-related osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
M81.6	Localized osteoporosis [Lequesne]	Diagnosis	ICD-10-CM
M81.8	Other osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
Overweight			
E66.3	Overweight	Diagnosis	ICD-10-CM
Z68.25	Body mass index (BMI) 25.0-25.9, adult	Diagnosis	ICD-10-CM
Z68.26	Body mass index (BMI) 26.0-26.9, adult	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
Z68.27	Body mass index (BMI) 27.0-27.9, adult	Diagnosis	ICD-10-CM
Z68.28	Body mass index (BMI) 28.0-28.9, adult	Diagnosis	ICD-10-CM
Z68.29	Body mass index (BMI) 29.0-29.9, adult	Diagnosis	ICD-10-CM
Prostate			
185	Malignant neoplasm of prostate	Diagnosis	ICD-9-CM
233.4	Carcinoma in situ of prostate	Diagnosis	ICD-9-CM
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
V10.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-9-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
Rheumatoid Arthritis			
714.0	Rheumatoid arthritis	Diagnosis	ICD-9-CM
714.1	Felty's syndrome	Diagnosis	ICD-9-CM
714.2	Other rheumatoid arthritis with visceral or systemic involvement	Diagnosis	ICD-9-CM
714.30	Polyarticular juvenile rheumatoid arthritis, chronic or unspecified	Diagnosis	ICD-9-CM
714.31	Polyarticular juvenile rheumatoid arthritis, acute	Diagnosis	ICD-9-CM
714.32	Pauciarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
714.33	Monoarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
715.00	Generalized osteoarthrosis, unspecified site	Diagnosis	ICD-9-CM
715.04	Generalized osteoarthrosis, involving hand	Diagnosis	ICD-9-CM
715.09	Generalized osteoarthrosis, involving multiple sites	Diagnosis	ICD-9-CM
715.10	Primary localized osteoarthrosis, unspecified site	Diagnosis	ICD-9-CM
715.11	Primary localized osteoarthrosis, shoulder region	Diagnosis	ICD-9-CM
715.12	Primary localized osteoarthrosis, upper arm	Diagnosis	ICD-9-CM
715.13	Primary localized osteoarthrosis, forearm	Diagnosis	ICD-9-CM
715.14	Primary localized osteoarthrosis, hand	Diagnosis	ICD-9-CM
715.15	Primary localized osteoarthrosis, pelvic region and thigh	Diagnosis	ICD-9-CM
715.16	Primary localized osteoarthrosis, lower leg	Diagnosis	ICD-9-CM
715.17	Primary localized osteoarthrosis, ankle and foot	Diagnosis	ICD-9-CM
715.18	Primary localized osteoarthrosis, other specified sites	Diagnosis	ICD-9-CM
715.20	Secondary localized osteoarthrosis, unspecified site	Diagnosis	ICD-9-CM
715.21	Secondary localized osteoarthrosis, shoulder region	Diagnosis	ICD-9-CM
715.22	Secondary localized osteoarthrosis, upper arm	Diagnosis	ICD-9-CM
715.23	Secondary localized osteoarthrosis, forearm	Diagnosis	ICD-9-CM
715.24	Secondary localized osteoarthrosis, involving hand	Diagnosis	ICD-9-CM
715.25	Secondary localized osteoarthrosis, pelvic region and thigh	Diagnosis	ICD-9-CM
715.26	Secondary localized osteoarthrosis, lower leg	Diagnosis	ICD-9-CM
715.27	Secondary localized osteoarthrosis, ankle and foot	Diagnosis	ICD-9-CM
715.28	Secondary localized osteoarthrosis, other specified site	Diagnosis	ICD-9-CM
715.30	Localized osteoarthrosis not specified whether primary or secondary, unspecified site	Diagnosis	ICD-9-CM
715.31	Localized osteoarthrosis not specified whether primary or secondary, shoulder region	Diagnosis	ICD-9-CM
715.32	Localized osteoarthrosis not specified whether primary or secondary, upper arm	Diagnosis	ICD-9-CM
715.33	Localized osteoarthrosis not specified whether primary or secondary, forearm	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
715.34	Localized osteoarthrosis not specified whether primary or secondary, hand	Diagnosis	ICD-9-CM
715.35	Localized osteoarthrosis not specified whether primary or secondary, pelvic region and thigh	Diagnosis	ICD-9-CM
715.36	Localized osteoarthrosis not specified whether primary or secondary, lower leg	Diagnosis	ICD-9-CM
715.37	Localized osteoarthrosis not specified whether primary or secondary, ankle and foot	Diagnosis	ICD-9-CM
715.38	Localized osteoarthrosis not specified whether primary or secondary, other specified sites	Diagnosis	ICD-9-CM
715.80	Osteoarthrosis involving more than one site, but not specified as generalized, unspecified site	Diagnosis	ICD-9-CM
715.89	Osteoarthrosis involving multiple sites, but not specified as generalized	Diagnosis	ICD-9-CM
715.90	Osteoarthrosis, unspecified whether generalized or localized, unspecified site	Diagnosis	ICD-9-CM
715.91	Osteoarthrosis, unspecified whether generalized or localized, shoulder region	Diagnosis	ICD-9-CM
715.92	Osteoarthrosis, unspecified whether generalized or localized, upper arm	Diagnosis	ICD-9-CM
715.93	Osteoarthrosis, unspecified whether generalized or localized, forearm	Diagnosis	ICD-9-CM
715.94	Osteoarthrosis, unspecified whether generalized or localized, hand	Diagnosis	ICD-9-CM
715.95	Osteoarthrosis, unspecified whether generalized or localized, pelvic region and thigh	Diagnosis	ICD-9-CM
715.96	Osteoarthrosis, unspecified whether generalized or localized, lower leg	Diagnosis	ICD-9-CM
715.97	Osteoarthrosis, unspecified whether generalized or localized, ankle and foot	Diagnosis	ICD-9-CM
715.98	Osteoarthrosis, unspecified whether generalized or localized, other specified sites	Diagnosis	ICD-9-CM
720.0	Ankylosing spondylitis	Diagnosis	ICD-9-CM
721.0	Cervical spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.1	Cervical spondylosis with myelopathy	Diagnosis	ICD-9-CM
721.2	Thoracic spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.3	Lumbosacral spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.90	Spondylosis of unspecified site without mention of myelopathy	Diagnosis	ICD-9-CM
721.91	Spondylosis of unspecified site with myelopathy	Diagnosis	ICD-9-CM
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.51	Distal interphalangeal psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.54	Psoriatic juvenile arthropathy	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
M08.842	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM
M08.849	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.851	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM
M08.852	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
M08.859	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.861	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM
M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM
M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM
M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.51	Unilateral post-traumatic osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.52	Unilateral post-traumatic osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.6	Other bilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.7	Other unilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.9	Osteoarthritis of hip, unspecified	Diagnosis	ICD-10-CM
M17.0	Bilateral primary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.10	Unilateral primary osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.11	Unilateral primary osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.12	Unilateral primary osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.2	Bilateral post-traumatic osteoarthritis of knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.31	Unilateral post-traumatic osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.32	Unilateral post-traumatic osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.4	Other bilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.5	Other unilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.9	Osteoarthritis of knee, unspecified	Diagnosis	ICD-10-CM
M18.0	Bilateral primary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.10	Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.11	Unilateral primary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.12	Unilateral primary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.30	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.4	Other bilateral secondary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.50	Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.51	Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.52	Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.9	Osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M19.011	Primary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.012	Primary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.019	Primary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.021	Primary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.022	Primary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.029	Primary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.031	Primary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.032	Primary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.039	Primary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.041	Primary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.042	Primary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.049	Primary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.071	Primary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.072	Primary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.A2	Non-radiographic axial spondyloarthritis of cervical region	Diagnosis	ICD-10-CM
M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.A4	Non-radiographic axial spondyloarthritis of thoracic region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.A6	Non-radiographic axial spondyloarthritis of lumbar region	Diagnosis	ICD-10-CM
M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region	Diagnosis	ICD-10-CM
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	Diagnosis	ICD-10-CM
M46.80	Other specified inflammatory spondylopathies, site unspecified	Diagnosis	ICD-10-CM
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.82	Other specified inflammatory spondylopathies, cervical region	Diagnosis	ICD-10-CM
M46.83	Other specified inflammatory spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M46.84	Other specified inflammatory spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M46.85	Other specified inflammatory spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M46.86	Other specified inflammatory spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M46.87	Other specified inflammatory spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M46.88	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.89	Other specified inflammatory spondylopathies, multiple sites in spine	Diagnosis	ICD-10-CM
M46.90	Unspecified inflammatory spondylopathy, site unspecified	Diagnosis	ICD-10-CM
M46.91	Unspecified inflammatory spondylopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.92	Unspecified inflammatory spondylopathy, cervical region	Diagnosis	ICD-10-CM
M46.93	Unspecified inflammatory spondylopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M46.94	Unspecified inflammatory spondylopathy, thoracic region	Diagnosis	ICD-10-CM
M46.95	Unspecified inflammatory spondylopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M46.96	Unspecified inflammatory spondylopathy, lumbar region	Diagnosis	ICD-10-CM
M46.97	Unspecified inflammatory spondylopathy, lumbosacral region	Diagnosis	ICD-10-CM
M46.98	Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.99	Unspecified inflammatory spondylopathy, multiple sites in spine	Diagnosis	ICD-10-CM
M47.011	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM
M47.015	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM
M47.016	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021	Vertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022	Vertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029	Vertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.12	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.13	Other spondylosis with myelopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.14	Other spondylosis with myelopathy, thoracic region	Diagnosis	ICD-10-CM
M47.15	Other spondylosis with myelopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.16	Other spondylosis with myelopathy, lumbar region	Diagnosis	ICD-10-CM
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified	Diagnosis	ICD-10-CM
Smoking			
1034F	Current tobacco smoker (CAD, CAP, COPD, PV) (DM)	Procedure	CPT-2
4001F	Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM) (PV)	Procedure	CPT-2
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD)	Procedure	CPT-2

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Procedure	CPT-4
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	CPT-4
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or referral to external smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco use cessation program) if identified as a tobacco user	Procedure	HCPCS
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Z87.891	Personal history of nicotine dependence	Diagnosis	ICD-10-CM
Transient Ischemic Attack			
430	Subarachnoid hemorrhage	Diagnosis	ICD-9-CM
431	Intracerebral hemorrhage	Diagnosis	ICD-9-CM
433.01	Occlusion and stenosis of basilar artery with cerebral infarction	Diagnosis	ICD-9-CM
433.11	Occlusion and stenosis of carotid artery with cerebral infarction	Diagnosis	ICD-9-CM
433.21	Occlusion and stenosis of vertebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.31	Occlusion and stenosis of multiple and bilateral precerebral arteries with cerebral infarction	Diagnosis	ICD-9-CM
433.81	Occlusion and stenosis of other specified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.91	Occlusion and stenosis of unspecified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
434.00	Cerebral thrombosis without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.01	Cerebral thrombosis with cerebral infarction	Diagnosis	ICD-9-CM
434.10	Cerebral embolism without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.11	Cerebral embolism with cerebral infarction	Diagnosis	ICD-9-CM
434.90	Unspecified cerebral artery occlusion without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.91	Unspecified cerebral artery occlusion with cerebral infarction	Diagnosis	ICD-9-CM
435.0	Basilar artery syndrome	Diagnosis	ICD-9-CM
435.1	Vertebral artery syndrome	Diagnosis	ICD-9-CM
435.3	Vertebrobasilar artery syndrome	Diagnosis	ICD-9-CM
435.8	Other specified transient cerebral ischemias	Diagnosis	ICD-9-CM
435.9	Unspecified transient cerebral ischemia	Diagnosis	ICD-9-CM
436	Acute, but ill-defined, cerebrovascular disease	Diagnosis	ICD-9-CM
997.02	Iatrogenic cerebrovascular infarction or hemorrhage	Diagnosis	ICD-9-CM
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
G97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
G97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I66.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I66.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I66.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I66.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I66.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I66.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
I66.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
I66.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Characteristics in this Request

Generic Name	Brand Name
Obesity	
Amino Acids/Multivit-Minerals/Dietary Supplement/Protein Sup	Optifast 70
Benzphetamine HCl	Benzphetamine
Benzphetamine HCl	Regimex
Diethylpropion HCl	Diethylpropion
Diethylpropion HCl	Diethylpropion HCl (bulk)
Liraglutide	Saxenda
Liraglutide	Victoza 2-Pak
Liraglutide	Victoza 3-Pak
Lorcaserin HCl	Belviq
Lorcaserin HCl	Belviq XR
Naltrexone HCl/Bupropion HCl	Contrave
Orlistat	Alli
Orlistat	Xenical
Phendimetrazine Tartrate	Bontril PDM
Phendimetrazine Tartrate	Phendimetrazine Tartrate
Phentermine HCl	Adipex-P
Phentermine HCl	Lomaira
Phentermine HCl	Phentermine
Phentermine HCl	Phentermine HCl (bulk)
Phentermine HCl	Suprenza
Phentermine HCl/Topiramate	Qsymia
Tea/EGCG/Caffeine/Digestive3	Resveratrol Diet
Smoking	
Nicotine	NTS Step 1
Nicotine	Nicoderm CQ
Nicotine	Nicotine
Nicotine	Nicotrol
Nicotine	Nicotrol NS
Nicotine Bitartrate	Nicotine Tartrate
Nicotine Polacrilex	Nicorelief
Nicotine Polacrilex	Nicorette
Nicotine Polacrilex	Nicotine (Polacrilex)
Nicotine Polacrilex	Nicotine Polacrilex (bulk)
Nicotine Polacrilex	Quit 2
Nicotine Polacrilex	Quit 4
Nicotine Polacrilex	Stop Smoking Aid
Varenicline Tartrate	Chantix
Varenicline Tartrate	Chantix Continuing Month Box
Varenicline Tartrate	Chantix Starting Month Box
Varenicline Tartrate	Tyrvaya
Varenicline Tartrate	Varenicline

Appendix F. Specifications for Defining Parameters Used in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 11.0.0, to assess utilization and uptake of the 2020 (part 2) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD).

Query period:	01/01/2020 - 12/30/2022
Coverage requirement:	Medical and Drug Coverage
Pre-index enrollment requirement:	183 Days
Post-index requirement:	0 days
Enrollment gap:	45 days
Age groups:	0-17, 18-24, 25-40, 41-64, 65+ years
Stratifications:	Age group, Sex
Restrictions:	Male and Female
Distribution of index-defining codes:	No
Envelope macro:	Reclassify encounters during inpatient stay as inpatient
Freeze data:	No

Exposure

Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
1	Capmatinib	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
2	Selpercatinib	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications for Defining Parameters Used in this Request

Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
				Exposure						
3	Ripretinib	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
4	Fluoroestradiol-F18	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
5	Artesunate	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
6	Flortaucipir F18	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
7	Inebilizumab-cdon	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications for Defining Parameters Used in this Request

				Exposure						
Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
8	Lurbinectedin	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
9	Triheptanoin	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
10	Remimazolam	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
11	Fostemsavir	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
12	Decitabine and Cedazuridine	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications for Defining Parameters Used in this Request

				Exposure						
Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
13	Abametapir	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
14	Tafasitamab-cxix	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
15	Belantamab Mafodotin-blmf	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
16	Nifurtimox	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
17	Risdiplam	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications for Defining Parameters Used in this Request

Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
				Exposure						
18	Oliceridine	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
19	Viltolarsen	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
20	Satralizumab-mwge	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
21	Clascoterone	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
22	Somapacitan-beco	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360.

NDC codes are checked against First Data Bank's FDB MedKnowledge®.

N/A: Not Applicable

	Covariates					
Characteristic	**Care setting/ Principal diagnosis[1]**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensing**	**Number of instances the covariate should be found in evaluation period**	**Forced supply to attach to dispensing**
Chronic Conditions Data Warehouse						
Acute Myocardial Infarction	IPP, IPS	-183	-1	N/A	1	N/A
Alzheimer's Disease and related conditions	Any	-183	-1	N/A	1	N/A
Atrial Fibrillation	IPP, IPS or	-183	-1	N/A	1	N/A
	AV*, ED*, OA*	-183	-1	N/A	2	N/A
Diabetes	IP*, IS*	-183	-1	N/A	1	N/A
	AV*, ED*, OA*	-183	-1	N/A	2	N/A
Heart Failure	IP*, AV*, ED*	-183	-1	N/A	1	N/A
Hyperlipidemia	IP*, IS*	-183	-1	N/A	1	N/A
	AV*, ED*, OA*	-183	-1	N/A	2	N/A
Hypertension	IP*, IS*	-183	-1	N/A	1	N/A
	AV*, ED*, OA*	-183	-1	N/A	2	N/A
Depression	Any	-183	-1	N/A	1	N/A
Ischemic Heart Disease	Any	-183	-1	N/A	1	N/A
Rheumatoid Arthritis/Osteoarthritis	Any	-183	-1	N/A	2	N/A
Stroke/TIA	IP*	-183	-1	N/A	1	N/A
	AV*, ED*, OA*	-183	-1	N/A	2	N/A
Breast Cancer	IP*, IS* or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A
Colorectal Cancer	IP*, IS* or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A
Prostate Cancer	IP*, IS* or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A

Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request

	Covariates					
Lung Cancer	IP*, IS* or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A
Endometrial Cancer	IP*, IS* or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A
Acquired Hypothyroidism	IP*, IS*, or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A
Anemia	Any	-183	-1	N/A	1	N/A
Asthma	IP*, IS*, or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A
Benign Prostatic Hyperplasia	IP*, IS*, or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A
Chronic Kidney Disease	IP*, IS*, or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A
COPD and Bronchiectasis	IP*, IS*, or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A
Glaucoma	AV*, ED*, OA*	-183	-1	N/A	2	N/A
Osteoporosis	IP*, IS*, or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A

Other

Obesity	Any	-183	-1	Evaluation period should search for evidence of days supply	1	N/A
Overweight	Any	-183	-1	N/A	1	N/A

Covariates						
Smoking	Any	-183	-1	Evaluation period should search for evidence of days supply	1	N/A
Alcohol Abuse or Dependence	Any	-183	-1	N/A	1	N/A
Drug Abuse or Dependence	Any	-183	-1	N/A	1	N/A
History of Cardiac Arrest	Any	-183	-1	N/A	1	N/A
History of Coronary Angioplasty or Bypass	Any	-183	-1	N/A	1	N/A

*These codes must be within 365 days of the index date, not each other as in version 1.

N/A: Not Applicable

[1]Caresetting/ Principal Diagnosis

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) **-** diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

| | Query start date 1 Jan 2020 | Cohort entry date[2] First dispensing of NME Day 0 | Query end date End of data |

Enrollment requirement *Drug and medical coverage* — Pre-index: [-183, -1]

Allowed coverage gap — 45 days

Episode length
Episode gap
Episode extension

Exposure Episode 1 (*NME days supply*)
None (0 days)
None (0 days)
Exposure Episode 2 or more (*NME days supply*)

Baseline characteristics[3] — I — II: (-183, -1)

Follow-up — (0, censoring[4])

[1] Includes all valid exposure episodes during the query period; only the first valid episode's incidence is assessed using the washout period.

[2] 22 scenarios defined based on initiation of NMEs approved in 2020 Part2 (one scenario per NME); Cohort entry date = first dispensing date for qualifying NME

[3] Baseline characteristics:

Window I: Age, sex, year

Window II: Chronic conditions warehouse (CCW), alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, history of coronary angioplasty or bypass, obesity, overweight, and smoking

[4] Censoring: earliest of death, disenrollment, data partner data end date, query end date